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ABSTRACT 
The current study characterizes the principal uncertainties smunding the application of 
environmental models in the assessment of potential health risks related to dioxin emissions from 
a PCB incineration facility. The objectives of the current research involved: (1) the empirical 
characterization and prelirninary validation of computer-based models used for exposure 
assessment and toxicological assessment; (2) characterization of the potential environmental 
consequences fiom ambient exposure to bioaccurnulative chernicals; and (3) improved scientific 
support for risk management decisions conceming such industrial activities. 
Based upon model specifications h m  the scientific literature, a physiologically-based 
pharmacokinetic (PBPK) model was adapted and revised to characterize the dispositional 
kinetics of the key polychlorinated dibeiuo-pdioxin and dibenzofuran congenen (i.e., 2,3,7,8- 
tetnchlorodibenzo-p-dioxin [TCDD], 2,3,7,8-tetrachlorodibetl~ot'uran, 1,2,3,7,8- 
pentachlorodibenzo huan, and 2,3,4,7,8-pentachloroâibenzo h) in the Sprague-Daw ley rat 
(Ruttus norvegicus) laboratory species and the Gapper's red-backed vole (Cfethrionomys 
gapperi) sentinel species. 
Results of the current application of the PBPK model developed for the vole sentinel species 
indicated that the revised model appears to provide a reasonably accurate estimation of chemical- 
specific disposition and elhination patterns. Furthemore, model results suggest that the 
internationally established methodology for Toxic Equivalency Factors (TEFs) may overestimate 
the apparent toxicity of the 2,3,4,7,8-PeCDF congener in relation to TCDD in the red-backed 
vole. Given that the 2,3,4,7,8-PeCDF congener represents the preponderance of the mas- and 
TEF-based concentration of dioxin~fùran congeners measured in biota near incineration facilities, 
a systernatic over-estimation of the TEF for this congener would have significant impacts on the 
outcome of an environmental nsk assessment, based upon the red-backed vole as a sentinel 
species. 
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1.0 INTRODUCTION 
hadvertent exposure to xenobiotic chemicals is an unavoidable consequence of living in an 
industrialized society. While the environment, and those organisms which dwell within it, has an 
incredible ability to absorb and neutralize the potential adverse impacts of released chemicals, 
often realization of the true impact these compounds have on biological systems comes too late 
to prevent adverse environmental effects. To this end, environmental rnodelling solutions are 
oRen used to provide an early warning of the potential impact of chemicals on hurnan health and 
ecosystem integrity -- either to evaluate the acceptability of various human activities, or to 
develop acceptable mitigation approaches for existing problems arising fiom human activities 
(e.g., rezoning, pathway-specific cleanup, etc.). 
Typically, the goal of environmental risk analysis is to develop methods of assessing the risk of 
adverse health effects from exposure to toxic chernicals, as an initial step in priontizing and 
managing the risk. To be effective as a tool in the decision-making process for assessing 
environmental health risks, exposure and toxicologicai assessment models must be "predictive" 
in nature, allowing a Cuture projection of the potential for exposure, and consequent nsk to 
human and ecosystem health, arising fiom a given exposure scenario. These assessment models 
typically use "sentinel" monitoring species as indicators of potential early warnings of risk to the 
sunounding ecosystems (i.e., canaries in a mineshaft). While these models are constructeci using 
the best available knowledge in the areas of environmental fate, toxicology, pharmacology, and 
environmental health nsk assessment as a whole, they are simplistic representations of natural 
processes that are incompletely understood. 
Consequently, to improve the usefùhess and confidence of decision makers in the predictions of 
environmental health risk models, it is imperative that they be vaiidated to "test" their predictive 
abilities in real-world scenarios. As the scientific underpinnings of environmentai processes 
increase, the inûicate components of environmental models will be tested by researchm and 
subsequently rnodi fied to improve their reliability in predicting human health nsks. However, in 
the short term, more ernpirical testing approaches are needed to provide decision makers with 
mater confidence in using environmental exposure assessment models in miving at 
management solutions for immediate health problems. This philosophy provides the basis for 
conducting the investigations proposed in this research study. 
The process of assessing the health nsks associated with human exposure to toxic environmental 
chernicals inevitably relies on a number of assurnptions, estimates, and rationalizations. Adverse 
impacts due to environmental contamination typically occur as a result of a sequence of events, 
beginning with the initial release of a contaminant from a specific source into the environment, 
movement via environmental fate and transport, accumulation in microenvironments, uptake by 
human and ecological receptors, biological transport to sensitive tissuedsites within the 
organisms, and ultimately resulting in a dose-response within the organisms expressing an 
adverse e ffect (Lioy, 1 995). 
Some of the greatest challenges for toxicological assessments result fiom the necessity to 
extrapolate outside the range of conditions found in experimental studies (Cleweli m, 1995; 
Bailer and Dankovic, 1997). As such, due to the use of animal data as the basis of many human 
health risk assessrnents, the need for tools and techniques that address these dose and species 
extrapolation questions becomes a vital concem. 
In the past, simple extrapolation approaches, such as allometric scaling, have been used to project 
h m  a test species to another species of concem. These approaches are rooted in the assurnption 
that al1 biological and physiological processes are inherently similm in nature, and differ only 
relationally to the relative size of the species being evaluated. As such, it is possible to 
extrapolate h m  an experimental outcome fiom one species to another by simply adjusting the 
endpoint in question by a ratio of the body weights of the hvo species to a specific power. Thus, 
this can be expressed through the following: 
y = a d  
where y is the variable in question, a is the allometric coefficient, and b is the allometric 
exponent. For example, the allometric relationship between blood circulation time (seconds) and 
total body weight (kilograms) has been expressed as 21 wo3', resulting in a blood circulation time 
of 15 seconds in a 250 gnun rat and 50 seconds in a 70 kilogram human (lin, 1998). While the 
simplicity of this approach makes it a usefbl technique, it does result in a considerable amount of 
uncertainty due to its generic, ernpirical nature and lack of specification for the intemal 
physiology of a given species of concem. 
When evaluating the potential impact of chemical exposures to a species of concem, it is also 
very important to properly assess the transition from extemal exposure, or dose, to what is 
termeâ the biologically efective dose (see Figure 1.1). The biologicall y effective (equivalent) 
dose represents the actual concentration of chernical which reaches the target site within the 
organism, resulting in a specified biological effect or outcome (beneficial or detrimental). In the 
past, many simple models calculated potential health nsks based upon the administered, or 
extemol dose. While more readily quantifiable (Le., ongoing ambient air monitoring prograrns). 
depending on the intemal phamacokinetics of the compound, very little of the extemal dose may 
actually result in a biological impact ai a target tissue site. As such, actual quantification of the 
internal dose (Le., chernical concentration found in the tissues or blood), or preferably the 
biologically effective dose, would provide a better representation of the actual health risk posed 
by exposure to the chemical of concem. However, as intemal dose typically depends on more 
than just the administered (or extemal) dose, using intemal doses in risk assessrnent rnodels 
generally requires a considerable increase in mode1 complexity and specificity. 
Figure 1.1 Progression of Potential Chernical Impacts on Biological Systems from 
Exposure to Dbease (NRC, 1989). 
Exposure Effective 
Function 
Pharmacokinetic models are used to provide a fûnctional relationship between external measures 
of chernical exposure and intemal, target tissue measures of exposure to the actual toxic moiety. 
Phamacokinetic models can provide a more appropriate bais for translating risk in animals to 
human risk and in some instances provide the ability to extrapolate between experimental 
doses/routes and potential human exposure patterns. The use of physiologically based 
pharmacokinetic (PBPK) modelling provides a scienti fically attractive method of conduc ting this 
aspect of risk assessments. 
The uptake and disposition of chemicals by living organisms, notably humans, has long been one 
of the primary concems of toxicological research. The study of the disposition of chemicals in 
animal bodies falls under the field of pharmacokinetics. in broad tenns, pharmacokinetics (PK) 
involves the study of absorption, distribution, metabolism, and excretion (ADME) of chemicals 
and their metabolites. Pharmacokinetics essentially provides the Iink beiween exposure analysis 
and toxicology, to provide a biologically-realistic evaluation of potential health nsks 
(Figure 1.2). 
Figure 1.2 The roles of physiologically basd  pharmacokinetic and 
pharmacodynamie modelling in a refined health risk 
assessrnent paradigm (Leuiig and Paustenbach, 1995) 
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The closely related subject of phamacokinetic rnodelling is the process of developing 
mathematical descriptions for these critical biological processes. Due to their quantitative nature, 
PK models undement considerable development for use in research by the dnig and 
pharmaceutical industry. However, more recently applied pharmacokinetic research has also 
proved highly usehil in describing the distributions of potentially toxic environmental chemicals, 
such as benzene, pentachlorophenol, pesticides, and their metabolites, within the body after 
inadvertent exposure. 
From the late 1950's through the late 1970's, the rnajority of phannacolcinetic models described in 
the literature were variations of two, three or more compartments with a central pool representing 
the blood, with a number of secondary, penpheral compartments representing tissues, typically 
grouped into "slow" and "fast" equilibrating compartments (Roth et al., 1995). These "classical" 
PK models represent the body as a system of homogenous compartments, which usually have no 
definite physiological or anatomicai reality (Knshnan and Andersen, 1994; Klaassen and 
Roman, 199 1 ). 
Within this "classical" model approach, the rate constants and concentrations describing the 
chemical, as well as the actual "topology" of the model itself (i.e., the number and size of 
compartments and the interconnections between them) are dependent on the expenmental data. 
As such, these models are also dependent on the chemical under study, the setup of the 
experiment, the route of exposure, and the dosing regime. Furthemore, while these data-based 
models cm be used for interpolation under specific conditions, due to their inherent calibration to 
a specific experimental situation, they should not be used for extrapolation outside the range of 
doses, dose routes, and species used in the study on which they were based. As such, due to the 
lack of an authentic depiction of actual anatomical, physiological, and biochemical processes, 
these data-based cornpartmental models cannot easil y be used in interspecies extrapolation, 
particularly to predict pharmacokinetic behaviour in hurnans (Krishnan and Andersen, 1994). 
Given these limitations, the use of more biologically-based models incorporating 
pbarmacokinetic and pharmacodynamie processes has become wide-spread over the past decade. 
The ment  development of biologically-based models to describe the pharmacolcinetics of 
chemicals of concem such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) has provided insight 
into the various biological factors which influence the disposition, metabolism. and excretion of 
this compound and related, lipophilic xenobio tics (Buckley, 1 995). 
Physiologicalfy bused phannacokinetic (PBPK) modelling is a powerful toxicological tool 
designed to convert an exposure, regardless of the applied route, into an ultimate target tissue 
dose. PBPK models are typically designed based upon known physiological processes (e.g., 
blood flow rates, tissue volumes, breathing rates, etc.), on chemical-specific processes (e.g.. 
partition coefficients, chernical volatility, metabolic constants, molecular weight, etc.), and on 
species- and dose-dependent processes (due to non-Iinear kinetics), especially enzyme 
biotransformation. These models are also particularly well suited for evaluating the potential 
impacts of non-linearity (e.g., threshold) in complex dose-response systems. Through the use of 
mechanisms, such as Hill or Michaelis-Menton kinetics, biological models representing the dose- 
dependent kinetics of a particular compound can be more accurately evaluated. 
Thus, a detailed PBPK mode1 can be developed and validated against the more readily available 
experimental animal data, and then extrapolated by computerized numencal simulation to predict 
concentrations of toxic compounds in the tissues of specific target organisms (Le., typically 
humans) following exposure. Through this physiologically-based process, nsk assesson can 
avoid many of the uncertainties associated with interspecies differences between test (laboratory) 
animals and humans, and improve the predictive accuracy of hurnan health and environmental 
risk assessments. 
While providing a viable tool for the toxicological evaluation of chemicals, PBPK modeis do 
have a number of limitations. The major disadvantage of the use of PBPK modelling in 
quantitative risk assessrnent is that the measured parameters are ofien difficult to obtain and 
require knowledge of hurnan metabolic processes that may be highly variable and difficult to 
assess (Naasen and Eaton, 1991). For example, despite considerable shidy in recent years, many 
of the uuderlying metabolic processes within the liver (i.e., specific P450 isomer binding 
efficiencies, potentially sahnable pathways, etc.) remain unclear and subject to considerable 
uncertainty. 




accuracy is lacking for individual dosing (i.e., unlike laboratory studies, it is not always 
possible to accuately estimate chemical exposure doses for a specific individual outside 
such a controlled setting); 
despite the development of a number of commercial PBPK simulation packages, the 
mathematically complex equations are difficult for most toxicologists and clinicians to 
handle, and; 
physiological parameten are oAen poorly defined across species and strains, disease 
States, and the like, dirninishing the accuracy of the predictions of this type of modelling 
(Klaassen and Roman, 1991). 
Nevertheless, despite these limitations, physiologically based toxicokinetic rnodels have proven 
to be very useful investigative tools, and offer considerable opportunity for insights into the 
kinetics of xenobiotics beyond what can be provided by classicai toxicokinetic methodologies. 
1.1 Research Objectives 
Using the extensive environmental monitoring database collated in conjunction with the 
operation of the Swan Hills Treatrnent Centre (a hazardous waste incineration facility) in Swan 
Hills, Alberta, the collected data will be used to attempt to characterize and validate 
environmental modelling methodologies for polychlorinated dioxins and furans. While 
polychlorinated biphenyls (PCBs) are also present in such an mvironrnent, their concentrations 
are not significantly elevated above the typical background levels encountered in regions such as 
western Canada, and therefore PCBs will not be addressed directly in this study. 
The principal objectives of the research include: (1) the empirical characterization and 
preliminary validation of cornputer-based models used for exposure and toxicological (i.e., 
PBPK modehg) assessment; (2) characterization of the potential health consequences related to 
environmental exposure to bioaccumulative chemicals; and (3) improved scientific support for 
risk management decisions concerning such industrial activities. 
Based upon the above methodological overview, the following are the key research aims and 
questions to be addressed through this doctoral research project. They are divided into three 
specific categones and follow a chronological order of bnplementation: a) modelling issues; 
b) empirical issues, and; c) application issues. 
Modeliing Issues 
Evaluation of relative merits of simpler (i.e., two-cornpartment or equilibrium-based) 
phmacokinetic models versus complex (i. e., multi-cornpartmental) PBPK models for the 
assessrnent of health risks related to environmental exposures to dioxins and furans; 
Evaluation of the feasibility of using a PBPK model developed using laboratory rodents for 
use with the vole sentinel species (i.e., availability of detailed physiological data for the vole 
receptors or adequate allometric methodologies to produce equivalent data for the 
appropriate biological receptor), and; 
Discussion of the relative strengths and weaknesses of the selected PBPK model for dioxins 
and furans. Objective measures of model strength and weakness such as i) robustness, ii) 
sensitivity, iii) parsimony, and iv) explanatory value will be evaluated to provide a better 
indication of the potential uncertainty related to the application of this particular model 
design. 
Einpirical Issues 
1. Evduate the apparent ernpirical relationship between the octanol-water partitionhg 
coefficient (log KW) and Bioaccumulation Factor (BAF) or Bioconcenüation Factor @CF) 
of dioxuis and huans in the vole sentinel receptor; 
2. Evaluate whether the Toxic Equivalency Factors (TEFs) for dioxins and fùrans provide a 
suitable surrogate for toxicity in the vole species, considering such parameters as chemical 
bioavailability, pharmacokinetic factors, and toxicodynamic equivalency, and; 
3. Evaluate the "fractionation" charactenstics of the dioxinlfuran congener emission mixtures 
in both the environment and within the vole receptor, on a (i) mass ratio and (ii) TEQ ratio. 
More specifically, the relative congener and isomeric "fingerprint" breakdown of dioxin and 
hiran concentrations present in both environmental (e.g., water, soii, and sediment) and 
biological (e.g., Labrador tea plants and voles) sinks are highly dependent upon a variety 
factors. For example, each specific congener group has diffenng physico-chemical 
properties, leading to diffking physiological disposition, metabolism and ultimately 
toxicological impacts on biological teceptors, such as the red-backed vole. These 
"fractionation" charactenstics provide much of the basis for the TEQ methodology for 
evaluating the toxicity of individual dioxh-like congenen as an overall functional group. 
Application Issues 
1. Discuss the implications of researc h results on marnmalian (botb vole and human) ri sk 
assessments, and the applicability of laboratory developed TEF values under environmental 
conditions; 
2. Using uncertainty analyses, evaluate the potential impacts of leverage variables on the PBPK 
model, and accordingly the results of a health assessrnent involving these variables, and; 
3. Discuss the value of the results of the research as well as tunw empirical research needs. 
n i e  key empirical question for the current research snidy is whether it is feasible to use 
physiologically-based pharmacokinetic models with existing biological monitoring data to 
preâict potential toxicological nsk to human populations. üîtimately, this can only be answered 
by determining whether the Gapper's red-backed vole is a valid sentinel species to evaluate the 
pharmacokinetic and phamiacodynamic implications of environmental exposure to POPs, such 
as polychlorinated dibenzo-p-dioxiw and huans. 
2.0 BACKGROUND 
Incineration, as a methocl for the permanent destruction of persistent hazardous wastes, has 
received significant concem fiom many environmental groups rnemben of the public, and, 
consequently, some governments. This opposition m s e  fiom public apprehensions related to 
quantities of chemicals in incinerator stack emissions, in some cases without consideration of the 
rates of exposure to the chemical emissions, how rates of exposure may compare to those kom 
ambient beckground sources and the likelihood of adverse effects to hurnan andor ecological 
health fiom such exposures (Delzell et al., 1994). Trace concentrations of a variety of chemicals 
remain following combustion even in properly designed and operated incineraton. These 
chemicals typically arise from two general sources: a) unburned organic constituents, metals and 
metallic chemicals, and residual ash (i.e., bottom ash and fly ash), and; b) products of incomplete 
combustion (PICS) that are formed within the incinerator by the combination of atoms from 
dissociated molecules. Typically these emissions are thought to be well below levels at which 
human or environmental health risks would be evident. However, if the incinerator is not 
properly designed and/or operated, the concentrations of chemicals from these sources increase in 
the incinerator emissions and in the residual ash (Travis and Cook, 1989; Lee and Hufban, 
1990; Acharya et al., 199 1 ; Deizezell et al., 1994), and could result in an elevated health risk. 
Of particular concem with respect to the typical ernission releases from incineration facilities are 
a group of bioaccurnulative chemicais called persistent organic pollutunts (POPs). This group of 
compounds is so-narned due to its extreme stability in the environment, and long residency half- 
life within the iatty tissues of biological organisms. Perhaps the most important member of this 
group is the highly toxic compound, 2,3,7,8-tetrachlorodibenzo-p-dioxin (also widely refened to 
as TCDD or dioxin). TCDD belongs to the halogenated ammatic hydrocarbon family, which 
includes polychlorinated dibenzo-p-dioxins (PCDDs), dibenzofûrans (PCDFs), biphenyls 
(PCBs), and naphthalenes (PCNs) (Safe, 1986). They are well known as environmental 
contamlliants due to the extreme toxic potency of some members of the family, the wide variety 
of their toxic responses, and their ubiquitous presence w i t h  both biological organisms and the 
environment, as a whole (Safe, 1986). Given the high level of concem related to potential 
emissions of these persistent compounds, significant importance is typically placed on the 
monitoring of both emissions and biota (both plant and animal) concentrations of these 
compounds in the area smw1ding incineration facilities. 
The Swan Hills Treatment Centre (SHTC), operated by BOVAR Waste Management Limited, is 
Canada's oniy permanent, large-seale incinerator facility capable of destroying hazardous wastes 
such as environmentally persistent polychlorinated biphenyls (PCBs). It is located approximately 
12 kilometres northeast of the Town of Swan Hills (approximately 200 kilometres northwest of 
Edmonton), Alberta, and has been in operation since 1987. To the end of 1996, 143,000 tonnes 
of hazardous waste material, including 20,225 tonnes of PCBs, have been processed and 
destroyd at this facility. The normal destruction of these hazardous waste materials results in 
the controlled air emissions of waste gases h m  the facility's incinerators, transformer Fumace, 
and other sources on the plant site. 
Figure 2.1 Pbotograph of the primary Win Incinerator at the SHTC 
Facility 
A comprehensive monitoring program to provide environmental indicators of the performance of 
the SHTC has been in place since 1985, before the facility was operational. The current program 
includes ambient air, surface water, ground water, soils, vegetation, aquatic resources and 
wildlife indicator studies. This monitoring data has demonstrated that concentrations of PCBs, 
dioxins and furans in the environment were relatively stable at most monitoring locations 
through 1995, but showed increases at some locations from 1995 to 1996, largely attributcd to 
fugitive emissions. 
However, environmental concentrations of PCBs, dioxins and hirans increased significantly 
around the SHTC following an accidental release h m  the transformer h a c e  of the C.E. 
Raymond incinerator in mid-October 1996. The release was the result of the mechanical failure 
of an isolation flange and expansion joint that separated process gases fiom the flue gas duct. A 
stack mission survey being conducted at the time in the transformer fumace later showed that 
approximately 4.2 kilograms of total PCBs and 3.4 gram TEQ (toxic equivalent) of dioxins and 
furans were released over the estimated 8-how duration of the incident (CanTox, 1998). A 
detailed investigation of this event and statistical evaluation of potential congener-specific 
"fingerpnnts" related to normal and incident-related missions nom the SHTC was conducted 
for the candidate's Masten thesis work (Ferguson, 1998). 
The resulting elevated concentrations of both dioxins and furans in the environmental biota in the 
area surrounding the facility following the incident provide an excellent temporal "sign post" by 
which to attempt to evaluate the short-tem disposition impact of PCDDPCDF concentrations in 
vole sentinel species. 
2.1 Environmental M o n i t o ~ g  Program at Swan Hills Treatment Centre 
The Swan Hills site for the Treatment Centre was selected in 1985 following shidies to determine 
the suitability of a number of potmtial sites in various regions and public consultations with local 
residents. The following features contributeci to the overall environmental acceptability of the 
site: i) thick clay soils providing a relatively impervious site; ü) location rernote fiom population 
centres; iii) good access route; iv) central provincial location; and v) lack of land use conflict 
(e.g., agriculture). The Treatment Centre is located on 130 ha of land owned by BOVAR Waste 
Management Limiteci. In addition, it is surrounded by 0.8 km development exclusion zone 
(Chern-Security, 1991). Constmction of the Treatment Centre began in Much of 1985, and it 
was officiaily opened September 1 1,1987. in the winter of 1993- 1994, a new rotary kiln was 
added to the facility, which increased its capacity by 15,000 to~edyear.  
A comprehensive environmentai monitoring program was initiated in the vicinity of the SHTC in 
1985, pnor to the initiation of plant operations (a year after the siting of the facility was 
finalized). Baseline data were collected over a two-year period prior to the Treatment Centre's 
operation. The baseline monitoring provided an unique opportmity to est ablish existing 
environmental conditions in the vicinity of the plant site. in addition to environmental 
monitoring, the program also included incoming waste assessment, personnel sarnpling, health 
surveillance, industrial hygiene and plant boundary air quality monitoring (Chem-S ecurity, 
199 1). 
The current monitoring program includes ambient air, surface water, ground water, soils, 
vegetation, aquatic resources and wildlife indicator studies. The program has been moâified on 
several occasions since 1987 in response to changes in monitoring pnorities. These 
modifications have involved the consolidation of some monitoring sites and the addition of 
others (Penner, 1994; Westworth, 1997). The normal monitoring program was also expanded 
following a release incident in 1996 to address concerns raised by the Alberta Department of 
Health, Department of the Environment, residmts of the Town of Swan Hills, and nearby indian 
band councils. 
Figure 2.3 provides a site map of the SHTC, indicating the relative positions of each key 
monitoring location, both near the facility (i.e., sites 1 1, 107, and 144) and in what would be 
termed "background" locations (i.e., sites 70 and 7 1). 
Fi y re 2.2 Map of Alberta Depichg the Relative Position OC the Town of Swan Hills 
and the Swan Hills Treatment Centre (SHTC) 
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The small mammal population monitoring program involved two annual livetrapping sessions, a 
springfsummer session, which was conducted in June, and a fdl session, which was conducted in 
September. During each session, population monitoring was conducted on IS livetrapping plots, 
each approximately 1.1 hectares in area. Each plot consisted of 48 trapping stations spaced at 15 
metre intervals in a 7 by 7 sampling grid (Westworth, 1998). Animais were also collected for the 
analysis of tissue chemistry in two snap-trapping sessions annually (in February and June) by 
SHTC consultants. It is the results of these sarnpling sessions which will be used to evaluate 
potentiai red-backed vole dioxin and hiran body burden concentrations. 
The vegetation monitoring program typicaily involved two annual sarnpling sessions, a winter 
session, which was conducted in February, and a fa11 session, which was conducted in 
September. Additional sarnpling was aiso conducted in November of 1996 to assess potential 
deposition and surficial concentrations arising from emissions during the October 1996 incident. 
As part of this sampling program, Labrador tea shnibs were sampled at 2 1 plots and analyzed for 
a suite of chernical parameters. Lesser amounts of wildlife browse, lichen and moss, and bemes 
were also sampled as part of the program (AGRA, 1997). 
2.2 Biological Receptors 
As noted previously, the ongoing environmental monitoring program includes arnbient air, 
surface water, ground water, soils, vegetation, aquatic resources and wildlife indicator studies. 
The selection of wildlife receptors for the ongoing assessrnent of SHTC facility emissions was 
based upon a combination of factors, which included: i) the availability of long-term monitoring 
data; ii) trophic level; iii) year-round residency in the study area, and; iv) the likelihood of being 
consumed or handled by hurnans (Chem-Security, 1999). 
For the purpose of the curent study, two biological indicator species were initiaily selected as the 
most appropriate receptors to evaluate: i) the Gapper's red-backed vole (Clethrionomys gapperi), 
and ii) Labrador tea (Leduni groenlandimm). Both selected receptor species have been 
historically sampled since the beginning of the environmental monitoring program at al1 of the 
key sites sumunding the faeility and in background locations. While historically not sampled as 
consistently or extensively as the Labrador tea, monitoring data has also demonstrateci that 
sampling data on live mou provided more accurate reflections of environmental concentrations 
immediately following the accidental release event. As such, these three species provide 
excellent biological indicators, on a historical basis, for relative dioxin and furan emissions for 
the incinerator facility into the surrounding environment. 
L2.2 The Gapper 's Red-Backed Vole (CIethrionornys g~pperi) 
The Gapper's red-backed vole, a smdl rodent typically weighing approxirnately 16-42 grams, 
was chosen as the primary wildlife indicator species for the overall environmental monitoring 
program because of its relative abundance in the area and its sedentary nature, allowing 
information obtained to be related to specific locations in the study area. The red-backed vole 
also has a short life span and is easily trappeci, making it an ideal sentine1 species for the long- 
term monitoring study. The red-backed vole, which typically comprises over 90% of the animals 
captured during the smail rnammal monitoring program, is the rnost abundant small mammai in 
the Swan Hiils Snidy area (Westworth, 1998). 
The Gapper's red-backed vole (Clethrionomys gapperi) is a dark gray microtîne rodent (i.e., a 
rnernber of the rodent subfarnily Microtinae, sometimes called Arvicolinae) with a prominent 
ut-coloured dorsal stripe extending fiom the eyes to the tail, and a dark date gray to almost 
white underbelly (see Figure 2.4). It's head and body lengch is typically 70-1 12 mm, with a short 
tail approximately 25-60 mm long. The fur is dense, long, and soft in the winter, but changes to 
shorter, coarser fh during the surnmer months. Males and females tend to be similar in size and 
colour, with the younger, immature voles tending to be darker than the adults (Hoheister, 1986; 
Ballenger, 1 996). 
Figure 2.4 The Red-backed Vole, CIetkrionomys gapperi 
(Erwin, 2000) 
The habitat for red-backed voles range fiom British Columbia to Labrador and throughout the 
northem United States fiom the Rocky Mountains to the Appalachians (see Figure 2.5). They 
tend to inhabit cool, mossy and rocky boreai forests (typically coniferous, although deciduous or 
mixed forests are also accepted) in both dry and moist areas (Burt and Grossenheider, 1976; 
Nowak and Paradiso, 1983; Ballenger, 1996). Their nests are typically constructed under the 
roots of stumps, logs, or brush piles. The home range of the red-backed vole is about 1/4 acre 
(0.1 hectares). While populations of C. gapperi often fluctuate widely from year to year with no 
apparent periodicity, their numbers are fairly low with approximately 2-3 voles per acre, in 
favourable habitat (Ballenger, 1986). 
During the SHTC monitoring program, vole density has fluctuated widely (6 to 35 volesha) with 
peak numbers occurring at 2 to 4 year intervals. Year-to-year variations in other demographic 
characteristics, such as the percentage of adult voles in breeding condition, age structure, sex 
ratios and survival rates, are fairly consistent and appear to be largely related to events associateci 
with population cycling (Westworth, 1998). 
Figure 2.5 North American Dispersion Pattern for Clethrionomys gapperi 
(Hall, 1981) 
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Red-backed voles exhibit seasonal changes in food habits consume a variety of plant materiais 
during the year. Field research has indicated a daily consumption rate of approximately 0.3 1 
g/g/day (McManus, 1974). They tend to be opportmistic feeders and change their diet as the 
seasons progress. They tend to eat leaf petioles and young shoots in the spring, add bits and 
berries to their diet in the surnmer, and then mvitch to nuts and seeds in the autumn months. 
While underground h g i  also comprise an important part of the diet, especially in the fdl, they 
also consume some bark, mots, lichens, and insects. They sometimes store food (Le., bulbs, 
stems, tubers, and nuts) in their nests for use in the winter when it becomes difficult to forage 
Red-backed voles are active night and day (more so during the night) year round (i.e., they do not 
hibernate), staying close to fallen logs or rocks, and fiequently travel through underground 
passages to reach their foraging areas. They are highly susceptible to predation. Their maximum 
loagevity is approximately 20 months, but most individuals do not survive more than 10 to 12 
months, due to predation and mortality during the winter months (Burt and Grossenheider, 1976; 
eNature, 2000; Ballenger, 1996). 
Theu young are bom typically between March and October, with a litter size of averaging 
between 3 to 7 pups, depending on environmental conditions. Females are typically able to rear 
2 or 3 litters per year, with breeding beginning as early as late winter and continuing into the late 
fall. The offspring are weaned at 17 to 16 days, with sexual matuity occwing at approximately 
3 months of age (Burt and Grossenheider, 1979; Ballenger, 1986). 
As the voles can live to about 12 to 18 months of age, and have very small foraging and habitat 
temtones, they make excellent indicator species for an environmental monitoring study. The red- 
backed vole also represents a key species in avian and mammalian food chahs in Alberta's 
boreal forests (Westworth, 1997). 
2.2.2 Labrador Tea (Ledurn groenlandicum) 
The use of vascular plants is primarily an indirect and long-tm technique to monitor airborne 
pollution. Research has demonstrated that the uptake of metal or organic-complexed particulates 
is primarily a huiction of the availability of the pollutant in the soi1 and secondarily a result of 
direct absorption by the leaves and the needles of the plant species (Martin and Coughtrey, 1992). 
The sampling of plant leaves is useful as it is a relatively inexpensive and simple method of 
monitoring the relative pattern and levels of stack-related releases from the incinerator facility. 
Labrador tea is a small (up to 1 metre in height) evergreen shrub with green leaves and dense 
msty hairs on its twigs. They are typically found in moist to wet forest and bogs in lowland and 
montane zones. They typically grow in wet, usually very acid and poor organic soils (Douglas et 
al., 1990; Angove and Bancroft, 1983). 
F i p n  2.6 Photograph of Labrador Ter and Other Commooly Prevaknt 
Plant Species found in the Sampüig Plot Undentoreys 
Labrador tea leaves were chosen as the primary foliar analysis because of their abundance, ease 
of sarnpling and low susceptibility to trampling. Furthemore. the leaves represent an annual 
deposition because their leaves are retained through the year, including the winter months. While 
these plants are classified as evergreens, they do gradually exchange their leaves. typically on a 
yearly basis (generally in the late spring). As such, new leaves can be collected during the fa11 
sarnpling period after a 3 to 4 month period of exposure. As there appears to be minimal 
translocation of PCBs and dioxidfurao compounds within the plant's vascular system, only the 
curent yean' accumulation of the assessed compound would likely be present in the leaves 
(Mahanty, 1990). Labrador tea is also viewed as an excellent receptor of airborne pollutants due 
to the fine hairs on the underside of the leaves which capture airborne contaminateci particulate 
complexes (AGRA, 1997). 
Based upon these characteristics, ambient chemical concentrations detected on the surface of the 
Labrador tea was deemed an acceptable conservative surrogate for ambient chemical 
concentrations found upon food sources utilized by the red-backed vole. 
2.2.3 Live Moss 
Vegetation data collected fiom near the SHTC indicates that, after an incident such as that in 
October 1996, PCBs, dioxins and k a n s  tend to penist much longer in moss than in other 
vegetation, such as Labrador tea or browse. These compounds tend to accumulate in moss via 
both vapour uptake and particulate deposition. Prior to the accidental release in 1996, vegetative 
data indicated that there was no consistent difference between concentrations in moss and 
Labrador tea. However, for a number of years following the incident, concentrations in moss 
remained relatively high, particularly for dioxins and furans, while concentrations in Labrador tea 
and browse decreased significantly and rapidly (within one year) aAer a short-terni peak 
following the incident (likely due to the annual turnover of exposed leaves) (Chem-Security, 
1 999). 
As moss, particularly those that contain huigi, is a primary food of choice for the red-backed 
vole, use of the Labrador tea concentrations as a surrogate for the overall concentration in al1 
food source may underestimate dietary exposures. As such, moss were also selected as an 
appropriate environmental indicator species for the current assessment. 
2.3 Criteria Chernicals 
The environmental monitoring program at the SHTC has historically monitored a large number 
of chemical compounds, both organic and inorganic. However, as the SHTC is primarily a PCB 
incineration facility, environmental concentrations of P a s ,  dioxins and furaw have always been 
of chief concem to al1 parties involved. 
Both polychlorinated biphenyls (PCBs) and polychlorinated dibenzo-p-dioxins and dibenzo- 
furans (PCDDlFs) belong to a family of chemicals called halogenated aromatics, a group of 
environmental pollutants which have been identified worldwide in diverse environmental media 
(Safe, 1994; Environment Canada, 1997a;b). Due to their persistent (i.e., bioaccumulative) 
nature and widespread distribution in the environment, they have been the subject of 
considerable study with respect to the hazards they pose to both humans and the environment, as 
a whole. As noted previously, this group of bioaccumulative chemicals, and othen Like them, 
have become known as Persistent Organic Pollutants (POPs). 
2.3.1 Poljchlorinated Dibenzo-pdioxins and Dibenzofurans (Dioxins and Furans) 
M a t  are dioxins and furans? 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is the prototype for a family of chemicals which 
have the same mechanism of action, are stnicturally related, and induce a comrnon spectrum of 
biochemical responses and adverse e ffects. The polychlorinated dibenzo-p-dioxins (PCDDs) and 
polychlorinated dibenzofwans (PCDFs) are structural homologues (see Figure 2.7), which 
produce a similar spectrum of bioiogical and toxicological responses in living organisms, at 
varying degrees of potency. Chlorine substitution at the 2,3,7, and 8 position is generally 
considered necessary for dioxin-like behaviour, with TCDD representing the most potent and 
extensively studied of the PCDDs and PCDFs (Safe, 1986). 
Figure 2.7 Generic structural diagrams of the PCDD and PCDF 
chemical families, as well as the specific TCDD and 
TCDF congeners. 
Polychlorinated dibeazo-p-âioxin Polychlorinated dlbenzofuran 
There are 75 chlorinated dibenzo-p-dioxins, ranging in degree of chlonnation fiom the two 
monochlorinated congenen to the fûlly chlorinated octachlorodibenzo-p-dioxin congener. 
Similady, there are 135 chlorinated d i b e n z o h s  ranging in degree of chlonnation fiom the fou. 
monochlorinated congeners to the fully chlorinated octach1orodibenzohu;ui congener. There is a 
wide range in the physicaVchernical properties of chlorinated dioxins and furans both within 
isomenc groups and between congener farnilies (Delzell et (il., 1994). Each of the dioxin and 
furan isomers are never found alone in either the environment or living tissue, but are typically 
found in mixture with other isomen at varying percentages depending on the source and 
environmental and biological degradation processes. 
It is important to note that both dioxins and furans are not produced commercially. Rather, 
mixtures of specific congeners of these substances are released into the environment as 
contaminants or by-products associated with various anthropogenic activities and natural 
processes (e.g., Forest fires). Specifically, chlorinated dioxins and furans are formed during a 
variety of combustion processes, inciuding the incineration of hazardous chernicals (e.g., PCBs) 
and municipal waste incineration, dthough thei. concentrations are typicaily mal1 in emissions 
of incinerators employing best-available technologies (BAT), such as the SHTC. They are aiso 
produced through the chlorine bleaching of papa and pulp products, production of certain 
herbicides, metal srnelting, and other industrial processes. As a result of this production, dioxins 
and furans are ubiquitously present at low concentrations in the environment in industrialized 
countries. Long-range airbome transport of these compounds has also resulted in their 
distribution to more pnstine environments around the world (i.e., the arctic). 
As a result of their high lipid solubility and resistance to rnetabolic breakdown in biological 
systems, PCDD/Fs tend to bioaccumulate in the food chah, and ultimately end up in the human 
body where they can be detected in fatty tissues (i.e., senun, adipose) and in mother's milk. 
Their presence has also been shown to change normal fat metabolism at higher doses, and result 
in decreased food consumption, wasting, hyperlipidemia, and fatty liver (Delzell et al., 1994). As 
a result, TCDD has become a mode1 compound for the pharmacokinetic study of transport of 
such chemicals between pools of lipid within biological systems (Roth et al., 1994). 
in broad terms, interactions between chemicals and living organisms in the environment typically 
initiate a chah of biological events within the organism which can lead to either beneficial (i.e., 
phmaceutical drugs) or harmful (i.e., toxic compounds) impacts upon health. These 
interactions can be associated with direct "reactivity" with target molecules, or through the 
binding of the compound to specific biological recepton within the organism. In recent years, 
considerable effort has been made by the toxicological comrnunity to undentand the potential 
interactions of chemicals with membrane-localized or cytoplasmic receptors (Andersen, 1995). 
Perhaps one of the best examples of this scientific research is the investigation of how PCDD/Fs, 
and some PCBs, interact at the pharmacokinetic (and pharmacodynarnic) level with a cellular 
protein known as the aryl hydrocarbon (Ah) receptor. 
The PBPK models proposed for PCBs, dioxins and furans, in recent years, are a11 rather similar. 
They typically involve five or six notional physiologic comparmients (distinguished by their 
p a o n  and tissue binding kinetics), consisting of the blood, slowly perfi,tsed tissues, and richly 
perfûsed tissues, with separate compartments for the principal target tissues: the fat and liver. 
However, it is how these compounds interact with the hepatocellular Ah protein receptor which 
determines their ulthate toxicological (pharmacodynamie) impacts on a given biological system. 
The Toxicity of Dioxins and Furans 
The toxicity of polychlorinated dioxins and h s  differ markedly among species, as do their 
pharmacokinetics and disposition. The chlorinated dibenzodioxins and dibenzohirans tend to 
accumulate in the liver and adipose tissue, although considerable species and strain differences in 
their relative tissue distribution has been noted in the scientific literature (discussed in detail in 
the following section). This is likely due in part to differing binding tendencies (affinity) and 
efficacies to the Ah and other ce1:ular receptor proteins, as well as basal levels of hepatic 
microsomal monooxygenases such as CYP 1 Aî, in responsive and nonresponsive biological 
species (Krewski et al., 1994). 
The overt signs of toxicity in animals from exposures to chlorinated dioxins and hirans are 
characterized by a general wasting syndrome, with an overall loss in body weight, even though 
food consumption is normal. These effects are typically accompanied by abnonnalities in 
functions of the reproductive, adrenocortical, and ihyroid endocrine systems (Delzell et al., 
1994). Dioxins and kans ,  particularly the most toxic TCDD congener, have been identified as 
carcinogenic and tumeur promoters in rodents, in addition to demonstrating irnmunotoxic, 
reproductive, and teratogenic effects (Krewski et al., 1994). 
Several possible mechanisms have been postulated in the scimtific literature to explain the toxic 
actions of chlorinated dioxins and furans. Two relate to their effects on enzyme systems within 
cells of the body, and one is based on their potential interference with the functions of DNA. 
The potential impacts upon enzyme systems relate to the induction of the CYPl A family of aryl 
hydrocarbon hydroxylase (AHH) enzymes associated with the Ah receptor system and the 
inhibition of glucoco~coid-regulated enzymes (Delzell, 1994). Research has also indicated that 
the Ah receptor-TCDD complex can impact negatively on levels of growth factor receptoa (e.g., 
c-fos pprotosncogenes, epidermal growth factor receptors [EGFR], trans foming growth factor 
[TGF], etc.), resulting in the induction of various important growth factors. For example, 
TCDD's interaction with the Ah receptor has been shown to up-regulate an EGF-like peptide 
(treated nomhally as tram fonning growth factor-alpha, TGF-a) by synergisticall y reacting with 
the estrogen receptor-estrogen complex (Kohn et ai., 1993; Portier et al., 1993) and decreasing 
concentrations of the plasma membrane EGF reçeptor (Lee et al., 1996). TCDD binâing to the 
Ah receptor complex has also been noted to result in endocrine disruption activities which mimic 
or antagonize endogenous hormone action (i.e., estrogens) in vivo. While the mechanisms 
underlying these antiestrogenic impacts are unknown, they are thought to be mediated by "cross- 
talk" (i.e., a sharing of cornmon intermediates in signaling pathways) between the TCDD1A.h 
complex and estrogen response elements (EREs) (Klinge et al., 2000). This impacts are 
discussed in greater depth in the section on Ah receptor mediated toxicity. 
To properly charactenze a physiologically-based pharmacoicinetic mode1 describing the toxic 
impacts of dioxins and hirans on a biological system, one must fint evaiuate these potential 
mechanisms to determine their relative impacts. Based on information on PCBs of similar 
structure, some researchers believe that the metabolic activation of various PCDD/F isomers to 
reactive intermediates may interfere with DNA hction, resulting in toxic action. However, the 
available information on this theory is tiagmentary, and the relevance of these mechanisms to 
environmental concentrations of dioxins and hirans remains unclear. The important information 
fiom the mechanistic studies of chlorinated dioxins and furans indicate that they do not produce 
self-replicating lesions (i.e., mutations or other self-replicating effects on DNA), and as such are 
not considered toxicants with nonthreshold dose-response relationships. Furthemore, the 
available literature indicates an exposure threshold in their dose-response relationship, and that 
below this exposure threshold, no adverse effects would be expected (Delzell et al., 1994). 
Based on this information, the current scientific consensus indicates that the toxic effects of 
PCDDIFs are likely dependent on the interaction of dioxin, and dioxin-like compounds, with a 
specific cellular protein, the Ah (aryl hydrocarbon) receptor. While none of the correlations 
between the various adverse effects associated with PCDDF and interactions with the Ah 
receptor conclusively proves that the Ah receptor system is the primary mecbanism of toxicity of 
chiorinated âioxins and hrans, weightsf-evidence evaluations (Safe, 1990; Borlakoglu and 
Haegele, 199 1) concluded that the Ah receptor-mediated response was a critical cornponent in 
th& action (Delzell et al., 1994). 
M a t  is the Ah Receptor? 
Over the past twenty years, much research has been directed at clarifjmg the occurrence, 
structure, and tùnction of a cytosolic protein called the aryl hydrocarbon (Ah) receptor (AhR). 
The Ah receptor protein evolved about 450 million years ago, early in vertebrate evolution 
(Hengstler et al., 1999), and exists in teleost fish, birds, and mammals (Hahn et al., 1994). A 
variety of anthropogenic and natural chemicals have been shown to bind to the AhR and act as 
receptor agonists to elicit the prototypical AhR-mediated biochemical responses. interestingly 
enough, no endogenous ligand for the Ah receptor has been identified. However, indolo[3,2- 
blcarbazole, which is fonned h m  the acid-catalyzed conversion of the natural plant dietary 
metabolite indole -3-carbinol, binds with moderately high affinity to the Ah receptor 
(Santostefano et al., 1992). One of the major differences between many anthropogenic and 
natural chemicals is their pharmacokinetics and its ultimate toxic impact on the organism. Many 
anthropogenic chemicals capable of binding to the Ah receptor are persistent and bioaccumulate 
in wildlife and humans. in contrast, most if not al1 of the naturab Ah receptor ligands are rapidly 
metabolized and eliminated fkom biological systems (U.S. EPA, 2000). 
Briefly, the Ah receptor is a ligand-activated transcription factor that is a member of the basic- 
helix-loop-helix-Per-Amt-Sim (bHLH-PAS) superfarnily. The basic-helix-loop-helix (referred 
to individually as bHLH) DNA binâing and dimerization motif also identifies the Ah receptor as 
a member of the broad class of bKLH gene regulatory factors. Members of this large family of 
transcription factors are often involved in regulation of ce11 type differentiation and proliferation, 
and are typically characterized by the requirement of formation of homo- or heteroâimeric 
complexes with other bHLH-demonshating partner factors io achieve DNA binding activity 
(Poellinger, 2000; U.S. EPA, 2000). These proteins are known to regulate such diverse areas as 
circadian rhythms and steroid receptor signaling, and are involved in sensing oxygen tension 
(Hahn, 1 998). Interestingly, the AhR is the only member of the bHLH class known to require 
ligand-dependent activation for heterodirnerization and transcriptional actinty (Gasiewicz et al., 
1996; Hushka et al., 1998). The classification of the AIiR as part of the bHLH-PAS superfamily 
and its evolutionary conservatism (Le., present in al1 vertebrate classes examinecl) appears to 
imply that this protein may play an important, but yet unknown, role in normal physiological 
function (US. EPA, 2000). 
The unbound (i. e., non-ligated) Ah receptor is an oligomeric complex located in the cytoplasm, 
where it is associated with two molecules of the 90-kDa heat-shock protein and the another 
protein which may be a 60-kDa c-Src protein (Andersen. 1995; Alexander et al., 1999; Hengstler 
et al., 1999; Hu and Bunce, 1999). This complex is termed the unliguted uryl hydrocarbon 
receplor complex. 
The 90 kDa molecular chaperone hsp90 proteins appear to be required for maintaining the 
receptor in a non-activated, ligand binding conformation. For example, research has 
demonstrated that ligand binding to the Ah receptor is severely impaired upon expression in a 
yeast strain in which hsp90 expression levels are down-regulated to about 5% of wild-type levels 
(Poellinger, 2000). 
There is considerable uncertainty in the scientific literature as to the tnie size and nature of the 
smaller associated protein. A number of researchers (described in Hu and Bunce, 1999) feel it is 
possibly the 60-kD protein c-Src, and ultimately results in biological responses due to impacts on 
tyrosine kinase activity. ûther researchers feel it is a 23-kDa (Kadauskas et al., 1999) or 50-kDa 
(Santostefano et al., 1998) CO-chaperone protein thought to play a role in stabilizing the complex 
containing the receptor and hsp90. Ongoing research should provide a more accurate depiction of 
this protein and its tnie role in the Ah receptor binding process. 
The cascade of biological effects is initiated by TCDD entering the ce11 via passive difision 
through the ce11 membrane, and the process of binding to the Ah receptor (see Figure 2.8). After 
binding of a dioxin molecule or similar ligand, the Ah receptor is released fkom the 90-kDa heat- 
shock proteins and the other smaller chaperone protein (as discussed previously, possibly a 60- 
kDa C-SR: protein), and becornes associated with the Ah receptor nuclear translocator protein 
(Amt) after entering the nucleus of the cell. This traaslocator complex also contains the bHLH 
domain, which allows for binding to specific asymmetrical recognition motifs of DNA in 
promoter regions of specific genes, resulting in enhanced transcriptional activity (i.e., production 
of mRNA). For example, these DNA recognition sequences, termed a dioxin-responsive element 
(DRES) or xenobiotic-responsive element (XREs), have a consensus sequence [T(T/A]GCGTG] 
located in the 5'-flanking region upstream of the cytochrome P450 CYPl Al gene (Andersen et 
al., 1995; Hengstler et al., 1999; Poellinger, 2000). While it is essential for the binding of the Ah 
receptor to the DNA sequence, contrary to what its name suggests, the A n i  protein is not 
involved in translocating the Ah receptor to the nucleus (when first identified, it was thought to 
be a transporter protein). Studies have demonstrated TCDD-induced nuclear translocation of the 
liganded Ah receptor also in Amr-deficient mouse Hepa-1 ceils (Hankinson et al., 1996). 
Figure 2.8 Proposed Ah-Receptor Mediated Mecbanism of Action for Diorin-like 
Exposures (adapted from Hu and Bunce, 1999 and Santostefano et al., 1998) 
Responses 
The mRNA produced h m  the transcribed genes serve as templates for protein synthesis. 
Among the genes transcnptionally regulated by the Ah receptor-dioxin complex (although not 
necessady in conjunction with Amr) are several that regulate ce11 p w t h  and differentiation. 
Studies involving the Ah receptor have demonstrated it to have a saturable, high-aflinity binding 
site (typically with a K, of around 1 nM) for TCDD and similar ligands, and has been identified 
in a variety of animal tissues (Poellinger, 2000; Delzell et al., 1994). The Ah receptor is highly 
polymorphic, particularly when compared with other nuclear receptoa. This polyrnorphism has 
been shown to extend beyond the classical responsive and nonresponsive phenotypes (Le., CS7 
strains of mice have been shown to be highly responsive, while DBA and AKR strains have been 
descnbed as nonresponsive) to include significant differences in receptor pnmary structure. For 
example, three different murùie Ahr alleles (typically denoted with a "b" subscript fiom the 
prototype C57BL strain) have been identified that encode high-affuiity receptors in responsive 
strains (Schmidt and Bradfield, 1996), and differ by only a few point mutations in the common 
open reading h e  (also known as ORF) and by additional sequences at their carboxyl ends 
(Poland et al., 1994). Specifically, the allele found in CS7 strains (AhP1) encodes a 95-kDa (805 
amino acids) receptor with hi& affkity for agonists, whereas the 1MkDa (848 amino acids) 
high-amnity allele (AhP3 is found in most other commonly used laboratory strains, such as 
C 3 W e  and BALB/c (Poland et al., 1 987). Finally, several wild-mouse strains (Mur sp.) 
demonstrate a third hi@-anity allele (Ahe3) encoding a 105-kDa (883 amino acids) receptor 
protein (Poland and Glover, 1 990; Po land et al ., 1 994). 
However, only a single allele (Nd) has been identified which encodes for the low-affinity 
receptor (- 104 kDa) found in nonresponsive strains. This allele is denoted with a "d" superscript 
based upon the prototype nonresponsive DBA strain, and is most appropriately compared with 
the Ahf2 allele because the two alleles express proteins of the sarne size that differ in only two 
amino acids (Swaason and Bradfield, 1993; Poland and Glover, 1990; Smith et al., 1998; Poland 
et al., 1994). As a result of these differences in receptor binding afiinity, studies into the 
induction of hepatic AHH activity by TCDD have noted a 9-fold difference between activity 
levels of C57BU6J and DBN2 mice, and an approximate IO-fold difference between strains 
demonstrating the high-afnnity Ak&l or AhP2 alleles and the low-affinity Ahf allele (Poland et 
al. ,1994). 
It is also important to note that the structural and functional variability of the Ah receptor is also 
sipificant across species. Research conducted into photoamnity labelling of hepatic cytosol has 
indicated that the Ah receptor can Vary in molecular weight by nearly 30 kDa (e.g., 95 kDa in 
CS7 mouse, 101 kDa in chickens, 103 kDa in guinea pigs, 104 kDa in rabbits, 106 kDa in rats 
and humans, 1 1 3 kDa in monkeys, and 124 kDa in hamsters) (Poland et al., 198 7) .  As such, the 
considerable species and strain variability in size and specificity of the Ah receptor can have 
large impacts on the binding affinity of the TCDD ligand to the receptor. Research has 
demonstrated that while the binding ûmnity to the Ah receptor varies significantly behveen 
mouse strains (Poland et al.. 1994). it does not appear to Vary dramatically between strains of rats 
(Pohjanvirta and Tuomisto, 1994). However, there is some evidence indicating that the binding 
afEnity of TCDD to the Ah receptor can vary by a factor of approximatelyl0 to 20 in hurnans, 
and this range encompasses binding affinities similar to those observed in sensitive (i.e., 
responsive) and resistant, nonresponsive mice (Micka et al., 1997; Okey et al., 1997). 
Interestingly enough, there are also gender- and age-specific differences in the toxicity of dioxins 
and Furans. A number of studies have identified a clear, although small, gender difference in the 
acute, subchronic, and chronic toxicities of TCDD in rats. In general, females have been 
demonstrated to be more sensitive to TCDD than males, and while the profile of TCDD 
distribution in fmale rats is similar to that in male rats, the concentration of TCDD in most 
tissues were higher in females than in males (Li et al., 1995). Recent investigations in mice have 
indicated that this can likely be linked to an increased biliary excretion level in males, as 
compared to females, and even older senescent males (Jackson et al., 1998). Other studies have 
suggested that advanced age may have differentiai effects on Ah receptor-mediated enzyme 
induction, resulting in potential toxicological implications for older animals (Pegram et al., 
1995). 
Ah Receptor Mediuted Toxici~y 
Exogewus Ligands for the Ah receptor, particularly TCDD, can cause severai toxic effects, 
including cancer, progressive weight loss, toxicity to the immune system, fetal toxicity, birth 
defects, dysregulation of endocrine (thyroid, androgen, estrogen, and growth factor) homeostasis, 
and decreases in male and fernale reproductive performance. TCDD has also proven to be the 
most potent tumour promoter analyzed and some researchers believe it can act as a complete 
carcinogen (i.e., has initiator and a promoter capabilities) because rodents demonstrate an 
increased incidence of specific tumours in chronic toxicity studies, without pnor exposure to an 
experimental initiator (Schmidt and Bradfield, 1996). However, unlike many potent carcinogens 
such as polycyclic aromatic hydrocarbons (PAHs) or heterocyclic amines, dioxins are not 
genotoxic and do not covalently bind DNA, RNA, or protein, and are not mutagenic in the Ames 
assay (Hengstler et ai., 1999; Schmidt and Bradfield, 1996), calling into question their ability as 
an carcinogenic initiator. Proposed mec hanisms for the carcinogenic e ffects of TCDD on 
biological systems include: i) increased cytochrorne P4SO-mediated metabolic activation of other 
carcinogens or endogenous compounds such as estrogen; ii) DNA single-strand breaks resulting 
fiom lipid peroxidation, and; iii) alterations in ce11 proliferation through transcriptional 
regulation of cytokines and growth factors (Huff et ai., 1994). 
The impact of dioxin on these critical processes can result in broad spectrum toxicity on multiple 
organ systems, hcluding action as a hepatic tumour promoter (Andersen et ai., 1995). Genes 
which have been s h o w  to exhibit increased transcriptionai rates by this rnechanism include 
microsornai monooxygenases (i.  e., P450 CYP 1 A 1, 1 A2, and 1 B 1 ), the glutathione S-tram ferases, 
UDP-glucuronosylhansferase, aldehyde dehydrogenase, and NAD(P)H:quinone reductase 
(Santostefano et al., 1998; Hengstler et al., 1999). 
Dioxins aiso mediate increases in the Iiver concentration of transfoming growth factor-a (TGF- 
a) by a mechanism which requires the Ah receptor. TGF-a subsequently binds to the epidennal 
growth factor (EGF) receptor, a process which is known to cause internalization of this receptor 
in hepatocytes. This action is thought to be an early event in the generation of a rnitogenic signal 
(Kohn et al., 1993). EGF is a potent mitogen with tumour-promoting activity in vivo, and 
alterations in EGF receptor (EGFR) regulatory systems may play a role in carcinogenesis. 
Research has indicated that the EGFR (encoded by the c-erb proto-oncogene) is a transmembrane 
glycopro tein with a ligand-dependent ktrinsic tyrosine kinase activity (Sewell and Lucier, 1 995). 
As TCDD decrrases binâing of EGF in the livers of intact fernale rats but not in ovariectomized 
rats, this effect was m e r  assumeci to be dependent on estrogen action. Given these AhR- 
mediated impacts, dioxins and h s  have also been widely labelled as endocrine disruptor 
chernicals (EDCs). 
TCDD and related compounds have been shown to rnodulate several intracellular endocrine 
response pathways. For example, in the rodent uterus, in addition to the impacts outlined above 
(i.e., epidermal growth factor receptor binding, c+s and EGF receptor mRNA levels, etc.), 
TCDD inhibits such I7p-estradiol (E2)-induced responses as uterine wet weight increase, 
peroxidase activity, and progesterone receptor binding. Despite these effects, TCDD does not 
bind either the uterine estrogen receptor (ER) or progesterone receptor (PR) (Safe et al., 1998). 
The mechanisms underlyhg these observations are unknown, but are thought to be mediated by 
"cross-taik" (i.e., a sharing of common intemediates in intracellular signaling pathways) 
between TCDD and homones including estrogens (Klinge et al., 2000), typically in extrahepatic 
tissue. TCDD has been shown to cause a rapid downregulation of nuclear ERa levels and this is 
typically accompanied by induction of CYPl Al  resulting in the rapid oxidative metabolism of 
any available E2 (Safe et al., 1998a). One proposed mechanism of this inhibitory AhR-ER 
crosstalk involves direct interaction of the A h .  complex with inhibitory DREs identified in the 
5'-promoter regions of E2-responsive cathepsin D, pS2 and cfos genes. However, other studies 
have identified AhR agonists which can inhibit E2-induced expression of several genes that do 
not have functional DREs (Womike et al., 2000). While the molecular mechanisms underlying 
the apparent "cross-taik" between ER- and Ah receptor-mediated activities are unknown, recent 
research has suggested that this rapid inhibition of available ERa may be facilitated through the 
unidirectional activation of protewmes, and that the E2-activated degradation of ERa by 
proteasornes rnay be an important pathway for Limiting the duration of estrogenic responses in 
target tissues. Thus, TCDD not only activates proteasorne-dependent downregulation of the Ah 
receptor, but also induces degradation of ERa protein via other pro teasorne-dependent pathways 
(Wonnke et al., 2000). Additional mechanisms by which TCDD may interfere with the ER 
action include inhibition of ER-DNA binding and interference with critical ER-protein 
interactions that mitigate transcriptional activation. As transcription factors of many diffemt 
families appear to use common coactivator proteins, cornpetition for these proteins rnay provide 
awther mechanism for the antiesttogenic behaviour of TCDD (Klinge et al., 2000). 
As noted previously, dioxin and dioxin-like cornpounds that bind these regdatory genes 
demonstrate dose-dependent kinetics. in other words, as the administered dose increases, a larger 
proportion of the total dose is found in the liver. For example, it appears likely that dose- 
dependent hepatic sequestration is related io induction of CYPlA2, but other proteins may also 
be involved (Diliberto et al., 1997, 1 999; Wang et al., 2000). Thus, any comprehensive mode1 of 
dioxin pharmacokinetics must include the induction of these dioxin-binding proteins, mediated 
by the interaction of a dioxin-Ah-receptor complex with specific DRE binding sites on DNA 
(Leung et ai., 1988, l99Oa,b; Andersen et al., 1993). 
mat are cytochrome P450? 
The cytochrome P450s are a group of hemoproteins associated with the smootb endoplasmic 
reticulurn, which mediate the primary (phase I) oxidative metabolisrn of a broad spectrum of 
lipophilic substrates, both endogenous and exogenous (xenobiotic) in nature (Nims and Lubet, 
1995). For example, the cytochrome P4SOl A 1 (CYP 1 A 1 ) enzyme catalyzes oxygenation of 
polycyclic aromatic substances as the initial step in their metabolic processing to water-soluble 
denvatives, and ultimate excretion f?om the body. While most CYP induction response occurs in 
the liver (as the main site of detoxification and metabolism in the body), these CYP genes are 
present in an uninduced state throughout the body, and play a significant role in many tissue 
organs (i-e., mal1 intestine, lung, kidney, and placenta). 
The CYP l A subfamily includes two genes, CYP l A 1 and CYP 1 A2, which show a relatively high 
degree of nucleotide homology (-75% in rats). Typically, the same compounds will induce both 
of these proteins, usually with similar kinetic patterns (Nerurkar et ai., 1 993). The CYP 1 A 
subfamily is associated with the metabolic activation of planar, hydrophobie compounds such as 
polycyclic aromatic hydrocarbons (PAHs), PCDDRs, and other related compounds (Nims and 
Lubet, 1995; Ziegler, 199 1). CYP 1 A 1 preferentially catalyzes the oxidation of PAHs, while 
CYP 1 A2 preferentially metabolizes a variety of heteroammatic amines through N-hydroxylation 
(Nerurkar et al., 1993). Exposure to such a xenobiotic can also markedly enhance the ability of 
an organism to metabolize the same xenobiotic (and other similar compounds) through a process 
tenned enzyme induction. This process is discussed in further depth in Section 3.0. 
When exposed to such a ligand, CYPl A2 induction is largely limited to hepatic (liver) cells, 
while CYPl Al is expressed both in liver and many extrahepatic tissues, such as the lungs, skin, 
and kidneys (DeVito et al., 1996; Gonzalez, 1988). Particularly relevant to the disposition, 
metabolism, and excretion of dioxin and dioxin-like compounds is the ability of CYPlA2 to 
temporarily sequester these compounds in the liver, on a dose-dependent basis. As such, 
sequestration of TCDD by binding to CYPlA2 cari result in a considerable shifi of localized 
TCDD tissue concentrations fiom the more lipophilic adipose tissue to the liver, and have 
significant impacts on the organism's ability to sequester and excrete the compound. Thus, it is 
vital to address this phmcokinetic and pharmacodynamie issues when designing an accurate 
PBPK mode1 of TCDD exposure. 
There have historically been four distinct methodological approaches for determining CYP 
induction following potential exposure to a contaminant. These included: i) quantification of 
total CYP via UV spectrophotometry; ii) substrate conversion assays; iii) immunochemical 
detection of protein, and; iv) quantification of gene-specific RNA (Nims and Lubet, 1995). 
Research has demonstrated that the spectral technique for assessing CYP induction is relatively 
insensitive, and does not provide sufticient detail with respect to the specific subfmilies or 
isozymes being induced (i.e., it may indicate that a CYP 1 A family member has been induced, but 
not which one). Each of' the remaining techniques, while demonstrating much greater sensitivity, 
have certain specific advantages and disadvantages, depending on the circumstance (Nims and 
Lubet, 1995). Perhaps the most commonly used methodology is that of the substrare conversion 
assay. This assay relies on the ability of the individual CYP isozymes to catalyze a reaction in a 
specific substrate, which can then be quantified through laboratory analysis. For example, 
induction of the CYPI Al  isofom has been linked to the O-deethylation of the substrate 
ethoayesorufin (otherwise known as EROD), while other researchen have linked CYP lA2 
induction to the O-demethyiation of the substrate methonyresorufin (otherwise known as 
MROD). Acetanilide 4hydroxylase (ACOH) has also been proposed as a potential enzymatic 
marker for CYP 1 A2 induction @eVito et al., 1996). Many researchers believe that conversion 
levels of these substrates cm be used as enymatic biomarkers to estimate the relative induction 
of the related CYP isozyme following an exposure event @eVito et al., 1 996). However, 
considerable uncertainty has been expressed in the scientific literature as to the selectivity and 
specificity of these substrates for one particular isozyme. This issue will be discussed in greater 
depth later in this paper. 
Use o f  Toric Equivalency Factors (TEFs) 
Biological species, including humans, are constantly exposed to complex mixtures of 
polyhalogenated aromatic hydrocarbons (PHAHs), such as PCDDs, PCDFs, and PCBs through a 
variety of routes of exposure. The composition of these complex mixtures of PHAHs can Vary 
dramatically in both the environment and living biota, with environmental and biologicai 
degradation (i.e., di ffering environmental fates of congenea with di fferent solubilities, 
volatilities, and rates of degradation/metabolism) playing a key role. According to their inherent 
physical-chexnical nature, each of these compounds is variably persistent, undergoes 
environmental transport, and can pre ferentiall y bioconcentrate in higher tropic levels of the food 
chah (Safe, 1998a). As a result, the congener profile of PHAH mixtures c m  change both 
spatiaily and temporally wiihin the environment, and are usually very different fiom the source 
mixtures originally released into the environment (Van den Berg et al., 1998). The complex 
nature of these PHAH mixtures complicates the risk assessment for humans, fish and wildlife. 
To allow nsk assessors to better evaluate their potential mixture-based toxicities, these 
compounds are typically classified as either "dioxin-like" or "nondioxin-like" (Bimbaum and 
DeVito, 1995). The dioxin-like compounds are grouped according to their common structure 
(i.e., coplanar and non-oriho substituted ammatic rings) and mechanisrn of action (Le., they 
induce their biochernical and toxicologicai effects by specific, high-af'fïnity binding to the Ah 
receptor) (DeVito et al., 2000; Van den Berg et al., 1998). 
in order to estimate the toxic potential of a mixture of such dioxin-like compounds and better 
facilitate their evaluation in hazard and nsk assessments, the scientific community bas developed 
a system of toxic equivalency factors (TEFs). The idea behind this is to produce a "sttandardized" 
estimate of potency of a specific chemical within a complex mixture of dioxin-like compounds, 
for which relatively iittle direct toxicological uIformation is available, based upon information on 
another structuraily-similar congener for which there is substantial toxicity data and an 
understanding of the inhereut mechanism of action (DtVito and Bimbaum, 1995; 
Birnbaum, 1999) or the same chemical under a different exposure scenario (e.g., individual 
versus mixtures, different species, different exposure biological exposure systems, etc.). TEFs 
for these PHAHs are typically calculated by determinhg the relative biological potency (REP) of 
a compound compared to that of the keystone chemical 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD), which is the most potent and best characterized of this "family>' of dioxin-like 
compounds. The TEF approach assumes that the effects of the individual compounds are strictly 
additive and proportional to their individual potencies and concentrations (Safe, 1998a). 
The concentration of each specific congener is multiplied by its correspondhg TEF value, and 
the resulting potency-weighted concentration values are sumrned to fom an expression of the 
mixture's overall toxic equivalency (TEQ) to TCDD. This value can then be emplo yed as a 
concentration of TCDD toxic equivalents (i.e., TCDD TEQ-equiv.) representing the overall 
toxicity of the assessed mixture. 
Chemicals included in this TEQ methodology must meet certain criteria. They rnust be: a) 
persistent; b) bioacurnulative, and; c) induce toxicities by binding to the Ah receptor (Van den 
Berg et al., 1998). Ultimately, the REP of a dioxin-like chemical is dependent upon both binding 
affinity to the Ah receptor and pharmacolcinetic pmperties of the chemical, when compared to 
TCDD (DeVito et al., 1997). In developing TEFs, the relative potency for each assessed 
chemical is evaluated using both in vitro and in vivo experirnental methodologies, cornparhg 
enzyme induction, thymic atrophy, imrnunotoxicity, teratogenicity, and several other related 
cnteria endpoints (e.g., reproduction, development, endocrine function, etc.) (DeVito and 
Bhbaum, 1995). 
The TEF approach k t  began to be introduced as a viable approach in the late 1980s to early 
1990s, with proposed sets of guidelines and TEF values provideci by various researchers and 
regdatory agencia. The f h t  international set of TEFs (1-TEFs) was presented and adopted after 
a 3-year study conducted by the North Atlantic Treaty Orgarüzation Cornmittee on the 
Chailmges of Modem Society (NATOKCMS). The most recent re-evaluation of the TEF 
scheme was conducted at an expert meeting organized by the World Health Organization and 
held in Stockholm, Sweden, on h n e  15-18, 1997. The objective of this meeting was to derive 
consensus TEFs for PCDDs, PCDFs, and dioxinlike PCBs for both humans, fish, and wildlife 
risk assessrnent (Van den Berg et al., 1998). 
Table 2.1, below, provides a list of previous TEF schemes, in addition to the cunent scientifically 
accepted set of TEF values for the dioxîn and h a n  congeners, proposed by WHO. 
Table 2.1 Various Toxic Equivalency Factors (TEFs) Schemes Recommended for 
Mammalian Risk Assessments (Van den Berg e# al., 1998). 
Conntner I-TEF ' CEPA Sale' WHO 
a Initial international scheme for TEF proposeà by Healîh and Welfare Canada (HWC) and the Ontario Ministry of the 
Environment (OMOE) and adoptcd by NATOICCMS (Boddington, 1988). 
Initial Canada-wide standard out lincd in the first CEPA Priority Substance List Assessmcnt Report (CEP A, 1990). 
Safe proposai a set of TEFs based on structure-activity fclationships, labratory enzyme induction studies, and acute 
and chronic in vivo studics (Safk, 1990). 
Set of d i a n  TEF values recornmended by the WHO expert panel (Van dm Berg et al., 1998). 
The TEF approach is not without a degree of uncertainty, and is still the subject of much debate 
in the scientific Iitera!ure. In addition to the large variance in assay snidies used to quanti@ the 
relative toxic potentials, uncertainties such as the potential impacts of differences in shape of the 
dose-response curve (e.g., questionable low-dose linearity of REP responses), species 
responsiveness, and the antagonistic non-additive role of certain non-dioxinlike PCBs al1 call 
into question the applicability of the TEF approach in the environmental nsk assessment process. 
Furthexmore, the high monetary and labour costs of detennining these TEQ values in 
environmental samples has limited the practicality of mounting extensive environmental 
monitoring prograrns for these compounds (Bunce, 1997). Despite al1 these uncertainties, the 
consensus fiom the WHO expert panel was that the additive TEF mode1 remains the most 
feasible risk assessment rnethodology for assessing complex mixtures of dioxin-like PHAHs 
(US EPA, 2000). 
2.4 Environmental Properties and Fate of Criteria Chemicals 
Polychlorinated dioxins and furans, as well as dioxin-like PCBs, have been found throughout the 
world in practically al1 media including air, soil, water, sediment, and biota. Their widespread 
occurrence is not unexpected given the nurnerous sources that have emitted these compounds 
into the atmosphere and the overall resistance of these chemicals to both abiotic and biotic 
transformation/degradation (U.S. EPA, 2000). While TCDD is commonly the primary focus of 
environmental nsk assessments due to its inherent toxicity, it is important to note that chernical 
analysis of environmental media and biotic receptoa have indicated that TCDD is a minor 
component (by mas) representing less than 1%, whereas the higher isomers typically account for 
over 99% of the total PCDD/F mass (Czuczwa and Hites, 1995; Rappe et al., 1987). 
The prirnary mechanisrn by which both PCBs and dioxins/furans are believed to enter the food 
chah is via atmospheric deposition. Consequently, they can be transportecl long distances in the 
atmosphere before they are deposited ont0 vegetation, soil, and water via dry and wet deposition. 
Deposition ont0 vegetation and subsequent ingestion of that plant material by animals is thought 
to be the primary mechanism by which these compounds enter and bioaccurnulate within the 
terrestrial food chah (U.S. EPA, 2000). M e r  direct deposition ont0 water bodies or indirectly 
via soil erosion and nuioff, PCBs and dioxinihuans (since they are relatively insoluble in water) 
tend to become incorporated into suspended partîculates and bottom sediments where they can 
enter the aquatic food chah (Deizell et al., 1994). 
These chemicals tend to be quite stable and persistent in the environment, particularly the higher 
chlorinated congeners. Available information indicates that while variability in the sampling 
data can be significant, the more highly chlonnated (tetra-CDDR and above) congeners of 
dioxins and furans and certain PCB congeners do accumulate in biota, as demonstrated by 
ambient levels detected in human breast mik and in animals at the top of the food chain (U.S. 
EPA, 2000; Delzell et al., 1994). The only environmentally significant transformation processes 
for these congeners are believed to be atmospheric photo-oxidation and photolysis of nonsorbed 
species in the gaseous phase or at the soil or water-air interface (U.S. EPA, 2000). As such, 
burial in-place or erosive movement of soil to nearby water bodies appean to be the predominant 
environmental fate (i.e., sink) of dioxins and furans sorbed to soils (U.S. EPA, 2000). 
Since PCB production was banned in the late 1970s, the major source of PCB exposure in the 
general environment appears to be the redistribution of PCB previously introduced into the 
environment as well as releases associated with the disposa1 of commercial PCB products. Such 
redistribution typically involves volatilisation fiom soil and water into the abnosphere with 
subsequent deposition and then re-vofatilization (WHO, 1993). As a result of this redistribution, 
PCBs can be ultimately ûansported over great distances. 
Chlorinated dioxins and h s  also appear to be widespread in the environment due to nurnerous 
chemical reactions occming during the combustion of naturally occurring and man-rnade 
organic materials in the presence of chlorine. Thus, dioxins and hu;ins can arise kom a diverse 
variety of combustion sources, including incineraton, chemical tar burnen, fossil-fueled power 
plants, vehicle mufliers, chimeys of wood buming stoveslfireplaces, cigarette smoke, backyard 
trash buniing, and even charcoal-broiled foods. Research has also demonstrated that nahirai 
combustion during forest tyes and slash bumuig are also contributors to the concentrations of 
these chemicals in the environment (Delzell et al., 1994). Given the ubiquitous nature of these 
chernicals in the environment, it is important to realize that d l  Canadians are exposed to 
background concentrations of PCBs, dioxins and furans to varying degrees. 
This bas particular importance when evaluating potential ambient concentrations of these POPs 
observed as part of a long-terni monitoring program, such as that in place at the SHTC. By 
evaluating concentrations prior to the operation of the facility and in localized regions outside the 
potential "area of influence" of the facility, a more accurate charactenzation of the actual facility 
impacts on the surrounding ecosystem can be achieved. 
While environmental fate modelling can play an important role in evaluating risk as part of a 
environmental risk assessment, given the similar physical-chernical properties of PCDD/F 
congeners, it is likely that the greatest arnount of uncertainty in a health assessment would be 
represented by toxicokinetic and toxicodynamic properties of the individual congenen. 
Exposure concentrations of chemicals in air, food, water, soi1 dust, or other media with which 
populations are in contact are the dose scales rnost commonly used when evaluating potential 
health effects of chemicals in the envuonment. However, extemal exposure is often only a rough 
estimate for intemal exposure delivered at the critical target in the body. An estimate of the 
intemal dose is a more appropriate measure for use in mechanism-based risk assessments 
(Bemillon and Bois, 2000). As such, biologically-based toxicological analyses, such as 
physiologically-based pharmacokinetic modelling, of key sentinel organisms (i.e., a vole) can 
play a vital role in evaluating health risks as part of an overall environmental health risk 
assessment process. 
3.0 PBYSIOLOGICALLY-BASED PHARMACOIUNETIC (PBPK) MODELLING OF 
POLYCHLORINATED DIOXINS AND FURANS 
3.1 Introduction 
The uptake and disposition of chemicals by living organisms, notably humans, has long been one 
ofprimary concem to phannacological and toxicological research. The study of the dispersion of 
chernicals in animal bodies entails the field ofphannacokineiics. Pharmacokinetics combines 
the words pharmocology and kitletics, and studies the rates of absorption, distribution, 
metabolism, and elimination of chemicals and metabolites in biological systems (Wen et al., 
1999). The closely related subject of pharmacokinetic modelling is the process of developing 
mathematical descriptions for these critical flow rates. As such, pharmacokinetic modelling can 
be best descnbed as the process of developing mathematical descriptions for absorption, 
distribution, metabolism, and excretion of chemicals in biota (Knshnan and Andersen, 1994). 
There are two comrnonly used types of pharmacokinetic models: a) the classical (empincal) 
model, and b) physiologically-based (PBPK) pharmacokinetic models. With the former, an 
unique set of experimentally-derived kinetic data are used to statistically fit an unique (non- 
generalizable) model and determine the value of each rate constants. In the case of the PBPK 
models, the description of the distribution relies on standardized physiological parameten which 
are appropriate values detemined a priori, independently of the kinetic data. Even with PBPK 
models, however, a few " fitted" parameters, usuall y the ones describing metaboii sm, are adjusted 
using statistical goodness-of-fit criteria to optimize the model parameters, until an acceptable fit 
to the data is obtained. However, as PBPK models use standardized physiological parameters, 
they can presurnabl y serve as  appropriate vehicles for inter-route and interspecies extrapolation 
(Wwdniff et al., 1992). 
To fully understand the potential implications and uses of pharmacokinetic modelling on the 
assessrnent of human health risks associated with exposures to persistent organic pollutants, one 
must first have an adequate understanding of the basis behind these forms of pharmacokinetic 
researc h methodologies. While the use of classical pharmacokinetic modelling is of some 
interest in addressing this goal, the current discussion paper will focus on the PBPK methodology 
as the majority of recent toxicological research into POPs has been primarily concentrated on the 
development of more efficient and accurate physiologically-based phamiacokinetic models. 
Physiologically based phamiacokinetic (PBPK) modelling refen to the development of 
mathematical descriptions of the uptake and disposition of chernicals based on quantitative 
intmelationships arnong the critical biological factors and systems within a specific test species. 
Perhaps Andersen (1 994) provided one of the best overviews of the area when he described 
PBPK models as an "... attempt to provide both a realistic anatomic description of the animal to 
which a drug or toxic chemical has been administered and a biologically accurate representation 
of the physiological pathways for chernical storage, metabolism, and elimination in the animal." 
As such, the ultimate aim of using PBPK modelling in risk assessment is to accurately provide a 
measure of dose which better represents the interna1 tissue dose (a phamiacokinetic measure) or 
the "biologically effective doseT' (a phmacodynarnic measure) which causally results in the 
potentially toxic outcome (Clewell Ui, 1995). 
3.2 Ovemew of PBPK Modelling 
PBPK modelling has been used for more than 70 years to evaluate the disposition (i.e., 
absorption, distribution, rnetabolism, and elimination) of phannaceuticals and other foreign 
substances (i.e., xenobiotics) within living organisms. Research in this area began in 1924 with 
studies of volatile anaesthetics, using fairly simple models that evaluated the impact of 
ventilation, blood flow and b1ood:air solubilities on chernical uptake within the body (Aarons et 
al., 1 999). PBPK models have since evolved over the past nearly 80 years to the current states f- 
the-art tools, capable of evaluating chemical disposition within complex, multi-cornpartmentai 
systems, and incorporating many aspects involving the pharmacodynamies of particula. 
compounds. 
As noted previously, the ultimate aim of using PBPK modelling in risk assessment is to provide a 
measurement of dose which better reflects the internai dose (deliverd to target and non-target 
organs) or the "biologicaily effective dose" which is causaily related to the ultimate toxic 
outcorne. As such, PBPK modelling attempts to describe the relationship between the extemal 
measures of applied dose (e.g., amount admuiistered or concentration in food, water, or air) and 
measures of intemal dose or biologically effective dose (e.g., arnount metabolized or 
concentration in the tissue displaying the toxic response), using as realistic a description of 
mammalian physiology and biochemistry as is necessary and feasible (Figure 3.1). PBPK rnodels 
differ from the more iraditional empirical cornpartmental approaches in that the model 
compartments are based largely on the acnüil physiology and anatomy of the test species 
(Andersen, 1994). For example, in PBPK rnodels the compartments represent actual tissues, or 
groupings of tissues, with realistic weights and blood flows denved from the literature, or 
determined through experirnental study. Thus nonlinear biological processes (i.e., saturable 
systems, complex receptor binding arrangements, etc.) can be incorporated into the model and 
evaluations of the potential interactions between the chernical and animal systems c m  be 
attempted over a wide range of conditions (Clewell m, 1995). 
At their core, PBPK models envisage the organism as a network of compartments rqresenting 
individual organs or tissue groups intercomected by the arterial and venous blood flow. Uptake, 
distribution, metabolism, and excretion in a PBPK model are described in ternis of quantitative 
interrelationships among certain physiological, physicochemical, and biochernical parameters. 
Intercompartmental transfer rate constants are developed based upon blood flow rates, tissue to 
blood partition coefficients, and tissue volumes for that particular test species (Krewski et al., 
1995; Mason and Wilson, 1999). 
Figure 3.1 Overview of sequeoce of events foUowiag chemical exposure 
(Hoang, 1995) 
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in general, even the most minimal PBPK model (i e., for aqueous or lipid soluble substances) 
will generally contain at l es t  three compartments: 1) rapidly perfused tissues, 2) slowly perfùsed 
tissues, and 3) fat. These tissue groupings are chosen by virtue of characteristic differences in 
pemision-to-volume ratio and chemical composition; properties which jointly determine the rate 
and magnitude of quilibration between chemicais transported in the blood and those isolated in 
tissues. (Bailer and Dankovic, 1997). Absorption of chemicais in the environmental medium 
may be via pulmonary, derrnal, or oral routes. The amount absorbed per unit tirne can either be 
calculated within the model, or the change in chemical concentration in blood or the tissue 
representing the portal of entry may be simulated using appropriate equations. The chemical in 
the arterial supply binds to blood components ancilor enters the various tissue comparûnents 
where it may be dissolved in lipid and water components and be bound to tissue mano- 
molecules. The rate of change in the amount of chemical in each tissue cornpartment is 
descnbed with mass balance differential equations (MBDEs), defined and solved by numencal 
methods . 
In the case of metabolizing tissues, these MBDEs represent appropriate mathematical 
descriptions of the processes involved. This is typically achieved by modifyuig the basic 
differential equation by including ternis describing either a first order clearance process O<,) or 
saturable metabolism characterized by Michaelis-Menten type enzyme kinetics (involving Y, 
and V,). As with other model parameters, these constants can be either obtained fiom the 
scientific literature, or estimated using either in vitro (e.g., via1 equilibration technique with 
homogenates) or in vivo (e.g., measuring gas uptake or exhalation rates of animals in an exposure 
chamber) techniques (Leung, 1993). 
Xenobiotic metabolism or biotransformation is the pnnciple process that detemines the fate of 
most persistent organic pollutants (POPs) in the body. A primary characteristic of phase 1 (e.g., 
cytochrome P450 enzymes) and phase 2 (e.g., glucuronidation, sulfatation, etc.) metabolism is 
often to render lipophilic compounds more water soluble, which in most cases permits their rapid 
excretion fiom the body through urine and bile. Lipophilic compounds, such as POPs, are 
readily absorbed into the body and have a greater potential for bioaccumulation. Thus, the ability 
of the organism to clear these lipophilic compounds via biotransformation reactions influences 
the apparent toxicity displayed by these POPs by detemining the delivered dose at critical target 
organs and tissues (Larsen, 1995). It is also important to note that the bioaccumulative nature of 
these compounds typically results in non-linearity in the dose-response relationship. This is ofien 
referred to as the "dose-dependency" of the compound as a fùnction of the concentration, 
duration, and pattern of long-term exposure. As such, multicompartmental mas-balance PBPK 
models allow for the integrated use of saturable enzyme kinetics (Le., Michaelis-Menton or Hill) 
to better describe disposition, metabolism and excretion kinetics of these compounds. 
Finally, the concentration of chernical excreted in biological tluids (e.g., exhaled air, urine, etc.) 
can be calculated using algebraic or di fferential equations (Haddad and Krishnan, 1 998; Krewski 
et al., 1995; Mason and Wilson, 1999). The key consideration when constnicting such a model 
is to maintain the correct mass balance within each tissue cornpartment as well as the entire 
model by carefully accounting for the input and output mass flows of the chernical in various 
cornpartments. 
PBPK models are primarily limited by the availability of congener- and species-specific data that 
accurately represent the dose- and time-dependent disposition of TCDD and related PHAH 
compounds. Thus, congener- and species-specific rate constants for metabolism and excretion 
are considered essential in developing accurate PBPK models for these compounds in a given 
target species. 
Typically, the modelling of TCDD disposition within an organism by a PBPK mode1 system cm 
be divided into two specific methodologies: i) steady-state (time-dependent), and; ii) 
equilibrium-based (time-independent). Both models assume an existing PBPK methodological 
Mework ,  and allow for the movement of TCDD between the various model compartment 
groups. However, models incorporating equilibriurn-based kinetics assume that a stable 
concentration relationship exists between al1 physiological compartments, regardless of time aAer 
exposure. As such, the chemical concentrations in each compartment will not change over time, 
once this equilibrium condition has been reached. Steady-state models, on the other hand, 
assume that the influx and outflow of chemical will be variable over time, and that chemical 
concentrations within the various cornpartmental groups will be govemed by rate and mass 
transport kinetics of the individual compartments. Each type of model design has its advantages 
and disadvantages, depending on the desired modelling application, and will be discussed in 
fùrther depth within this study. 
A complete literature review of the histoncal up to most ment development of PBPK models for 
dioxins and hirans was conducted for the current research project. This review will be used as 
the bais  of the current model developmemt and application to address the key objectives for this 
research projec t. 
3.3 Phy siologicaUy-Basd Pharmacokinetic Modelling of Dioxin Exposu res 
Over the past 20 years, a variety of methodological approaches have been used to describe the 
pharmacokinetic behaviour of PCDDs and dioxin-like compounds in mamrnalian biological 
systems. These approaches have mirrored the continuing refuiements in dosimetry modelling 
associated with increasing sophistication both in mathematical modelling techniques, as well as 
the methodological understanding by the scientific community of the modes of action of 
PCDDRs within biological systems (Wang et al., 1997a,b; Andersen et of., 1997a). 
The early PBPK models evaiuated the disposition of PCDD/Fs (and PCBs) by taking into 
account the role of lipid solubility in tissue uptake. Unfortunately, these earlier models were 
unable to explain the greater concentration of the PCDDFs in the liver than in the adipose tissue 
at high doses, as well as the increase of the compounds in the liver over tirne (Bimbaum et al., 
1980; Bimbaum, 1986; Wang et al., 1 997). TCDD model tissue concentration ratios, especially 
those present in the liver cornpartment, were demonstrated to be complexly reiated to both the 
intrinsic partitionhg and to the presence of specific cytosolic and microsomal TCDD-binding 
proteins. This discrepancy led to the development of the next generation of PCDD/F PBPK 
models, bas4  upon the hypothesis of an inducible hepatic protein responsible for hepatic 
sequestration of the PCDD/F compounds (Leung et al., 1988, 1 WOa,b; Andersen et al., 1993). 
These models were extended with the inclusion of hepatic binding proteins in response to 
interactions of TCDD, the Ah receptor, and the correspondhg dioxin response elements @RE) 
on the DNA (Andersen et al., 1993). These mode1 methodologies continued to evolve through 
the early and into the late 1990s, M e r  delineating the role of hepatic binding on the absorption, 
distribution, and excretion O f dioxin-like compounds within biological systems. 
A review of the scientific literature has indicated that the current statesf-the-art equilibriurn- 
based PBPK model for dioxins and furans (Wang et al., 1997a) was established based on the 
anatomy and preliminary analysis of t h e  course tissue distribution of TCDD in female Sprague- 
Dawley rats. Eight compartments (see Figure 3.1) were chosen based upon TCDD-iuduced 
response (Bhbaum, 1994) and experimental data, and the model is largely similar in structure to 
the predecessor Andersen et al. (1993) and Leung et al. (1990a,b) versions. The Wang et al. 
(1997) PBPK mode1 for dioxin incorporates four main de tdnants :  i) a high fatîblwd partition 
coefficient; ii) specific, inducible binding in the liver; iii) dihion-limited tissue distribution, 
and; iv) first-order biliary excretion/elirnination of TCDD. This model was developed with the 
time course tissue distribution data obtained following a single oral dose of 10 pg ['H]TCDD/kg 
to female Sprague-Dawley rats, and later validated using other dosing regimes (i.e., 0.00 1,O. 1. 
0.3, 1 .O, 10, and 30 pg [3H]TCDD/kg). Tissue distribution information at early time points was 
gathered to allow for better approximation of some unique parameters related to mass transfer, 
such as capillarytissue permeability. The interaction between TCDD and the Ah receptor and 
the binding of TCDD to hepatic induced protein (i.e., CYPIAî) was also based on a time senes 
analyses, and previous work done in this area. As with previous models, hepatic induction of 
CYP 1 A2 was assumed to be a direct result of the formation of a TCDD-Ah receptor-DNA 
complex (Andersen et al., 1993). The Hill equation was used to describe the induction dose- 
response interaction between the TCDD-Ah receptor complex with DRE binding sites on DNA. 
The model described the change of CYPI A2 with time based upon a stimulation process 
proposed by Dayneka et al. (1 993), and the process goveming quantification of TCDD 
specifically bound to either the Ah receptor or CYPI A2 was simplifieci using a Michaelis- 
Menton saturable binding kinetics equation (Lauffenburg and Lindemann, 1993). 
The Hill equation is commonly used for modelling ligand-receptor binding data and allows for 
both sigrnoidal and proportional response below a given maximal induction level (Portier et al., 
1993). In general, standard Michaelis-Menten kinetics can be thought of as one specific type of 
Hill model, where the Hill exponent is estimated to be 1. In the case of CWlA2, a Hill 
exponent of 0.5 indicates a strong degree of negative cooperativity in binding. 
Figure 3.2 A schemaüc representation of a steady-state based PBPK model for 
TCDD (Wang et al., 1997) 
**.................. '............-.. (Co) f . . . . . . . . . . . . . . . . Ks, Ms, 
Lymphatic ilow a * K ~ i  ML., 
Typically, a PBPK model includes a large number of equations and parameters. To obtain the 
unique value of each parameter, model simplification is important. In addition, the appropriate 
approach for parameter estimation and the experirnental design to obtain the complete time 
course data for parameter estimation are critical (Wang et ai., 1997). As noted previously, 
species differences in response are largely due to differences in pharmacokinetics and 
biotransformation. However, mamrnals, including primates, have similar anatomy, physiology, 
biochemistry and cellular structure. As numerous research shidies have noted that organ size and 
physiological Cunction can be correlated with the body weight of the test species (Rhodes et al., 
1993), allometnc scaling by weight is commonly employed to extrapolate from one biological 
system to another. 
The primary means by which xenobiotic chemicals are transported throughout the body is via the 
blood. Chemicals in blood typically partition into fiee and protein bound fractions, with the fiee 
hction typically driving the movement of the chemical into tissue via passive transport. In 
basic PBPK models, the transport of these chemicals between blood and tissues is assumed to be 
perjiision- orflow-limited. This means that barriers to transport of the chemical between the 
blood and tissue are negligible, and that equilibriurn between the fiee and bound fractions in 
blood and tissue is rapid (Andersen, 1994; Bailer and Dankovic, 1997). As such, concentrations 
of chemicals in specific tissue groups and the venous blood exiting the tissue are assurned to be 
at equilibrium. The flow-limited assumption is usually employed to simpli fy the PBPK model 
due to the lack of information on membrane transfer, and is typically appropriate for lipophilic or 
low molecular weight compounds, which easily partition or difise through ce11 membranes. in 
the current model, the lungs and the spleen are considered flow-limited tissue compartments due 
to the similarity of their time course concentration profiles to that of blood (Wang et al., 1997). 
Other tissue compartments demonstrate what is tenned membrane-limited behaviour in which 
membrane pemieability is the dominant mass transfer factor in tissue uptake. Under these 
conditions, equilibrium between the free and bound fiactions in blood and tissue is much slower 
and entirely dependent on the ability of the chemical to penetrate tissue membranes in the 
cornpartment. In the current model, compartments representing the kidneys, adipose tissue, and 
the rest of the body were considered to be membrane-limited. 
A third fom of cornpartmental mass transfer behaviour, termed membrane-injluenced, is also 
attributed to certain tissue groups within this model. The membrane-infiuenced condition is a 
more generai case than either flow-limited or membrane-limited condition, in which both blood 
flow (perfusion) rate and membrane pemieability contribute to tissue uptake. in the current 
model, the skin and liver tissue groups were considered to be membrane-influenced 
compartments (Wang et al., 1997). 
Some of the physiological data, for a female Sprague-Dawley rat, onginally used in this 
equilibrium-based mode1 are described below in Table 3.1. 
Table 3.1 Sprrgue-Dawley Rat Pbysiological Parameten used in TCDD Equiübrium- 
Based PBPK Model (Wang et al., 1997). 
Mode1 Parameters Abbrev. Physiolqicd ~ u i m c t e r  ~stinuîiw Parameten 
Bo& weight (g) * 1 250 Measured 
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PAF PAdQ, = 0.08 Fitted to experimental data 
PA, PAK/QK = 0-0 1 
P A ,  P&/Qs = 0.09 
PA, PAJQ, = 0.03 
Liver PA,, PA, ;/QI; = 0.35 
Table 3.1 Sprague-Dawley Rat Physiological Parameten u s d  in TCDD Equilibrium- 
Based PBPK Model (Wang et ai., 1997). 
Madel Parameten Abbrev. Physia'gicrl  aram me ter ~ s t i m t i o n  Parameters 
Eqirilibrium distribution ratio 
Adipose tissue 
Kidney 
S b  




Ah receptor Inel  (nM) 
Adipose thsue 
Kidne y 
S b  
Rest of the body 
Liver 
Spleen 





Basal induction rate 
Maximum induction fold 
Degradation rate 
TCDD-Ah-DNA interaction constant 
Hill coefficient 
Holding time 
Oral absorpri'on ( l h )  





Fitted to cxperirnental data 
Fitted to experimental &ta 
Gasiewicz and Rucci, t 984; 
Safi. 1988 
Kedderis et al., 199 1 
Webber et al., 1993 
Adjusted 
Adjustcd based on 
Tritschcr et al., 1992 
Fitted 
Fitted 
Roth et al., 1993 
Fined to experimental data 
Estimated f?om Allen et al., 
1975 and Dili'berto et al., 1996 
Note: '-' indicates the paraaieter is not sensitive to tissue distribution 
Recently, an alternative equilibrium-based model has been describeci by Evans and Andersen 
(2000). The goal of this particular model was to restructure the available PBPK models in order 
to calculate TCDD dosedependencies in terms of the total dose of TCDD in the animal. The 
authon attempted to achieve this objective by calcuiating a hction of administered dose in liver 
or liver-to-fat concentration ratios for multiple doses to produce a typical dose-response 
representation of these variables. The PBPK model used to generate these dose-response 
representations was based on an earlier TCDD mode1 for the rat descnbed by Andersen et al. 
(1993), adapted for what was termed "steady-state" conditions (based upon methodologies 
presented in Canier et al., 1995). It is questionable as to whether this methodology can be 
correctly specified as "steady-state" given the lack of time-dependencies within the model. 
The equilibrium-based model was represented by two compartments (liver and fat) connected by 
a pooling blood supply (see Figure 3.2). As with the Wang et al. (1 997) methodology, the 
induction of CYPlA2 was described through the formation of the Ah-TCDD cornplex and its 
binding to DNA using the Hill equation. Transport of TCDD into the cell by dimision (i.e., 
application of a pemeability coefficient) was assumed to be very rapid and thus not included to 
maintain quasi "steady-state" conditions. The model methodology used assumed that al1 body 
stores of TCDD were in fat and liver, and as the model was at equilibrium, al1 blood 
concentrations leaving each compartment and re-entering as artenal blood had achieved the same 
level (i.e., C, = CJ. 
Figure 3.3 A schematic representation of an equiiibrium-based model for 
TCDD (Evans and Andersen, 2000) 
Liver Corn partment 
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Some of the physiological data, for a femde Sprague-Dawley rat, used in this equilibnum-based 
model are described below in Table 3.2. 
Table 3.2 Sprague-Dawley Rat Physiological Parameters used in TCDD SteadyState 
PBPK Model (Evans and Andersen, 2000). 
Model Parameters Abbrev. physio'aca' Parameter Estimation Parameters 
Liver-to-bld partition coefficient 
Fat-to-blood partition coefficient 
Percent liver/body volume 
Percent fatibody volume 
Ah receptor availability 
Ah receptor binding constant 
CYP 1 A2 basal levels 
CYP 1 A2 induction factor 















Andersen et al., 1 993 
Andersen et al., 1993 






Ah receptor complex and DNA receptor Kd 0.05 nM Estimated 
3.2 Evaluation of Uncertainty Inhemt  in PBPK Model Methodologies 
3.2.1 ûverview of Model Uncerrointy and Variobifity 
The evolution of physiologically based phmacokinetic (PBPK) models for the assessment of 
risk related to persistent organic pollutants has not been restricted to advancements in the 
understanding of underlying physiological processes (e.g., hepatic protein binding and 
sequestration within the liver). Considerable work has also been invested in establishing the 
inherent uncertainties present within a given model, and the sensitivity of each contribuhg 
physiological parameter. Since al1 empincal data have inherent errors, any model will have a 
certain degree of uncertainty associated with it. As Lao T m  aptly stated in The Tau, '?O know 
one's ignorance is the best part of knowledge", and the potential impacts of uncertainty can have 
significant implications on the true validity of any environmental nsk assessment model. 
Two factors play a key role when evaluating the validating and applicability of a model and its 
results to a specific risk assessrnent scenario: i) uncertainty, and ii) variability. Uncertainty refers 
to a lack of knowledge about specific factors, parameten, or models. Regdatory agencies, such 
as the U.S. EPA, typically classi@ uncertainty based upon a framework presented by Dr. Adam 
Finkle of OSHA. In addition to natural variability, this framework recognizes three different 
types of uncertainty: i) parameter uncertainty, ii) model uncertainty, and iii) decision mle 
uncertainty. Parameter uncertainty is the uncertainty associated with the model inputs used in a 
calculation (i.e., measurement errors, sampling errors, or systematic errors). Model uncertainty 
results fiom the effec t of simplifymg nature for use in models and the associated uncertainty (i. e., 
uncertainty due to necessary simplification of real-world process, mis-specification of the model 
structure, misuse of the model, or use of inappropriate smgatdpararneter variables). Finally, 
decision rule uncertainty addresses disagreements or poor specification of social objectives (Le., 
descriptive errors, aggregation mors, errors in professionai judgernent, or incomplete analysis) 
(U.S. EPA, 1991). The uncertainty inherent within a model or its parameters can be potentially 
reduced by more detailed study of the parameters or processes involved. 
Variability, on the other hand, refers to observeci differences attributable to hue heterogeneity or 
diversity in a population or exposure pararneter. Sources of variability are generally viewed the 
result of natural random processes, and can arise fiom environmentai or genetic differences 
among the species being evaluated (i.e., natural variation in the bodyweights of sampled voles) 
(U.S. EPA, 1997). It is important to note that while M e r  study can better charactenze the 
variability within a given population, this type of uncertainty is usually not reducible by M e r  
measurement or study. 
Phamacokinetic variability can have a large influence on the toxicity of a chemical by aecting 
the extent to which the chemical is absorbed, distributed, metabolized, and excreted. One of the 
main advantages of using PBPK models to describe pharmacokinetic variability is that 
parameters developed for these models are physiologically meaningful, and can in principle be 
estimated by independent methods. Generally, more information is available on chemical 
independent PBPK model parameten (such as blood flows and tissue volume) than on chemical 
specific parameters (such as partition coeficients and metabolic constants). Despite the best 
efforts, there will always be some uncertainty associated with the values of model parameters for 
an individual due to random error (or systematic bias) in the data used to estimate the parameter, 
intra-individual variability, and assumptions that are inherent in any model of physical processes 
(Krewski et al., 1 995; Fredenc k, 1 995). Furthemore, inter-individual variability among 
individuals in a population will ultimately lead to a distribution of values for a given PBPK 
model pararneter, making the selection of a '%est9' singular value a difficult task. 
3.2.2 Application of Sensitivity Analjses 
Given this variability and uncertainty withh the model parameters, systematic testing of the 
effects of these parameters on the model predictions within the PBPK mode1 should be also be 
conducted to validate the developed methodology. This systematic testing is typically termeci 
sensi t~ty or varïabiliîy analysis. Sensitivity generally refers to the variation in output of a 
mathematical model with respect to changes in the values of the model's input. A sensitivity 
analysis typically attempts to provide a mathematical characterization of the model's parameter 
values (i.e., parameter uncertainty) and input assumptions (i.e., mode1 uncertainty) with respect 
to the magnitude of their contribution to the overall model output variability or uncertainty. It 
also attempts to characterize the magnitude of prediction error associated with model parameter 
enors and the extent to which model structure affects the reiationship between parameter and 
output e m  (U.S. EPA, 1997; Clewell et al., 1994). As such, a sensitivity analysis is able io 
focus on changes in model predictions due to changes in specific model parameters, and evaluate 
the contribution that the variability of each specific parameter has on the overall calculation of 
the chernical's intemal dose within a specific tissue. Based upon this information, m e r  
research efforts can be focused on the evaluation of the parameten which most strongly impact 
upon the model output. This process would also assist in the pnontization of data-gathering 
efforts to venQ experimentally derived model parameters during future sarnpling, and m e r  
reduce model uncertainty (Clewell et al., 1 994). 
Certain caveats must be expressed when conducting uncertainty and sensitivity analyses on 
PBPK model methodologies. Many researchers have indicated that models which incorporate 
nonlinear responses (i.e,, receptor-binding kinetics) may be sensitive to certain parameters during 
low dose simulations, but sensitive to other parameters during hi& dose simulations (i.e., 
parameter sensitivity may be dose-dependent) (Frederick, 1995). As such, it is important to 
conduct a carefùl and complete evaluation of the model response over a wide range of 
hypothetical conditions (e.g., doses) to ensure the overall effectiveness of the sensitivity analysis. 
3.2.3 Techniques for the Evaluation of Uncertainty and Sensitivity 
The general pupose of sensitivity and u n c e h t y  analysis, as applied to PBPK models, is to 
evaluate the degree of uncertainty in model predictions of tissue-delivered doses induced by 
uncertainty in the model parameters (Krewski et al., 1995). The results of the sensitivity and 
uncertainty analyses can also be used to estimate the potential impact of proceeding with a risk 
assessrnent without filling specific data gaps (Clewell DI, 1995). The methods most fiequently 
used for determining the uncertainty and sensitivity of model parameten include Monte Carlo 
simulation, response surfixe analysis, and univariate sensitivity techniques (Krewski et al., 
1995). ûther techniques, such as the application of numerical Bayesian methods for reducing 
uncertainty, c m  also be applied. 
Briefly, Monte Car10 simulations involve establishg a probabiliiy distribution for each of the 
model input parameters, based upon available experimentdobservation data or incorporating 
expert opinion ( ie . ,  Bayesian pnors). The uncertainty distributions of parameter estimates are 
then derived based upon their individual probability distributions (e.g., uniform, normal, log- 
normal, triangular, etc.), and used to calculate the outcome variables based upon the model 
methodology. This sampling process is repeated a large number of times, tenned model 
iterations, until a statistically significant probability distribution for the desired model output has 
been created. Latin Hypercube sampling methodology is also one widely used variant of the 
standard Monte Carlo method. In this method, the typical range of probable values for each of 
the uncertain input variables is divided into ordered segments of equal probability. This allows 
for more "efficient" sampling of each parameter once from each of its possible segments, and 
ensures that the random samples are generated from al1 the ranges of possible values, thus giving 
insight into the extremes of the probability distributions of the outputs (Morgan and Henrion, 
1990). The main disadvantage to this methodology is that it greatly increases the computational 
and computer memory requirements in conducting the model nuis. 
3.2.4 Application of Validation to Environmental Models 
The ultimate goal of pharmacokinetic modelling is preâiction, and model validation is a 
necessary step to ensure the overall predictive quality with respect to the model outcornes. As 
such, the potential impacts of uncertainty within the model can only be adequately addressed 
through a process of model validation. The purpose of the validation process is to detennine 
whether al1 parameten and model forms that are essential for describing the modelled 
pharmacokinetic behaviour have been adequately identified and characterized. One approach 
used by many researchen is to compare the model output with the experimental observations. 
The greater the commonality between the simulateci and experirnental data, the greater the 
confidence one will have in the overall mode1 (assuming the data used for validating the results is 
not the same as that used to parameterize the model). The standanl statistical techniques 
kequently used for the validation of modets include: tests of means, analysis of variance, 
goodness-o' fit testing, regression and correlation analysis, Cm k' s statistics, confidence interval 
comparisons, the chi-squared test, the Kolmogorov-Smimov test, factor analysis, and a variety of 
nonparametric tests (Wen et al., 1999). However, this process cm be made more difficult due to 
a lack of sufficient data (either experirnental or modelled), resulting in insuficient predictive 
baselines to properly evaluate the underlying scientific hypotheses. While model validation is a 
partly subjective process and there are no absolute criteria for model "conectnesd', it is 
important to use standardized cnteria to determine the appropriateness of the model (Wen et al., 
1999). 
The following are other cntena by which one can evaluate the overall appropriateness of the 
model in question: 
Generalizability of the model (i.e., not locked into one specific application or use due to 
"custom" fitting parameters); 
Intemal consistency (e-g., blood volumes in each compartment add up to the total organisrn- 
based blood volume; Kd values for enzymatic activity the same in al1 compartments); 
Computational correctness (i.e., model does not coniain any mathematical mis-specifications 
or oversights); 
Mode1 form is correct (i.e., overall structure and equations, regardless of parameter values, 
accurately reflects model objectives); 
Robustness to changing input parameters (i.e., model does not break d o m  under differing 
input and exposure scenarios); 
Sensitivity to changing input parameters (i.e., changes to key input parameters results in 
biologically appropriate changes to model outcomes); 
Biological realism and relevance (i.e, correctly specifies or approximates the underlying 
biological mechanism); 
Agreement between different models characterizing the same process (i.e., does the 
equilibnum-based model duplicate the results produced by the steady-state model, under 
similar conditions); 
Heuristic value (Le., provides usable indicator variables, such as receptor occupancy, 
induction fold, Liver-to-fat ratio, etc.); 
Capacity to deal with dose-dependent biological responses; 
Parsimmy in the model (i.e., the model is not over-pararneterized or unduly cornplex); 
Absence of numerical (computational) arti facts (i. e., outcome oscillations at low dose), and; 
Usehl in extrapolations to other conditions (e.g., route, dose, dose-rate, etc.). 
4.0 METEODOLOGY 
The following methodological approaches were used to attempt to answer the individual 
questions raised in the objectives of the current research project. 
4.1 Gathering of Field Monitoring Data 
4.1.1 Objective Ovrwiew 
One objective of the current research project is to compare estimated whole body TCDD 
concentrations for a theoretical vole receptor to those measured as part of the long-tenn 
environmental monitoring programme conducted at the SHTC. Thus, the environmental 
concentrations of PCDDR-s detected in sampled red-backed voles, as well as plant species such 
as Labrador tea and moss, were gathered from the SHTC environmental monitoring database for 
the key monitoring sites with the highest detected concentrations (Le., sites 1 1, 107, and 1 14). 
For the cument research, environmental ambient concentrations were represented by those 
concentrations detected on the leaves of the Labrador tea or moss. Concentrations fiom site 107 
(closest to the facility) were used as the primary source, with data fiom the other near-site 
sarnpling locations (e.g., sites 1 1 or 1 14) used for the purposes of cross-validation and 
comparative analysis. To maximize potential ambient environmental PCDD/F concentrations, 
temporal data sampled just prior and following the accidental release event in October 1996 were 
selected. 
4.1.2 Enviconmentai SampIing of PCDD/F Concenîrations 
Two primary objectives of the SHTC wildlife monitoring program were to monitor the 
concentrations in the tissues of red-backed voles of various chernicals in emissions h m  the 
Treatment Centre, and to monitor the demographic characteristics of the red-backed vole (e.g. 
abundance. sex ratios. reproduction) in the vicinity of the Treetment Centre (Westworth, 1998). 
Voles sacrificed for the analysis of chernicals in theu body tissues were collected ihrough the use 
of saap traps by SHTC contractors. They were placed in sealed glass jars, which were labelled 
with the following information: species, date of capture, location, specimen number, sex and 
body weight. The collected sarnples were then stored on ice until sent to an accredited laboratory 
for detailed congener-specific chernical analyses of their whole-body tissues (Westworth, 1998). 
Further details of the sarnpling program, as well as a field study conducted by this author 
involving a statistical evaluation of potential impacts of the SHTC on sumiundhg vole 
populations, can be found in a research practicum conducted by this author (Ferguson, 1999). 
4.1.3 Cdloron and Selection of SHTC Monitoting Data 
Al1 sampling data used in the current project were obtained fkom the Swan Hills Treatment 
Centre environmental monitoring database, developed by CanTox Inc. for BOVAR Waste 
Management Limited, and later supplemented as part of this research project. The current 
research database contains sampling analytical results on a chernical-specific basis Cor al1 
analyzed environmental media from June 1990 to February 1998. 
Distribution of Bodyweights for SHTC-Sampld Voles 
A variety of external physiological parameters were recorded as part of the ongoing SHTC 
biological monitoring program, including species, sex, bodyweight, reproductive condition and 
general external condition (Wesîworth, 1998). Table 4.1 provides an overview of bodyweights 
of the red-backed voles sampled beîween June 1995 and 1998. 
Tabk 4.1 Ovewiew of Red-Backed Voles Bodyweighb Sampled as part of the SHTC 
Monitoring Program between June 1995 and June1998. 
-- - 
Body Weights' (gram) 
Sampllng Time Male F e d e  Combinai 
June 1995 21.8 13.7 (n=97) 22.3 î 5.5 (n=70) 22.0 * 4.5 (n=167) 
Scptcmber 1995 16.1 * 3.0 (n=96) 15.4i3.9 (n=157) 15.6 * 3.6 (n=253) 
June 1996 20.8 I 2.7 (n=38) 2 1.7 * 4.5 (n=32) 21.2 * 3.6 (n=70) 
September 1996 14.4 I 5.0 (n=54) 14.8 k 5.2 (n=48) 14.6 5.1 (n=102) 
June 1997 21.6 * 2.3 (n=35) 25.3 2-7 (n=23) 23.1 * 3.1 (n=58) 
September 1997 16.1 3.0 (n=146) 16.5 * 3.6 (n= 122) 16.3 I 3.3 (n=268) 
June 1998 24.8 * 3.8 (n=lOl) 26.3 k 5.9 (n=82) 25.5 * 4.9 (n=183) 
' lncluda tmpped vola h m  juvcnilc to adult life-stages. 
No detailed bodyweights were available for Febniary monitoring, however, bodyweights were 
typically between 8 and 12 gram @. Skinner, Westworth and Associates, persona1 
communication). This is in line with the observations and conclusions in the scientific literature 
indicating that voles substantially decrease their body mass during the rnonths preceding winter 
@ark and Zucker, 1986). 
Measured Congener-Specinc PCDD/F Concentrations 
To achieve the aims of the current research project, dioxin and furan concentrations fiom various 
biological specia were evaluated at three sarnpling locations directly surrounding the facility 
(Le., sites 1 1, 107, and 1 14). A detailed map providing specific plot locations is provided in 
Figure 2.3. These three sites have the largest amount of historical dioxin/furan congener-specific 
data for the prirnary biological monitoring species (i.e., voles, Labrador tea, and moss), when 
compared to other monitoring programme sampling locations. Tables 4.2 through 4.4 
demonstrate the available histoncal sampling data on voles, Labraâor tea, and moss at these sites, 
respectively. 
Table 4.2 Available PCDDlF Congener-Specific Data in Vole Receptors for SpeciTie 
Exposure Impact Pefiods. 
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Table 4.4 Available PCDD/F Coogener-Specific Data in MOSS amples for Specific 
Exposure Periods. 
Site 
1 1  
Pre-Incident 
9/92 9/93 9/94 9/95 5/96 9/96 
d d d d 
Al1 dioxin/furan congener-specific laboratory results for the key biological monitoring species 
were extracted fiom the SHTC environmentai monitoring database for the three key monitoring 
locations (Le., 1 1, 107, and 1 14) in time-series for the sampling events immediately prior to and 
following the accidental release incident in October 1996. Actual sampling dates were 
dependent upon the particular sampling teams involved, sarnpling site initiation, receptor 
availability and li fe-cyc le issues, and seasonal site access restrictions. In certain speci fic cases, 
sampling could not be conducted at the scheduled time (e.g., vole sampling at site 107 in 
d fl d 
d b' v 
Site 




9/92 9/93 9/94 9/95 5/96 9/96 : 2197 9/97 2/98 
d 
fl 
September 1996), while in other cases, additional unscheduled sampling was conducted for 
speci fic reasons (i. e., vegetation sampling during November 1 996 to evaluate potential 
deposition following the October 1996 release incident). 
4.1.4 Daru Cleanup und Quality AssurancdQuaii@ Contrd 
The initial methodological step invohed a complete qudity assurance/quality control (QAQC) 
evaluation of the extracted SHTC dataset to identify and attempt to fil1 existing data gaps with 
supplementary information fiom BOVAR or CanTox Inc. QNQC datastarnps and surrogate 
recovery rates for the laboratory chernical extractions of each sample set were evaluated to ensure 
the quality of the data being used. 
4.2 Development of TCDD PBPK Prototype Models 
To evaluate the potential efficacy and validity of the use of physiologically-based 
pharmacokinetic models as a appropriate tool in the assessrnent of health risks related to 
environmental exposure to POPs, a thorough nview of the scientific literature was conducted to 
select the most appropriate PBPK model methodology for absorption, disposition, metabolism, 
and excretion (ADME) of PCDDIFs. A steady-state (tirne-dependent) PBPK model, proposed by 
Wang et al. (1 997) was selected as the prototype analysis model for the current research. 
To evaluate potential "over-parameterkation" of existing steady-state based models (i.e., Wang 
et al., 1997), an additional lessîornplex, equilibnum-based model, describeci by Evans and 
Andersen (2000), was also evaluated. 
d 2 a 1  Steudy- State PBPK Model 
The Wang et al. ( 1997) was selected as the prototype steady state-based (tirne-dependent) PBPK 
model to evaluate the absorption, disposition, metabolism, and excretion (ADME) of TCDD for 
the current research project. A complete overview of the methodology and mathematical 
equations used in this model is provided in Section A-1 of the Appendix. The mdei  was 
prograrnmed in the Advanced Continuous Simulation Languuge (ACSL) PBPK programrning 
system, b a s 4  upon the rnethodology published in Wang et al. (1997). The ACSL Tox software 
suite, which includes the ACSL Model (PBPK model design), ACSL Optimize (PBPK parameter 
estimation, optimization, and sensitivity analysis) and ACSL Math (Monte Carlo routines, 
transformations, graphing, etc.), was licensed fiom the Pharsight Corporation (product support 
and distributor for developer, AEgis software). The model system was run on a Pentium-II 200 
MHz computer (with 128 MB of RAM) Nnning the Windows NT 4.0 operating system. 
Figure 4.1 shows a graphical representation of the deveioped PBPK model within the ACSL 
modelling system. 
Figure 4.1 Screenshot of TCDD PBPK Model developed in the 
ACSL Modelling System 
4.2.1.1 Revisions to Prototype PBPK Model 
Inaccuracies and gaps within the published methodologies were noted during the development of 
the model and corrected by incorporation of methodologies fiom other original source literature 
(i.e., source material referenced within Wang et al., 1997) and more recent publications by these 
and other authors (i.e., Wang et al., 2000, DeVito et al., 1997; Santostefano et al., 1998; Evans 
and Anderson, 2000). These inaccuracies included incorrectly transcribed formulas for certain 
tissue groups, as well as incomplete descriptions of certain formula steps with the model 
methodology (particularly with respect to binding interactions between the liver and CYP1 A2 
compartrnents, and related physiological induction delays). 
This initiai model was also demonsûated to be highly unstable at low administered doses. Given 
the need to evaluate the extremely low concentration levels typically found within environment 
and tissue of biota, this posed a dennite impediment to its use as a suitable mode1 to evaluate 
potential toxicity and risk. An extensive breakdom and evaiuation of the model methodology 
indicated that low ligand concentrations resulted in numerical artifacts in the nonlinear Ah- 
TCDD binding term. These numerical difficulties appear to be related to the inability of the 
mode1 (or modelling software) to properly calculate implicit differential equations at very low 
doses, resulting in oscillations in predicted cornpartment-specific TCDD concentrations. 
Figure 4.2 demonstrates the fluctuations present in the model's ability to calculate various tissue 
concentrations in a Sprague-Dawley rat at an administered dose of 0.001 pg/kg bodyweight. 
Figure 4.2 Example of TCDD Tissue Concentration Fiuctuations in Model 
Predictions at Low Administered Doses 
Further research and bnef discussions with the model's original author (X. Wang, personal 
communication, 2001) indicated that at low doses, where the amount of available TCDD ligand 
is significantly less than the Ah receptor binding coefficient &), TCDD sequesttation related to 
the nonlinear binding term (i. e., binding to the Ah receptor) could be essentially eliminated. This 
can be confïrmed by an evaluation of the underlying Michaelis-Menton kinetics, where at very 
low concentrations ligand (i.e. [LI CC I Q ,  receptor occupancy occurs but may be trivial (i.e., the 
curve approaches 0% occupaacy of receptors) (Lucier et al., 1993). 
Further testing also indicated that these mathematical resolution issues could also be alleviated 
by greatly reducing the size of the iterative timestep within each ACSL model run (i.e., from the 
model's typical timestep of one hour to as low as measurements every 5 minutes). Reduction of 
the iterative timestep allowed for improved mathematical resolution of the differential equations 
used within certain compartments, but resulted in an extended run time of computer simulations. 
Other modifications/improvements made to the base model for the current project included: i) the 
ability to provide the administered dose as a one-time bolus (i.e., acute exposure) or as a constant 
dose spread over time (i.e., chronic exposure); ii) the ability to either maintain the initial 
bodyweight or allow growth of the test organism, and; iii) the ability to better control the 
proportion of administered dose that is transferred via lymphatic flow into the venous blwd 
supply and that which is directly absorbed into the arterial blood supply. Finally, to evaluate the 
potential impacts of CYPlA2 ligand binding on overall disposition patterns (i.e., liver versus 
adipose sequestration ratios), the ability to diminish or completely disable binding to CYPI A2 
was incorporated into the developmental PBPK model. 
4.2.1 .2 Development of a Multi-scenario Managing Interface 
While the ACSL Tox modelling system provides an excellent design and programming 
environment in which to develop a complex PBPK model, it is not well suited for detailed 
evaluations under multiple scenario, chernical, and species designs. 
To bridge this gap, and allow for the necessary output and statistical analyses required for the 
cumnt research project, an interactive interface was created in Microsoft ExcelTM (version 7.0, 
Microsoft Corporation) using underlying Windows DDE (direct data exchange) systems to link 
the spreadsheet with the underlying ACSL model systw. This sheli spreadsheet allowed for 
easy transition between test organisrns (i-e., Sprague-Dawley rats, C57BU6J mice, and red- 
backed voles), test chernicals (i.e., 2,3,7,8-TCDD, 2,3,7,8-TCDF, 1,2,3,7,8-PeCDF, 2,3,4,7,8- 
PeCDF) and exposure scenarîos (i-e., diRering exposure concentrations, durations, etc.) by 
passing the representative PBPK &ta to the uaderlying model based upon the user's selection. 
Upon model run completion, al1 relevant cornpartment- and nui-specific data was automatically 
displayed and analysed by the shell system. Figures 4.3 through 4.5 provide screenshots of the 
developed Excel-based model interface, while Figures 4.6 through 4.8 provide screenshots of 
both tissue-specific and receptor binding results from a completed model run. It should be noted 
that Windows DDE support appears to have degraded badly lrom Windows NT version 4.0 (the 
operating systern on which the model was run) to more current versions of the Windows platform 
(i.e., Windows 98 and Windows ME). Considerable hstration was incurred by this researcher 
when he attempted to upgrade to a research machine using an operating system other than 
Windows NT. 
Monte-Carlo simulations and unceriainty/sensitivity analyses were conducted using the Crystal 
Bail (Decisioneering Lirnited) simulation add-on (version 4.0~)  to the MS Excel environment. 
Figure 4 3  Scenari+specific Data Entry for ExceCBased Interface 
to the Prototype PBPK Model. 
Figure 4.4 Chemical-specific Data Eitry for Ercel-Based Interface 
to the Prototype PBPK Model. 
Figure 4.5 Species-SpeciTc Data Entry for ExceCBased Interface 
to Prototype PBPK Model 
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Figure 4.6 Interactive Moàel Run Results Displayed in Excei- 
Based Interface to Prototype PBPK Model 
Figure 4.7 Overview of PBPK Model Resdb Displayed in ErceC 
Basecl Interface to Prototype PBPK Model. 
Figure 4.8 Receptor Binding Run Results Displayed in ExceC 
Based Interface to Prototype PBPK Model. 
4.1.2.3 Species-SpecUic Physiological Data 
Three distinct species of rodents, the Sprague-Dawley rat, the C57BU6J mouse, and the red- 
backed vole, were selected as test organisms to evaluate the efficacy and validity of the selected 
equilibrium-based PBPK methodology for assessing the disposition of TCDD within living 
organisms. While there are similarities in the phamacokinetics of TCDD between various test 
species, there are also subtle differences between species that must be incorporated into the 
proposed PBPK methodology. 
Sprague-Da wley Rat 
The initiai model, based upon the Wang et al. (1997) methodology, was developed using the 
Sprague-Dawley rat as the test organism. Biological and physiological parameters for this rat 
strain were obtained fiom the Wang et al. (1 997) source paper. 
CS 7BUU Mouse 
As a mid step between the rat and vole specific PBPK models, physiological parameters for the 
CS7BU6J mice were gathered. The C57BU6J mouse is a hybrid mouse strain (based on the CS7 
black laboratory mouse), weighing approximately 20 grams, and was selected due to its general 
similarities to those physiologicai parameters found in the red-backed vole sentine1 species. 
Biological and physiological parameters for this mouse strain were obtained f?m the research 
presented by Wang et al. (2000), or modified allometrically as a function of bodyweight f?om 
data presented in Wang et al. ( 1  997). 
To evaluate the appropnateness of these parameters, experimental data provided by Diliberto et 
al. (1999) were compared to the results of the PBPK model run under similar exposure 
conditions (i.e., 25 pg TCDD/kg bodyweight). Results of this cornparison indicated that both the 
urinary and fecal excretion rates provided in Wang et al. (2000) were too low and under- 
estimated the contribution of TCDD e b a t i o n  at the earlier exposure periods (i.e., 54 days). in 
a study involving TCDD-treated mice, fecai excretion of TCDD-denved radioactivity ranged 
h m  18% to 28% of adrninistered dose by 4 days Piliberto et al., 1999). Resuits of multiple test 
nuis indicated that values of 1.5 and 6 hour" provided better matches to the presented time-series 
results for urinary and fecal excretion, respectively. 
Wang et al. (2000) also recommended that 1.5 nmoledgram of liver tissue be selected as the 
basal level of CYPl A2 with the liver. However, modelling analysis indicated that this value 
resulted in an underestimation in the level of CYPlA2 within the liver, and a related lower 
calculated liver-to-fat ratio when compareci to the Diliberto et al. (1999) experimend results. 
Testing of the revised model indicated that using a value of 1.6 nrnoledgram (as specified for the 
Sprague-Daw ley rats) resulted in sequestration patterns w hic h more accuratel y re flec ted the 
experimental data Fit between expenmental data and model results were fùrther improved by 
reducing the CYPlA2 physiological delay period to 1 hour from the value of 1.5 hours suggested 
in Wang et al. (2000). 
Table 4.5, below, provides a summary of the parameter revisions made to the prototype PBPK 
model to better fit the experimental results observed for C57BU6J mice. 
Table 4.5 Summary of Panmeter Revisions made to Better Fit the Prototype PBPK 
Mode1 to C57BW6J Mire Experimental Results (Diliberto e~ al., 1999). 
Parameter Original Value Rcviscâ Value 
Urinary exmtion rate (houf ') 1 1.5 
Fecal exmtion rate (houf') 2.2 6 
Basal lcvel of CYP 1 A2 in liva (nrnoles/gram) I .5 1.6 
CY P 1 A2 physiological delay pcriod (hours) 1.5 1 
Gapper P Red-backed Vole 
Vole biological and physiologicai parameters was gathered fiom researchers using voles as their 
Uivestigative species, and the scientific literature. Any remaining data gaps were filled using 
ailometricaily adjusted data obtained fkom Wang et al. (1 997) or other relevant studies (Andersen 
et al., 1997a; Diliberto et al., 1996; Kedderis et al., 1991; Webber et ai., 1993). Given the 
minimal amount of data available for voles (puticularly related to liver-based metabolism), many 
of the parameters were assumed to be equivalent to those used to characterize the C57BY6J 
mouse, given the similar sizes and organ weights. 
Tissue-specific organ weights for rd-backed voles were obtained from an extensive database of 
small mammal and bird sampling measurements (Mallory, 2001) and are presented below in 
TabIe 4.6. 
Table 4.6 Red-backed Vole Summary Organ Weights (MaUory, 2001). ' 
Weigbt (gram) - - -- Parameter 
Total Liver Lungs Kidneys Spleen 
Bath Sercs 
Count (n) 42 1 420 419 4 18 389 
Mean 28.5 1.7 0.364 0.264 0.164 
Standard Deviation 7.2 0.985 O. 164 0.0785 0.187 
Mde Y& 
Count (n) 247 246 246 246 233 
Mean 28.6 1.66 0.362 0.268 0.187 
Standard Devia tion 6.65 1.17 0.143 0.076 1 0.212 
Female Voles 
Count (n) 174 1 74 173 172 165 
Mean 28.4 1.77 0.366 0.257 0.131 
Standard Deviaaon 7.94 0.634 0.191 0.08 14 O. 14 
Confidential d-backed vole data was provided by Dr. Frank Mallory of Laurcntian University. This dam is not to bc uscd 
without the express permission of  Dr. Mallory (fmallo~ickel.Iaurcntian.ca)- 
Using a daily consumption rate of 0.3 1 g/g/d for the Gappa's red-backed vole (McManus, 1974), 
daily consumption rates of congener-specific PCDDIF concentrations in environmental media 
can be estimated nom the PCDD/F concentrations detected in surrounding biota (i.e., Labrador 
tea and moss). 
Table 4.7 provides a list of the species-specific physiological parameters used in the TCDD 
PBPK moûel, for each of the three test species. 
Table 4.7 PBPK Physiological Parameten Selected for each Test Species. 
Body weght (grams) 
Allometric coefficient for cardiac output fmm 
b m f w l h t  
Allometric parameter describing bodyweight change 
Allometric parameter describing bodyweight change 
Dissociation constant of Ah receptor binding (nmoldg) 
Absorption rate constant h m  GI tract to blood (hour') 
Oral bioavailabilii of TCDD (unitless) 
Tissue volume as percentage of body weight 
Iniüal TCDO compartmental concentration 
Ah receptor binding capacity 
Equilibrium raüo of tissue to blood concentration 
Percentage of blood flow rate through tissue 
Fracüon of oveiall tissue volume composed of blood 
Tissue volume as percentage of body weight 
Kidnev Commrtimnt 
Iniüal TCDO compartmental concentraüon 
Ati receptor binding capacity 
Urinary excreüon rate (hour ') 
Membrane pemeability'area 1 blood fiow rate 
Equilibrium ratio of tissue to blood concentration 
Percentage of blood fhw rate ttirough tissue 
Fraction of overall tissue volume cornposed of blood 
fissue volume as percentage of body weight 
Initial TCDD comparbnental concentration 
Ah receptor binding capacity 
Membrane peneability'area 1 blood flow rate 
Equilibrium ratio of tissue to blood concentration 
Percentage of blood flow rate through tissue 
Fraction of overall tissue volume composed of blood 
Tissue volume as percentage of body weight 
Membrane penneability'area 1 blood flow rate 
Equilibrium raüo of tissue to blood concentration 
Percentage of blood fbw rate through tissue 
Fraction of overall tissue volume composed of blood 


































Table 4.7 PBPK Pbysiological Parameten Selected for each Test Species. 
Rast ofthe Bodv Commrbnant 
Membrane pemeability'area I blood Row rate 
Equilibrium ratio of tissue to bkmd concentration 
Percentage of blood flow rate through tissue 
Fraction of overall tissue volume wmposed of blood 
Tissue volume as percentage of body weight 
S~Ieen  Commrbnent 
Initial TCDO com partmental concentration 
Ah receptor binding capacity 
Equilibrium raüo of tissue to bkmd concentration 
Percentage of blood flow rate through tissue 
Fracüon of overall tissue volume composed of blood 
Tissue volume as percentage of body weight 
Urnr Commrbnent 
Initial TCOD cornpartmental concentration 
Ah receptor binding capacity 
Dissociation constant of binding to CYP1A2 
Biliary elimination rate (houf ') 
Membrane pemeability'area / blmd flow rate 
Equilibrium ratio of tissue ta bkmd concentration 
Percentage of blood flow rate through tissue 
Fracüon of overall tissue volume composed of blood 
Tissue volume as percentage of body weight 
CYPfA2 Commrtmont 
Basal level of CYPIA2 within the liver (nmoldgram) 
Hill coefficient (unitiess) 
Value to cause half of the maximum induction folds 

























First-order degradaüon rate constant of binding (1Riour) K2 
CY P l  A2 physiological holding time (hours) tau 
Data obtained h m  Wang et al. (1997). unless otherwise specrfied. 
Data obtained h m  Wang et el. (2000), unless othenrvise specified. " Assumed based upon C57BU6J muse data, unless otherwise specified. 
a Assumed based upon Wang et el. (1997). 
Obtained h m  ILSI PBPK database information presented in Brown et al. (1997). 
Data obtained from red-backed vole sampling database (Mallory, 2001). 
Data obtained based upon fitang model results to experimental results (Diliberto et a/., 1999). 
The chernical-specific parameters used in the evaluation of gasîrointestinal absorption of TCDD 
(i.e., absorption rate constant and oral bioavailability) were assumeci equivalent across the 
various species. Research has indicated that no interspecies differences have been observed for 
the absorption of PCDDs and PCDFs h m  the gastrointestinal (GI) tract. This is thought to be 
due to molecdar sue and solubility being the rate limiting factors for GI tract absorption (Van 
den Berg et al., 1994). 
Where species-specific data were mavailable, data from the bener characterized Sprague-Dawley 
rat or C57BU6J mouse were substituted. This was viewed as a reasonable approach given that 
most of these parameten were allometrically-linked to the tissue volume of the specific 
compartment, and species-specific tissue volumes were available for al1 comparûnents in almost 
every case. 
An extensive review of the scientific literature, as well as discussions with various laboratories 
conducting research with voles, failed to provide any suitable infoxmation on which to base 
ligand-receptor parameter selection (i.e., for either the Ah or CYP 1 A2 receptor systems) for the 
vole sentinel receptor. Given this lack of information, data from the physiologically-similar 
CS7BU6J mouse receptor were used to represent the necessary ligand-receptor data in the vole 
receptor. 
4.1 .2.4 Chernical-SpecUie Physiological Data 
The initial prototype PBPK model was developed to evaluation the pharmacokinetic disposition 
of TCDD within the Sprague-Dawley rat. However, while TCDD is the most toxic of the 
PCDDiF congeners and is commonly the primary focus of environmental nsk assessments, 
chemical analyses of environmental media and biotic receptors have indicated that TCDD 
typically makes up a very minor component (approximately 0.8%) of the total PCDD/F mass 
(Czucnva and Hites, 1995; Rappe et al., 1987). This trend has also been observed in the 
chemical analyses conducted on environmental biota sampled as part of the SHTC long-term 
monitoring program, with results indicating very low or non-detect TCDD biotic concentrations 
in most cases (presented in Results section). This pattern is primarily due to the congener- 
specific pattern, or "fingerprint", typically associated with the combustion releases fiom an 
incineration process (i.e., hans ,  particularly the PeCDFs, tend to dominate). A more detailed 
discussion of this pattern and congener-specific fingerpnnting can be viewed in this researcher's 
Masters thesis project (Ferguson, 1998). 
Given the pariicular congener-specific fingerprint associated with incineration facility emissions 
and the very low levels of TCDD detected in the biota sarnpled as part of the SHTC monitoring 
program, it was necessary to attempt to evaiuate other congeners of interest, in addition to 
TCDD. B a d  upon the typical fingerprint dernonstrated in chemical samples, three additional 
congenen were selected for evaluation: i) 2,3,7,8-tetrachlorodibetl~ofuran (TCDF); ii) 1,2,3,7,8- 
pentachlorodibenzohiran (1 -PeCDF), and; iii) 2,3,4,7,8-pentachlorodibe1120fÛran( 4-PeCDF). 
To adapt the current TCDD-based model for these stnicturaily-related congeners, the shell 
interface was designed to allow for the adjustment of key pharmacokinetic and 
phmacodynamic parameters. 
Given that the current PBPK model was developed for TCDD and that many of its parameters 
were "fined" to experimental data derived h m  exposures to TCDD, ratio-based adjustments to 
the existing TCDD-d&ved parameters are more appropriate than sirnply substituthg values 
obtained for each parameter h m  the literature (S. Safe, penonai communication, 2001). 
As noted previously, the disposition (and ultirnate toxicity) of the PCDDF congeners is 
controlled by four key chernical-specific factors: 1) the lipophilicity of the chemical; 2) the Ah 
receptor ligand-specific aflhiv, 3) CYP lA2 sequestration affùiity, and; 4) metabolism of the 
c hemical. 
Lipuphiiicity of the Chemicaf 
To account for diffenng pharmacokinetic disposition due to the chernical's lipophilicity, a 
lipophilicity adjustment factor was calculated for each congener based upon the ratio of its 
octanol-water partition coefficient (K.W) to that of TCDD. This lipophilicity adjustment factor 
was then used to update the equilibrium ratio of tissue to blood concentration for each 
cornpartment (e.g., the equilibrium ratio for the lung cornpartment of 6 was adjusted by 0.2 for 
TCDF to provide a TCDF-specific equilibrium ratio of 1.2). The chemical-specific K, values 
were calculated Crorn the respective log &, values presented in USEPA (2000). Table 4.8, 
below, provides the specific calculation parameters and calculated lipophilicity adjustment 
factor, for each of the assessed congeners. 
Table 4.8 Specific parameten used in the calculation of congener-specifie lipophilicity 
ad justmea ts. 
Cbtmical LOI!&' Mmtd K, Lipopbilicity Adjostment Facîor 
2$,7,8-TCDD 6.8 63 10000 I 
2,3,7,8-TCDF 6.1 1260000 0.2 
l ,î,3,7,8-PeCDF 6.79 6 170000 0.977 
2J ,4,7,8-PeCDF 6.5 3 t 60000 0.50 1 
' U.S. EPA (2000) 
Following an oral dose, TCDD and related lipophilic compounds are delivered to the blood 
circulation via the lymphatic system as well as via the GI tract (Lakshmanan et al., 1986). As 
noted in Wang et al. (1997), the process of absorption for lipophilic compounds by the GI tract 
and delivery into the b l d  circulation via the lymphatic system were analyzed in detail by Roth 
et al. (1993). and were simplified in the current model thmugh the use of specific empirical 
parameters and 4. The ernptying rate of the stomach (IQ is an organism-specific value, and 
would not differ with the particular congener under study. The hction of total dose absorbed 
(&J was estimated for TCDD by Wang et al. (1997) by fitting the mode1 to the tissue 
distribution. Given that research has demonstrated that plasma lipoproteins act as carriers for 
extremely hydrophobic chemicals (Roth et al., 1993) and that the chemicals being assessed have 
very sirnilar lipophilicity, it was assumed that the K, value for TCDD absorption would be 
suitably representative for the other assessed congeners. This assurnption is strengthened by 
studies into PeCDF absorption and elimination by Brewster and Bimbaum (1987) which showed 
that more than 70% of the administered dose was absorbed fiom the gui, independent of the 
amount of PeCDF administered in the dose range studied. 
The potency of the ligand for eliciting a response ( ie . ,  the dose-response relationship) is 
dependent upon the properties of afin@ and eflcucy. Amnity refers to the strength of the 
interaction, or binding, with the receptor, and is a property of the ligand and receptor. Efficacy, 
on the other hand. is the ability of that ligand-receptor complex to ultimately produce a response 
and is influenced by both ligand- and tissue-specific properties (Hestermann et of., 2000). While 
separation of receptor-ligand action into the properties of affhity and efficacy allows for 
improved prediction of the behaviour of complex mixtures of ligands, as well as mechanistic 
cornparison across species and toxic endpoints (Hestermann et al., 2000). the current PBPK 
modeis only attempt to address the impacts of ligand-receptor afhity when evaluating ligand 
binding to the Ah and CYPIA2 receptor systems. 
Chemical-specific variations in ligand affinity to both the Ah and CYPl Aî receptor systems are 
primarily govemed by the dissociation constants (Kd for each of the receptors. There is 
considerable uncertainty with respect to the methodology used to calculate these ligand-specific 
K, values. The K, values are dependent on ligand, the source of the cytosol preparation, and the 
assay procedures (Safe, 1988). Absolute values for ligand-receptor binding affinities are 
typically calculated h m  studies of competitive displace of 'H-TCDD or saturation binding 
studies using Woolf or Scatchard plot analysis (a graph used to study molecular interaction in a 
mixed population of molecules in which different types of molecules are bound reversibly to one 
another). However, research has demonstrated that the rat cytosolic Ah receptor is thermally 
unstable, and therefore the results obtained h m  Scatchad plots are inaccurate and tend to 
significantly overestimate the tme value of KD (Brown et al., 1992; Rosengren et al., 1992). 
Furthemore, due to these issues some cesearchers question the accuracy of using Kd developed 
based upon these types of studies (Santostefano et al., 1994). 
Ah Reeeptor Ligand-Speciic Aflnity 
To account for differences in the chernical-specific K, values, in cornparison to TCDD, 
phamiacodynamic adjustment factors for each receptor were calculated for each of the chemicals. 
The receptor-specific K, values (to which the TCDD-based mode1 was onginally "calibrated") 
were then adjusted by these receptor-specific adjustment factors. Given the considerable 
variability in KD values presented in the literature, largely due to the type of assay and the 
conditions under which it was conducted (e.g., temperature, dose, etc.), it is likely that absolute 
KD values are a lot less reliable than calculated adjustment factor ratios which are self-calibrating 
assuming similar assay conditions or estimation methodology. 
A considerable amount of research in the past decade has been directed at the denvation of 
predictive Quantitative Structural-Acfiviv Relationsll@s (QSAR) and Quantitative 
Structure-Ploperty Relationships (QSPR) models. Previous QSAR analyses suggest that steric, 
electrostatic, hydrophobic, hydrogen bonding and dispersion properties may al1 be important for 
Ah receptor binding affinity (Tuppurainen and Ruuskanen, 2000). A number of ment  QSAR 
studies have indicated that the methodology appears to provide a reasonable estimate of Ah 
receptor binding afnnity for a large number of biphenyls, dibenzohirans, and dibenzo-p-dioxins 
(Tuppurainen and Ruuskanen, 2000; So and Karplus, 1997; Waller and McKimey, 1995). Given 
the considerable uncertainty inherent in the use of experimentally derived Kd values, and the 
complete lack of Kd information on the 2,3,4,7,8-PeCDF congener in the scientific literature, it 
was decided that the development of phamiacodynamic adjustment factors, based upon the 
differences in QSAR-estimated binding affinhies for each congener compared to that of TCDD, 
would be the more prudent methodology for the current investigation. 
Using structure and atnnity data, QSAR models developed by Tuppurainen and Ruuskanen 
(2000) predicted EC, values of 1 4 4 1  .O, 74.5, and 15.0 nM (calculated by taking the -antilog 
value of the pEC, values: 8.000,7.387,7.128, and 7.824 M) for TCDD, TCDF, LPeCDF, and 
4-PeCDF, respectively. The EC, values are one representation of the ligand's affinity to the Ah 
receptor, and typically indicating the concentration of the ligand required to elicit half-maximal 
response expression (typically CYPI A via quantification of EROD activity) (Hestemann et al., 
2000). As such, as the receptor-ligand amnity (or EC,J inmeases, the related K, value will 
conelationally decrease. 
Table 4.9 provides the chernical-specific EC, values and calculated receptor adjustment factors 
for both receptor sets, used to produce revised KD values for the other assessed congeners. For 
example, the species-specific Ah receptor KD value assumed for TCDD in the prototype steady- 
state mode1 (i.e., O. 1 nM for the Sprague-Dawley rat) was multiplied by the calculated adjustment 
factor to produce a revised, chernical-specific Ah receptor K, value for that particular species. 
Table 4.9 Chernical-specilic dissociation constants and calculated adjustmen t factors 
for Ah receptor afiinity. 
Ah Rectptor Afiiaity 
ECU (0M) Adjudmcnt Factor 
2,3,7,8-TCDD 1 O 1 
2,3,7,8-TCDF 4 1 4.1 
I ,2$,7,8-PeCDF 74.5 7.45 
2,3,4,7,8-PcCDF 15 1.5 
As the a d j u m t  factors will be applicd to the specics-spccific Ah rtccptor K, value, these factors represcnt an inverse 
fùnction o f  the affinity (i.e., as Ko incrtases, the ligand-receptor affinity dccreases). 
Unfomuiately, there is very little information in the scientific literature for the estimation of 
chernical-specific CYP 1 A2 dissociation constants, and conservative assumptions are typically 
used to estimate appropriate values. While quantification of enzyme induction, such as ACOH 
activity for CYP lA2, provides a good Uidication of relative potencies for the various congeners 
(DeVito et al., 1997), they are indicators which combine the impacts of both Ah and CYP lA2 
receptor binding events. As such, it would be di fficult to estimate either the Ah or CYP 1 A2 
ligand-receptor binding Kd based upon ACOH induction. There are a number of likely methods 
to get around this difficulty (e.g., mRNA expression assays, immuno-assays, extraction of 
CYPlA2 to an in vitro system for quantification of ligand binding, etc.). However, much of ihis 
research has been conducted on the CYPl A1 isozyme, with less focus being placed on its 1A2 
The CYPIA2 dissociation constant (K,) for TCDD was estimated by fitting the parameter based 
upon experimental time course tissue distributions (Wang et al., 1997). Research conducted by 
DeVito et ai. (1998) provided disposition, in % dose/gram units, of various PCDDs and PCDFs 
over a range of doses, following a 13-week subchronic gavage study. Given the close 
sirnilaities in the pharmacokinetics of TCDD and the other assessed congeners, at oral exposure 
doses sufficiently elevated as to result in maximal Ah receptor occupancy, one would expect any 
differences in congener-specific liver concentrations would be a result of di ffering CYP 1 A2 
binding anit ies.  DeVito et al. (1998) reported liver-specific concentrations of 6.62, 1.19,0.99, 
and 21.32 % dose/gram tissue for TCDD, TCDF, I-PeCDF, and 4-PeCDF, respectively, at the 
highest administered dose level. Given these relative concentrations, the ratio of K, for 
CYP1 A2 binding of each particular congener to that of TCDD was calculated as 5.56.6.69, and 
0.3 1 1 for TCDF, 1-PeCDF, and 4-PeCDF, respectively (e.g., 6.62 1 1.19 = 5.56-fold for TCDF, 
etc.). This results in a calculated K,, for CYPlA2 binding of 0.167,0.201, and 0.00932 for 
TCDF, l -PeCDF. and 4-PeCDF, respectively (e.g., 0.03 nmoldgram * 5.56 = 0.167 nmole/gram 
tissue for TCDF, etc.). Given the lack of other suitable data, these chemical-specific values were 
used as initial values in the assessment of CYPIA2 ligand binding in the current study (see Table 
4.1 O). 
Model run results based upon these assumptions were compared to tissue distribution data for 4- 
PeCDF dosed C57BU6N mice (Diliberto et al., 1999). Based upon a 300 pg 4PeCDFkg 
bodyweight dose, mode1 results indicated that the initiai CYPl A2 Km estimated was over- 
estimating sequestration of 4PeCDF in the liver. A more accurate reflection of the tissue 
distribution presented in Diliberto et ai. (1 999) was obtained when an adjustment factor of 0.45 
(rather than previously eshated value of 0.3 1 1) was used. 
Table 4.10 Chemical-specific dissociation constants and cakulated adjustment factors 
for CYPl A2 receptor afnnity. 
CY Pl A2 Receptor Amnity 
Chemical 
Dissociation Coart.nt (Kd Adjustment Factor 
2,3,7,8-TCDD 0.03 1 
2,3,7,8-TCDF 0.167' 5.56 
l,2$.7,8-PeCDF 0.201 6.69 
2,3,4,7,8-PKDF 
Initial 0.00932 0.31 1 
Revised 0.45 
Wang et al. ( 1997). 
Calculated (sec discussion above). 
The Hill coeficient (h), which descnbes the interaction between the ligand-Ah receptor complex 
and the binding sites on DNA, was obtained for TCDD by Wang et al. (1997) by fitting their 
model with both time course and Day 3 tissue concentration data. Given this term represents the 
interaction between a bound Ah receptor and DNA binding sites at the DRE, and is biologically 
meant to loosely reflect the number of available DNA bindirig sites with cooperative binding 
interactions, the value calculated for TCDD by Wang et al. (1 997) was assurned representative 
for the other assessed congeners (i.e., species-specific, rather than chernical-specific). However, 
it is important to remember ihat this is ultimately a "fitted parameter, based upon TCDD tirne- 
series data, and as such would have a degree of uncertainty associated with it when used for 
circumstances outside of the scenario for which the base model was designed. As it is a fined 
parameter, the default value specified by Wang et al. (1997) of 0.6 was assurned for other 
assessed congeners. 
Mduboiism and Ehinution of the Chernical 
Finally, differing rates of rnetabolic breakdown of the individual congenen can play a significant 
role in disposition and excretion patterns within biological species. Although the relative rate of' 
metabolism of TCDD and related compounds can be roughly estimated h m  tissue and excretion 
half-life data of the metabolic breakdown products, other factors such as relative body 
composition (e.g., amount of adipose tissue), hepatic and extrahepatic biading proteins (i.e., 
CYP1 A l  and CYPl AZ), and direct intestinal elimination of the parent compound cm also 
regulate excretion (molson et al., 1994). In the current steady-state model, the biliary 
elimination of TCDD from the liver was assumed to follow first-order kinetics, since research 
has demonstrated that very little TCDD is subject to metabolic breakdown in the liver (Wang et 
al., 1997). In addition, the excretion of TCDD parent compound and its metabolites from the 
liver via bile was aiso assumed to follow first-order kinetics. Given this, Wang et al. (1997) used 
on "lumped" empirical parameter to rqresent the unknown parameters of the metabolic and 
excretion rate constants. Research has also demonstrated that the amount of TCDD and its 
metabolites eliminated via urinary excretion is fairly small (Allen et ai., 1975; Diliberto et al., 
1996). It is believed that the excretion of metabolites fiom the kidney may be controlled by the 
metabolic rate in the liver or the membrane transfer process (Wang et al., 1997). As such, the 
current model assumes kt-order kinetics of urinary excretion, as show previously by 
Bimbaurn (1 986). To calculate the chemical-specific excretion rates. a ratio of half-lives for each 
congener to that of TCDD was used to create congener-specific adjustrnent factors. 
The elimination constants of TCDD lrom both kidney and liver were calculated by Wang et al. 
(1997) based on the kidney and liver time course data, as well as elimination data (Allen et al., 
1975; Diliberto et ai., 1996). As for TCDD (< 1.5%), studies have demonstrated that urinary 
excretion plays a very minor role in the clearance of TCDF (< 3%) and the PeCDFs (< 0.2%) 
fkom rodent species (Diliberto et al., 1996; King et al., 1983; Brewster and Bimbaurn, 1987). As 
such, the urinary elimination constant for TCDD was assumed for the remaining assessed 
congeners. 
Fecal elirnination is the primary route of excretion for TCDD and the other assessed congeners. 
Three days after an oral dosing of TCDD in rats, fecal excretion of percentage administered dose 
was 32.2%. with an overall calculated biliary linear elimination constant of 2.2 (hour-') 
(Diliberto et al., 1996). In studies on TCDD-treated C57BU6N mice, fecal excretion was 
determined to be 28% of administered dose by 4 days, while in 4-PeCDF-treated C57BU6N 
mice, fecal excretion was approximatel y 3 1 % of administered dose by 4 days (Diliberto et al., 
1999). Rates of fecal excretion of TCDF, on the other hand, are considerably higher than those 
viewed in TCDD or the PeCDFs. Studies have dernonstrated that the rat excretes 63 to 70% of 
an oral dose of TCDF in feces in 3 days (Bimbaum et al., 1980). 
As previously noted, model run results based upon these assumptions were compared to tissue 
distribution data for 4-PeCDF dosed C57BU6N mice (Diliberto et al., 1999). Based upon a 300 
pg CPeCDFkg bodyweight dose, modei results indicated that the initial estimated fecal 
elimination adjustment factor was under-estimating the excretion rate of 4-PeCDF. A more 
accurate reflection of the tissue distribution presented in Diliberto et al. (1 999) was obtained 
when an fecal elimination adjustment factor of 1.5 (rather than previously estimated value of 
0.278) was used. This revised elimination adjustment factor appears to be more in line with the 
results of the experimental excretion data, where TCDD-treated CS7BU6N mice demonstrated 
fecal excretion of 28% of adrninistered dose by 4 days, while in CPeCDF-treated C57BU6N 
mice demonstrated fecal excretion of 3 1% of adrninistered dose by 4 days (Diliberto et al., 1999). 
Table 4.1 1 provides the half-lives reported in a variety of studies for each congener, and the 
associated calculated excretion adj ustment factor (i. e., TCDD ha1 f-li fe divided b y the congener- 
specific half-life). 
Table 4.1 1 Congener-Specific Fecd Excretion Half-Lives and Cakulated Adjustment 
Factor. 
Half-Lift (âays) Cdculrted Adjusîmcnt Factor Rcferenct 
2,3,7,8-TCDD 3 1 '  I Rose et al., 1 976 
2$,7,8-TCDF 1.8 17.2 Bimbaum et al., 1980 
1 J,3,7,8-PcCDF 3.3 ' 9.39 Van den Berg er al., 1989 
2,3,4,7,8-PeCDF 
lnitial IO8 0.287 Van den Berg et al., 1989 
Reviscd 1.5' Estimated (se above) 
Calculatcd bascd upon an orally adrninisted dose of 1 .O pg TCDDkg to male and fcmaic Sprague-Dawley rats. 
Calculaicd bascd upon an iv administcd dose of O. 1 pmoükg to d e  Fischer 344 rats. 
' Caiculatcd basecl upon an orally administcnd dose of 4.0 pg 1-PeCDFkg to fcmalc Sprague-Dawley rats. 
Caiculafcd b d  upon an orally administd dose of 5.6 pg 4PeCDFkg to fcmale Spraguc-Dawley rats. 
Calculatcd by fiîting PBPK mode1 results to experimcntal data prcsented in DiIibcrto et al. ( 1  999). 
Due to inherent dose-dependencies in TCDF excretion, caution should be taken selecting one 
value for the elimination rate constant- In control, uninduced rat liver, the rate of TCDF 
metabolism was shown to be 2- to 7-fold greater than that of TCDD at dose rates between 0.01 
and 0.1 pM, depending on the degiee of CYPl Al induction (Olson et al., 1994). In vitro results 
suggest that TCDF is far more persistent in the rat at very low exposures due to little or no 
induction of CYPl Al  and CYPlA2. However, as the cment PBPK mode1 does not have a sub- 
module for assessing the potential impacts of CYPl Al  metabolisrn and ultimate elimination via 
uruiary and fmal excretion, it was conservatively assumed to be included in the fecal elimination 
term (i.e., it is likely underestimating excretion and overestimating body burden TCDF 
concentrations at elevateû exposure doses which highly induce CYP I A 1). 
4. 1.2.5 Validation of Model Outcornes 
Cornpartment-specific model outcomes were compared visually to those outcomes graphed in the 
Wang et al. (1997) paper to demonstrate an accurate reproduction of the published methodology. 
Model results were also compared to experimental time-senes results provided by Wang et al. 
(1997) both visually, and by residual sums of squares analyses to demonstrate the applicability of 
predicted model results to those shown under experimental conditions. 
Unfortunately, due to the lack of detailed cornpartment-specific data ( ie . ,  actual data, rather than 
the summaries available in the source literature), it is difficult to conduct any further detailed 
statistical analyses of the model's predictive accuracy (i.e., F-test, PRESS statistic, etc.) and 
produce conclusions which themselves have statistical validity and meaning. A request was 
made to the primary author of Wang et al. (1997) for the actual raw data for the TCDD time- 
senes experimental study to allow for a more detailed statistical analysis. Unfortunately, this 
data was no longer available (X. Wang, personal communication, 2001). 
4.1 .2.6 Sensitivity Analysis of Mode1 Parameters 
Limitations in the available data for adequately estirnating PBPK model parameters results in the 
unintentional introduction of uncertainty into overall model predictions. Uncertainty typically 
refers to the lack of kmwledge about specific factors, parameten, or models. 
In order to evaluate the level of confidence that could be given to the calculations perfomed with 
the PBPK model, a series of quantitative and qualitative analyses were perfonned to characterize 
the uncertaiaty in the model structure, parameterization, and dose metric selection. A sensitivity 
analysis was conducted on the current developed TCDD PBPK model based upon 5,000 
MonteCado iterations, to determine which variables pose the largest influence on the ultimate 
outcome of the model (i-e., overall body sequestration of TCDD). Extensive testing of model run 
performance at multiple doses and iteration counts indicated that at lest  5,000 iterations were 
required to ensure proper model stability and that model outcomes were not being skewed by 
extreme selections nom the disûibutional tails of model parameters. 
Standardized probabilistic distributions were applied to each of the key comparûnental 
parameten. Typically, where parameter-specific information was not available, a default 
standard deviation reflecting 10% of the mean was used. A normal distribution was applied to 
those "macro-biological" parameters thought to demonstrate nahual variability within a given 
strain or species, while a triangular distribution was applied to those 44micro-biological" 
parameten thought to demonstrate variance due to uncertainty in quantification or measurement 
of the underlying processes. As such, al1 mass transport parameters (e.g., percentage of blood 
flow through the tissue, tissue volumes, membrane permeability, etc.) were assumed nomally 
disûibuted, while al1 ligand-receptor parameten (e.g., Ah receptor binding capacity, dissociation 
constant of binding to CYPlA2, hi11 coefficient, etc.) were assumed to be rriangularly distributed. 
Briefly, the normal distribution is typically used to describe many natural phenornena such as 
IQ's, people's heights, or the inflation rate. The parameters for the normal distribution are the 
mean and standard deviation, and typically adhere to the following three conditions: i) some 
value of the unknown variable is the most likely (the mean of the distribution); ii) the unknown 
variable could as likely be above or below the mean (symrneûical about the mean), and; iii) the 
unknown variable is more likely to be close to the mean than far away (Le., of the values of a 
normal distribution, approximately 68% are within one standard deviation of the mean.) (Morgan 
and Henrion, 1990). 
The triangular distribution, on the other hand, demonstrates the distributional selection pattern 
when one knows the minimum, maximum, and most likely values. This disûibutional form is 
typically used in circumstances where a range of values are possible, but the underlying 
mechanism for the dispersal is unknown. The parameters for the triangular distribution are the 
minimum, maximum, and likeliest values, and it typicaily follows the following three conditions: 
i) the minimum number of items is fixed; ii) the maximum number of items is fixed, and; iii) the 
most likely number of items falls between the minimum and maximum values, forming a 
triangular shaped distribution (Morgan and Henrion, 1990). 
The PBPK model was nui stochastically (i.e., using Monte Carlo methods) for 5,000 iterations, 
and a quantification of the sensitivity of each parameter was achieved by cornputhg rank 
correlation coefficients between each key variable and the distribution of outcornes describing 
the overall body sequestration of TCDD under these varying parameten. Each variable was then 
assessed to evaluate their overall contribution to the total variance observed in the outcome 
measure. Essentially this statistical evaluation answers the question "what percentage of the 
variance or uncertainty in the outcome is due to the each model variable?". The contribution to 
variance calculations are achieved by squaring the rank correlation coefficients and normalizing 
them to 100%. This process was conducted for each of the following dose levels: 10,3.16, 1 .O, 
0.3 1 6, and 0.1 pglkg bodyweight. This will allow for the evaluation of the e ffect any apparent 
dose-dependencies may have on the key model leverage parameten. These doses were selected 
based upon a log scale Erom the original 10 pgkg bodyweight dose (i.e., 1 O[, 1 O*.', 1 oO, 1 O&.', and 
1 O-'). 
Evans and Andersen (2000) was selected as the prototype equilibrium-based model to provide an 
alternate cornparison methodology with which to evaluate the parameterization of the prototype 
steady state-based model. It should be noted that, while the authors have identified this model as 
a "steady-state" PBPK model, this would be an incorrect specification given there are no time- 
dependencies within the overall model methodology, and no mass balance of flow between the 
modelled compartrnents. 
A complete overview of the methodology and mathematical equations used in this model is 
provided in Section A-2 of the Appeudix. The model was programmed in the Microsoft 
ExcelTM, version 7.0, based upon methodology presented in the source paper (Evans and 
Andersen, 2000) and the S imulso lv~  source code received in communication with the primary 
author (M. Evans, personal communication, 2001). This source code is presented in Section A-3 
of the Appendix. 
Figure 4.9, below, provides a screenshot of the Excel-based mode1 design. Empirical solving of 
the implicit equation (i.e., the equation is iterative in nature with the variable in question is on 
both sides of the equation) used to calculate cornpartmental blood concentrations was conducted 
using the built-in Excel Solver tool (this system uses the Generalized Reduced Gradient [GRG2] 
nonlinear optimization code) or through manual adjustment if the convergence is not dii3cult to 
achieve by hand. 
Figure 4.9 Screenshot of equilibrium-basd mode1 developed based upon Evans and 
Andersen (2000). 
4.2.2.1 Revisions to Base Equilibrium Mode1 
Inaccuracies and gaps withui the published methodologies were also noted during the 
development of this steady-state model, and were corrected through detailed evaluation of the 
underlying PK or PD processes. These inaccuracies included incomplete descriptions of certain 
formula steps with the model methodology (particularly with respect to Ah receptor and 
CYP I A2 binding interactions in the liver compartment). Signi ficant discrepancies were also 
noted in the methodology published in the Evans and Andersen (2000) article when compared to 
the actual model source code provided by the primary author. The model methodology presented 
in the source paper assurneâ compartment interactions were on a concentration basis (i.e, nM), 
while the methodology presented in the model source code methodology used mass-based 
approac h (nmo les). 
in the methodology presented in the model source code, potential impacts of blood volume on 
overall TCDD blood concentration levels were ignored. Whle ihis particular variable was 
accounted for in the methodology presented in the Evans and Andersen (2000) source paper, the 
impacts of this variable would be negligible in cornparison to the much larger impacts of liver 
and adipose volumes. While not significant in the model output, to ensure methodological 
completeness, the blood volume term was included in the prototype equilibrium model 
developed for this research project. 
Of particular concem is a mis-spi fication present within the calculation of CYPI A2 induction 
provided in the model source code. Both the Evans and Andersen (2000) paper and the 
Simulsolv source code specify the total induction of CYPIA2 in the liver, BMZT, as follows: 
Ah: TCDDn 
BMZT = BM2o + BMti x 
Kd" + Ah: TCDD" 
Eq. 1 
The total induction of CYPlA2 in the tiver can be calculated by a d h g  the basal (initial) level of 
CYPlA2 available in the liver to the additional amount induced by the binding of TCDD to the 
Ah receptor. However, a problem is noted when one breaks down the Evans and Andersen 
methodology. The BM, variable is a dimensionlas parameter that is the factor by which BM, 
(a concentration) is increased. The remaining term is a Mic haelis-Menton kinetics relations hip 
providing a quantification of the Ah receptor occupancy hction (also a unitless parameter). By 
combining the two, a quantification of the induction fold increase over the basal level of 
CYPIA.2, based upon the current Ah receptor occupancy level, is achieved. However, for this 
value to properly quanti@ the amount of CYPlA2 induced as a result of this Ah receptor 
occupancy, the modified induction fold increase value must be multiplied by the basal level of 
CYPI A2 in the liver (as it is the induction fold increase over the basal level). 
Thus, the above equation should be modified to read: 
Ah: TCDLY 
B M ~ T  = BMto + BMzo x BM2, x 
Kdn + Ah:TCDDn 
or perhaps more clearly as: 
Ah: TCDDn 
B M ~ T =  B M Z O X  
Kdn t Ah: TCDD" 1 
Eq. 2 
Eq. 3 
By failing to hclude BM20 in the induction fold increase calculation, the model (as depicted in 
Eq. 1) proposed by Evans and Andersen (2000) would incorrectly limit the impact of CYP lA2 
induction on overall CYPlA2 levels in the liver . The case of the parameter set used for the 
default model (a BM20 of 10 nrnoles/liver), this would result in a 10-fold under-estimation of 
induced CYP I A2 concentrations at higher ligand (TCDD) concentration levels. 
This enor would not be apparent at the low doses dernonstrated by the authors due to the lower 
expected induction rates at these concentrations. However, if dose regimes outside these values 
were used (particularly in the higher dose range), the model would not accurately calculate the 
correct degree of CYP l A2 induction, and thus under-esthate potential hepatic sequestration of 
TCDD at these higher doses. To illustrate this problem, aaalysis results using the equilibrium 
based mode1 were presented using both the original, mis-specified methodology, as well as the 
corrected version. 
4.2.2.2 Species-Specific Physiological Data 
Table 4.12, below, provides a list of the species-specific physiological data used to assess TCDD 
disposition within the Sprague-Dawley equilibrium-based model (Evans and Andersen, 2000). A 
majority of the parameters appear to have been estimated though curve-fitting simulations 
conducted by the Simusolv modelling package. As such, the independent output variables of the 
model are specifically tied to the assurnptions and equations on which the model is built. Given 
this fact, it is likely that the assumed variables would not be applicable to the corrected model 
methodology, due to the considerable impact of the revised CYP 1 A2 induction and binding 
capacity. 
Table 4.12 Default physiological parameten specified for the equilibrium-based 
model by Evans and Andersen (2000). 
- - - -. .. -. - -. -  
Pbysiological Parameter Abbmiitiom Value Rtfertnec 
Liver-t+bld partition coefficient 
Fat-ta-bld partition c ~ ~ c i c n t  
Percent liver volumeibody volume 
Percent fat volumc/body volume 
Ah mcptor avajlability 
Ah rcccptor binding constant 
Ah nccptor/DNA rcccptor binding constant 
CYP I A2 basal levcls 
CYP 1 A2 induction fold increase 
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4.2.2.3 Corn parisons of Steady-State venus Equilibrium-Based Mode1 
Methodologies 
Cornparisons were conduc ted between the steady-state and equilibrium- based models for the 
predictions of cornpartment-specific TCDD concentrations in the blood, liver, and adipose tissue. 
The relative hctions present in both liver and adipose, as well as the overall liver-to-fat 
disposition ratio, were also evaluated. Doses of 0.00 1.0.0 1,O. 1, 1 .O, 10, 100, 1000, and 1 OOOO 
ng/kg bodyweight (a range of 0.000001 to 10 pgkg bodyweight) were used to illustrate any 
inherent dose-dependencies present within the model outcomes. 
To allow for an accurate cornpaison of these parameters following an initial dose, al1 
excretionary processes (i.e., urinas, and biliary excretion) in the PBPK model were eliminated. 
This allowed the PBPK model to achieve a "quasi" steady-state condition, and allow For 
cornparisons on the same footing as the equilibrium-based model. 
4.3 CongenerSpecilc PBPK Modeiiîng of Test Organisms 
Once characterized and corrected (for problems suc h as low-dose instability), the prototype 
PBPK model was used to evaluate the cornpartment-specific disposition pattern of each of the 
assessed PCDD/F congeners (Le., TCDD, TCDF, 1-PeCDF, and 4-PeCDF) for the two primary 
test organisms. The Sprague-Dawley rat was selected due to its use as the prirnary test species 
for the original development of the PBPK, and its common use in laboratory studies on which 
many of the PCDD/F TEQ values were derived. The Gapper's red-backed vole was selected to 
determine whether it is an adequate sentine1 species for use in long-term environmental 
monitoring programs. and if a PBPK model can be designed to approximate the pharmacokinetic 
and phannacodynamic properties controllhg PCDDE disposition within such a sentine1 species. 
4.3.1 Time-Seties Modelling of Congener-Specific Deposition Patterns 
As the current PBPK model is designed to assess PCDD/F disposition and elimination patterns 
based upon a single acute dose, it is most important to evaluate the various congener-specific 
phamacokinetic and phannacodynamic impacts at early time points following administration. 
For this reason, al1 PBPK modelling specifically focused on the first 96 houn (i.e., 4 days) 
following administration. 
To evaluate the dose-dependent impacts of congener-specific PCDDF administration, time- 
senes modelling was conducted for the Sprague-Dawley rat and the Gapper's red-backed vole for 
a multiple dose levels (i. e., 0.00 1,O.O 1.0. 1, 1, 10, 100 pg/kg bodyweight). This allows for an 
evaluation of the potential impacts of ligand-specific CYPI A2 sequestration within the liver on 
overall cornpartment-specific depositional patterns, for a wide range of potential doses. Research 
has indicated that the lower dose levels (i. e., 0 . 0  1 to O. L pglkg bodyweight), more typical of 
those observed in the environment, are unlikely to result in significant CYPIA2 induction and 
ligand-specific sequestration within the liver, while the higher doses (i-e., 1 to 100 (ig/kg 
bodyweight) represent elevated ambient concentrations which would iilcely stimulate 
considerable induction and sequestration, in those congenen which demonstrate a high affinity to 
CYPlA2. 
To evaluate the congener-specific impacts on each test species (i.e., Sprage-Dawley rat and red- 
backed vole), the following congener-specific parameters were estimated for each dose level at 1, 
24,48,72, and 96 houn following administration for TCDD, TCDF, 1-PeCDF, 4-PeCDF, and 
the TCDD-TEQ group: 
Mass @moles) in the liver, adipose tissue, and whole body; 
Concentration @moles/grarn wet weight) in the liver, adipose tissue, and whole body; 
Percent of administered dose/gram in the liver and adipose tissue; 
Percentage of overall Ah and CYP 1 A2 receptor occupancy; 
CYP 1 A2 fold induction, and; 
Percentage of administered dose excreted. 
The overall time-senes curve data for both whole body concentration and liver-to-fat ratio was 
also gathered for each congener at the various assessed dose levels. This data allows for an 
indication of dose-dependency in the overall body burden and deposition patterns in each of the 
congeners, over time. 
The same process was then repeated for the red-backed vole using administered doses 
corresponding to the maximum plant concentration measured as part of the SHTC monitoring 
program at site 1 O7 following the incident (i.e., Winter 1996). This data was then used to 
calculate vole-to-plant BAF values for each of the congeners, for comparison with the vole-to- 
plant BAF values calculated based upon environmental sampling data. 
5.0 RESULTS 
5.1 Summary of Field-Monitoring Results 
5. 1. 1 Temporal Congener-SpeciPc Biota Concentrations 
Temporal data for each of the biological species were grouped into five discrete seasonal sets: i) 
Summer 1996 (pnor to incident); ii) Fa11 19% (prior to incident); iii) Winter 1 996 (afier the 
incident); iv) Sumrner 1997 ( d e r  the incident), and; v) Fall 1997 (after the incident). Tables 5.1 
through 5.3 provide the results of the biological sampling conducted during these specified 
temporal periods for sites 1 1, 107, and 1 14, respectively. 
Of particular interest when evaluating the potential impacts of pharmacokinetics on the 
disposition of the PCDD/Fs within living organisms is the congener-specific pattern of 
concentrations (i. e., congener "fingerprint"). Figures 5.1 through 5.6 provide graphs depicting 
the congener-specific fingerprint breakdown for each of the sampled biological organisms (i.e., 
red-backed voles, Labrador tea, and moss) sampled prior to and following the October 1996 
release incident, for sites 1 1, 107, and 1 14, respectively. The data dernonstrate that the 
congener-specific fingerprint in al1 sampled biota, before and after the release incident, is 
dominatecl by TCDF and the two PeCDF congeners, with the HxCDF congeners providing a 
srnaller but significant portion of the profile. 
A congener-specific breakdown of the PCDDR mass and TEF-adjusted concentrations, as well 
as their relative overall percentages, for both vole and Labrador tea samples taken at each key 
monitoring si te (i. e., sites 1 1, 1 07, and 1 1 4) during summer and winter 1 996 (i. e., immediately 
pre- and post-incident) are provided in Table 5.4 and Figures 5.7 and 5.8. 
Table 5.1 PCDDIF Congener Concentrations (ppt) in Various Environmental M d i a  at Monitoring Site I 1. 








W D F  
TCDD TE0 
PcDD'F Sumnur 19% I Fall 
Cei8tneri * . 
VoleQ Ter i Vole Tca Mou 
2378-TCDD 0.4 nd i 0.4 nd nd 
12378-PECDD 1.6 nd j 1.2 nd nd 
123478-HXCDD nd nd i 0.9 nd nd 
1236711-HXCDD 1.8 nd 1.3 nd 1.2 
123789-HXCDD 0.7 nd 0.4 nd 0.0 
1234678-HPCDD L.4 1.2 2.9 O. 5 14 
OCDD 5 8.7 2.6 2.1 80 
Summcr 1997: FaII 1997 
Volt i Vole Ter M o u  Browrc krriea 
0.8 nd nd nd nd nd 
5.1 i 1 nd nd nd nd 
4.6 i 1.1 nd nd nd nd 
3.8 j 1.1 nd nd nd nd 
1.3 i nd nd nd nd nd 
12 i 3.6 2 13 1.1 4 
5.6 I 4.1 15 7 1 I I nd 
! 




Vole Ter MOII 
4.3 nd nd nd nd nd 
nd 15 0.6 0.6 nd nd 
nd 9.1 nd nd 0 .3  nd 
10 nd nd nd 0.6 nd 
1.7 nd nd nd 0.7 nd 
28 17 1.4 0.9 13 0.4 
nd 23 7.4 4.6 85 4.2 

Tabk 5.3 PCDD/F Congener Concentrations (ppt) in Various Environmental Media nt Monitoriog Site 114. 
Wiater 1996 FiII 1997 
Vole Ter M o u  Browici Vole i Vole Tt8 Broww Limer . 
5 4.4 nd nd nd nd n d :  0.6 i n& nd nd nd 
12378-YECDD 
I ! 
13 9.5 8.8 0.3 nd nd nd i 2 : 0.3 nd nd nd 
123478-HXCDD 
I 
nd 5.4 nd nd nd 0.7 n d !  1.3 i 0.5 nd nd nd 
123678-HXCDD 
I ! 




nd nd 1.3 nd nd 2 nd : 0.6 i 0.5 nd nd 1.6 
1234678-HPCDD 
I 
25 18 18 1.5 1.1 30 0.9 i 17 i 2 1.3 1.3 2 1 
: 
OCDD I Y  18 21 6.8 6.1 140 7 i 16 1 2.6 10 11 110 
2378-TCDF 
12378-PECDF 









Wholt body wct-wcigbl concentratioas. 
' ad- nordrtcct 
Figure 5.1 SHTC Congener-Specinc PCDDIF Disposition Pattern i i  Biological Simples 
from FaIl 1996 at Site 11 
TC00 E C O 0  HZDO HPCDO OC00 TCOF PECDF HZOF HPCOF OCOF 
P C û W  Congeners 
1 Red-ôac ked Vok . Labrador Ter O Moss 1 
Figure 5.2 SHTC Congener-Specific PCDDlF Disposition Pattern in Biological Samples 
from Winter 1996 at Site 11 
1 W Red-ôacked Vok . Labrador Ter O Moss 1 
Figure 5.3 SHTC CongenerSpecific PCDDlF Disposition Pattern in Biological Sampks 
from Summer 1996 at Site 107 
1 R Red-backed Vole R Labrador T ea 1 
Figure 5.4 SHTC Congener-Specifc PCDD/F Disposition Pattern in Biological Samples 
from Winter 1996 at Site 107 
I d = b a c k e d  Vole Labrador T ea O Moss 1 
Figure 5.5 SHTC Congener-Specifc PCDDm Disposition Pattern in Biological Samples 
from Fall IN6 at Site 114 
r. ~edaacked Vole rn Labrador Tea O Moss 1 
Figure 5.6 SHTC Congener-Specific PCDD/F Disposition Pattern in Biological Samples 
from Winter 1996 at Site 114 
/ . Redaacked Vok Labrador Tes O Moss 1 
Table 5.4 Congener-Specilc PCDDIF Miss and TER-Adjusteda Concentrations (ppt) and their Relative Overall Percentages for the 
Vole and Labrador Tea Samples taken at eacb Key Monitoring Site during Summer and Winter 1996. 
Summcr 1996 (pmincidcnt) Wlater 1996 (post-lacident) 
Vole Labrador Tea Vole Labrador Tcr 
Coagcacr M u r  TEQ-Eq Mus TEQ-Eq Masr TEQ-Q MM TEQ-Eq 
Conc. Percent Conc. Perce111 Conc. Percent Conc. Percent Conc. Pcrctat Conc. Percent Coac, Percent Conc. Perccat 




















Table 5=4 Congener-Specific PCDDJF Mass and TEF-Adjusteda Concentrations (ppt) and tbeir Relative Overall Percentages Cor the 
Vole and Labrador Tea Samples taken a each Key Monitoring Site during Summer and Winter 1996. 
-- -- 
~ u k r  =(pre-incident) Wiiittr 1996 (pst-incldent) 
Vole Labrador Tca Vole Labrador T a  
Coagener M a u  TEQ-Eq Mur TEQ-Eq Mms TEQ-Eq MW TEQ-Eq 
Conc. Percent Conc, Percent Conc. Percent Conc. Pcrccat Conc. Percent Coac. Percent Coac. Percent Conc. Ptrccnt 
Table 5.4 Congener-Specific PCDDlF Mass and TEF-Adjusteda Concentrations (ppt) and their Relative Overall Perceotages Cor the 
Vole and Labrador Tea Simples taken at each Key Monitoring Site during Summer and Winter 1996. - 
Summcr 1996 (prc-incident) Winter 1996 (pst-incident) 
Vole Labrador Te. Vole Labrador T u  
Congener M m  TEQ-Q M m  TEQ-Eq Mass Tw-Eq M m  T E W q  
Conc. Percent Conc. Percent Coiic. Percent Conc, Percent Cooc. Percent Conc. Percent Conc. Percent Conc. Percent 



















' Congener-specific mass concentrations were multiplied by thrir respective TEF value (Van den Berg et al., 1998) to obtaiii a TCDD-TEQ concentration. 
nd = non detect 
Figure 5.7 Congener-Specinc PCDDlF Mass and TEF-Adjusted Percentages for 
Rcd-backed Voles and Labrador Tea sampled at Site 107 duriig 
S u m e r  19% (Pre-Incident). 
Figure 5.8 Congener-Specific PCDD/F Mass aiid TEF-Adjusted Percentages for 
Red-backed Voles and Labrador Tea sampled at Site 107 during 
Win ter 1 996 (Post-Inciden t). 
Plant-to-Vole bioaccumulation factors (BAFs) w m  also calculated for each of the PCDD/F 
congeners at each temporal sarnpling period (i. e., Summer 1996, Fall 1 996, Winter 1996, 
Summer 1997, and Fa11 1997, where sarnpling data were available). Tables 5.5 through 5.7 
provide the congener-specific BAF values representing sites 1 1, 107, and 1 14, respectively. 
interestingly, this data demonstrates that, in addition to having the highest environmental 
concentrations, the highest plant-to-vole BAF values are observed in the PeCDF and HxCDF 
congeners. 
Table 5.5 Calculated Vole-teplant Bioaccumulation Factors (BAFs) for Site 11. 
Summer 1996 FaU 1996 Winter 1996 Fa11 1997 
Congener 




123678-HXCDD 1 .OS 
123789-HXCDD 0.50 
1234678-Hf CDD 5.33 5.8 0.2 1 
OCDD 0.59 1.24 0.03 
234678-HXCDF O 64.7 1 52.3 8 
123789-HXCDF 
1234678-HPCDF 24.44 9.47 2.07 
1234789-HPCDF 
OCDF 2.3 3.5 0.18 *.......*.................................................-*.***....-*.*.........*-.............--.--*.-. 
TC0 D-TEQ 105.8 26.9 54 
Table 5.6 Calculated Vole-t+Plant Bioaccumrlation Factors (BAFs) for Site 107. 
Summer 1996 Winter 1996 Ml1997 
Vole: Teu Vole: Tea VokMoss Vole= Tea Vole: MOSS 
-  - - -. . - --- 
2378-TCDD 4.50 63.75 85 .O0 
12378-PECDD 1 1.67 67.10 24.76 2.00 
123478-HXCDD 5.80 60.63 6.74 1.14 
123678-HXCDD 6.20 55.88 2.97 0.52 
123789-HXCDD 2.13 12.50 0.69 0.18 
1234678-HPCDD 1.39 8.47 0.33 16.67 0.16 
OCDD 0.24 1 .O7 0.04 2-17 0.03 
2378-TCDF 0.32 2.9 1 8.18 4.42 0.54 
12378-PECDF 1.83 10.67 20.00 1.74 
23478-PECDF 26.21 240.96 434.78 453.49 22.94 
123478-HXCDF 7.20 88-24 69.59 1 18.75 4.94 
123678-HXCDF 15.76 1 72.4 1 142.86 7.93 
234678-HXCDF 17.50 126.32 63.16 1.67 
123789-HXCDF 2 1.82 161.1 1 161.1 1 10.27 
1234678-HPCDF 3.94 41.19 7.2 1 20.00 0.87 
1234789-HPCDF 5.20 63.4 1 9.29 0.69 
OCDF 0.65 2.79 0.17 3.33 0.06 
........II............................. ~.................................*.........*.-..*...............*....................~.~...*............................-...-.---......~..........---.---......*....* 
TCDû-TEQ 37.1 323 373.8 239.4 16.3 
Table 5.7 Calculated Vole-toePlant Bioaccumulation Factors (BAFs) for Site 114. 
-- -- -- - -  - 
Congeners Summer 1996 Fa11 1996 Winter 1996 Fall 1997 
Vole: Tea Vole: Tm Vole: Moss Vole: Tea Vole: Moss Vole: Teu 
2378-TCDD 5.00 O O O 
12378-PECDD 8.25 61.00 
123478-HXCDD 9.33 O O 3.86 
123678-HXCDD 8.00 O O 14.75 2.1 1 
123789-HXCDD I O O 0.33 
1234678-HPCDD 2.02 0.04 13.85 0.60 1.54 










OCDF ................. ................................................................................................................................................................................... 
TCDD-TEQ 100.9 19.5 19.2 186.6 205.2 106.5 
-2 
It is important to note the significant differences in BAF values pnor to and after the accidental 
release incident in October 1996. 
5.1.2 Estimated Congener-Specific Consumption Rates for Red-Backed Voles 
Given their typical diet of the red-backed vole and the absorptive nature of the sampled plants 
(Le., Labrador tea and rnoss), detected concentrations of PCDD/Fs on sampled plant material cm 
be viewed as a suitable smgate for the calculation dietary intakes for the vole sentine1 species. 
Based upon a typical daily consumption rate of 0.3 1 g/g/d for Gapper's red-backed voles 
(McManus, 1974), estimated daily intakes were caiculated for each of the key assessed congeners 
for monitoring sites 1 1, 107, and 1 14. Table 5.8 provides a summary of the highest biota 
concentrations measured during Winter 1996 and the related estimated daily intakes. The Winter 
1996 sampling set was selected due to the elevated ambient PCDD/F concenûations arising fiom 
the October 1996 SHTC facility release incident and short-term acute nature of the ambient 
increase in PCDD/F concentrations. 
Table 5.8 Summary of Highest Biota Concentrations Measurd during Winter 1996 
for the Key Congeners, and Related Estimated Daily Intakes. 
Site I l  Site 107 Site 1 14 
TCDF 1 70 870 52.7 440 4600 136.4 280 1100 86.8 
TCDD-TEQ 38.2 17279 11.8 195 5î570 60.5 67 4990 20.8 
Estimatcd daily intakc calculations wcre based upon a daily food consumption rate o f  0.3 1 gfg/d for Gapper's red-backcd 
voles (McManus, 1974). 
nd = nondetect 
5.2 Validation of Prototype Steady-State PBPK Mode1 
Following construction of the prototype steady-state PBPK model, it was essential to validate the 
model against both the graphical output presented in the Wang et al. (1997) source paper, as well 
as the actual time course tissue distribution data presented in the Wang et al. (1997) paper. This 
step ensures an accurate replication of the Wang et al. methodology was used in the development 
of the base steady-state PBPK model used in this research project. 
5.2.I Cornparison of Modelled Results versus Wang et a& (1997) Graphs 
The initial TCDD PBPK model described by Wang et al. (1997) was developed with the time 
course tissue distribution data obtained following a single oral dose of 10 pg ['HITCDDAC~ to 
fernale Sprague-Dawley rats. Various t h e  points were selected by the authors to demonstrate 
the importance of early tirne points in accurately assigning unique parameter values such as 
permeability (Wang et al.. 1997). Based upon these t h e  points, the authors provided graphs of 
experimental results compared to the results predicted in their model simulations, for the key 
accumulative and non-accumulative cornpartmentai tissue groups (Figures 5.9 and 5.10). This 
experirnental design was duplicated using the current prototype steady-state model to 
demonstrate consistency between the rmlts depicted in Wang et al. (1997) and the reproduced 
model, based upon the Wang et al. (1 997) methodology. Figures 5.1 1 and 5.12 provide graphical 
comparisons of experimental data versus the predicted TCDD tirne series tissue concentrations in 
accumulative and non-accumulate tissue compartments, respectively, using the reproduced 
model. Visual comparisons of the two sets of model outputs indicate that the current prototype 
steady-state model appears to have accurately duplicated the results described in Wang et al. 
(1997). 
Tissue disposition at early tirne points (i.e., within the fint 24 houn) following the TCDD dose 
administration is of particular importance when evaluating the ability of the current 
developmental model to reproduce the results presented in Wang et al. (1997). Figures 5.13 and 
5.14 provide the early time point results presented in the Wang et al. (1 997) paper, and Figures 
5.15 and 5.16 provide the corresponding results produced by the cunent development model. 
Again, visual comparisons of the two sets of model outputs indicate that the current prototype 
steady-state model appears to have accurately duplicated the results descnbed in Wang et al. 
( 1997). 
Figure 5.9 Erperimentally-derived TCDD concentrations in rats compared to 
curves describing model simulation results in accumulative tissue 
compartments (Wang et al.. 1997). 
1 .OC5 
Figure 5.1 O Cornparison of erperimental (Wang et al., 199'1) versus predicted 
(with reproduced model) TCDD tirneseries tissue concentrations in 
various accumuîative tissue compartmenb. 
Figure 5.11 Erpcrimentally-detived TCDD concentrations in rats compared to 
cuwes describhg model simulation results in non-accumulative tissue 




O 1 0 0  200 300 400 Sm 600 700 800 
Figure 5.12 Comparison of experimental (Wang et al., 1997) versus predicted 
(with reproduced model ) TCDD tirneseries tissue concentrations in 
various non-accumubtive tissue compartments. 
aot , 
Figure 5.13 Experiwntally-derived TCDD concentrations in rats compared to 
cuwes describing model simulation mults in aecumulative tissue 
compartments, at early time points (Wang cl al., 1997). 
Figure 5.14 Cornparison of experimental (Wang et al., 1997) venus predicted 
(witb reproduced model) TCDD tirneseries tissue conceitrations ia 
various accumulative tissue compartwib, at eariy time points. 
Figure 5.15 Experimentaiîy-derived TCDD concentrations in rab compared to 
curves describing mode1 simulation results in non-accumulative tissue 
compartments, at early time points (Wang e~ al., 1997). 
Figure 5.16 Cornparison of experimental (Wang et al., 1997) versus modelled 
TCDD timeseries tissue concentrations in various non-accumulative 
tissue compartments, at early time points. 
5.2.2 Comparison of Ekperimental versus Modellrd Disposition Results 
Comparative evaluations were conducted to determine if the developed steady-state PBPK model 
accuratel y re flected the results of expeimental studies conducted with S prague-Dawley rats 
(Wang et al., 1997) and C57BU6J mice Piliberto et al., 1999). 
Sprague-Dawky Rat 
The experimental results (Wang et al., i 997) of the t h e  coune of TCDD distribution in al1 
relevant tissue compartments (i.e., the blood, liver, lungs, kidneys, spleen, skin, muscle, and 
adipose tissues) after an oral administration of 10 pg ['H]TCDD/~~ to Sprague-Dawley rats, and 
similar cornpartment-specific estimates calculated by the steady-state PBPK model, are provided 
in Table 5.9. 
Table 5.9 Comparison of experimental ' and modelled compartment-specirie time course 
distribution of TCDD (% administereà dosdg) after oral administration to 
Sprague-Dawley rats. 
Lrags Splna Rcst a l  tbc Body 
dosing 
(boum) Experimeitil Moddld Esperimtatrl Moddlcâ Experimrntrl Moddld Experimeobl Moddld 
Skin 
Experimcaui ModeIlcd 
0.005 I 0.003 0.00 i 
0.003 * 0.002 0.003 
0.02 1 0.005 0.02 
0.075 0.021 0.068 
0.093 * 0.025 0.092 
0.061 * 0.014 0.062 
0.056 * 0.008 0.049 
0.036 0.006 0.035 
0288 * 0.091 0.6 1 0.002 * 0.000 0.012 
' Tîmc counc tissue disaibution of TCDD afùr oral drninimtion o f  10 pg ['H]TCDWkg to Spraguc-ûawlcy rats; mean i standard 
dcviation (n = 3-5 aninials/gmup) (Wang et al., 1997). 
To assess whether the cornpartment-specific TCDD concentrations provide an accurate surrogate 
for experimentally-denved concentrations reported in Wang et al. (1 997), modelled 
concentrations were evaluated as to whether they fa11 within the 95% confidence intervals 
(represented by 2.575-times the standard deviation for 5 observations) of the experimental 
results. Table 5.1 O, below, provides the results of tbis analyses, and indicates that the modelled 
concentrations fell within the 95% confidence interval approximately 80% of the tirne with most 
of the excursions occuning at later time points (i.e., > 14 days following exposure). 
Furthemore, the vast majority of the excursions were observed in the lung and spleen 
compartments, with the important disposition compartments (i. e., the skin, liver, and adipose 
tissue) demonstrating a high degree of correlation between experimental and modelled data 
(falling within the 95% confidence interval approximately 89% of the time). 
Figure 5.17 provides a snapshot cornparison of the experimental data, including the 95% 
confidence intervals, and the modelled TCDD concentrations in the liver and adipose tissue 
compartrnents over t h e .  As indicated in Table 5.10, the figure demonstrates the high degree of 
consistency between the experimental results and modelled TCDD cornpartmental concentration 
predic tions. 
Table 5.10 Evaluation of Time Course Compartment-Specific Concentration 
(% Admiaistered DoseEram) for Modelled versus Experimental Data. 
Table 5.10 Evalration o f  Time Course Cornpartment-Specific Concentration 











Time course tissue distribution of TCDO after oral administration (Wang et ai., 1997). 
Does rnodeiled results fall within the 95% confiderice intewal(2.575~ SD for 5 observations)? 
P r e d i i  value was marginaliy outside of aie 95% confidence interval, with only a 0.05% difference betwwn 
the predicted value and the upper CI limit value. 
Figure 5.17 Cornparisoi of experimental (with 95% confidence intervals) venus 
modelld liver and adipose tissue cornpartmental TCDD distribution. 
A statistical analysis of the surns of squares variance between the experimental and modelled 
disposition results was also conducted, based upon the percentage of adrninistered dose per gram 
tissue in each cornpartment and tirne point. The surns of squares was 51.9 and 60.2 for the 
experirnental and modelled mean values, respectively. This results in a residual Sums of Squares 
of 1.66, indicaiing that the modelled data effectively represented the experimental data 96.8% of 
the time, based upon its residual sums of squares error. 
Based upon the above evaluations, it was concluded that the Sprague-Dawley TCDD PBPK 
mode1 appears to accurately duplicate the output of the mode1 presented in Wang et of. (1 997). 
Furthemore, it also appeais to accurately represent the expenmentally-derived data presented in 
Wang et al. (1997). 
The experimental results (Diliberto et ai., 1999) of the time course of TCDD distribution in al1 
relevant tissue compartments (i.e., the blood, liver, lungs, kidneys, spleen, skin, muscle, and 
adipose tissues) after an oral administration of 25 pg ['HITCDDkg to C57BU6J mice, and 
similar cornpartment-specific estimates calculated by the steady-state PBPK model are provided 
in Table 5.1 1. Unfomuiately, expenmentai results were only provided at 4 days post-treatment, 
and as such it is dificult to determine whether the model accurately reflects the expenmental 
results at differing time points. 
Tabk 5.11 Cornparison of experimental and modelled conpartment-speciflc time 
course distribution of TCDD (% administered dose/@ after oral 
administration to C57BLl6.J rnice, edays Post-treatment. 
Patrmcttr Exprimatai Modelled 
Lungs 0.27 i 0.07 O. 144 
Kidneys 0.17 * 0.02 0.21 3 
Spletn 0.14 I 0.02 O. 178 
Skin 0.89 O. 19 O. 79 
Liver 16.52 * 2.58 18.27 
Adipose Tissue 4.67 * 0.70 4.9 1 ...**................*.............................................*~..........-*...-..*......................*.....*...................~.*...*............*.*~.........***.~......~~*~*~~.....*.*~*.-...... 
LivcrfFat Ratio 3.55 * 0.41 3.72 
T i m  course tissue distribution (expresscd as mtons I SD) of TCDD &cr oral administration of 25 pg ['H]TCDD/kg IO 
C578U6J mice, 4-days pst-ûeatmcnt (Dilibcrto et al., lm). 
While the modelled results slightly overestimated disposition in most of the assesseci 
compartments, they were generally within one standard deviation of the experimental mean 
concentration (see Figure 5.18), and well within the 95% confidence interval of the experimental 
results. Given the agreement between experimental and modelled results in most compartments, 
as well as with the liver-to-fat ratios, it was coacluded (baseci upon the minimai experimental 
data available) that the modified model provided a reasonable estimation of TCDD disposition., 
based upon the Diliberto et d. (1999) data. 
Figure 5.18 Cornparison of experimental and modelled cornpartment-specilc TCDD 
concentrations (% adminisbred doselgram) after oral administration of 
25 pg/kg to C57BL/6J mice, 4days post-treatment. 
Diliberto et al. (1999) also conducted a time course study of 4-PeCDF distribution in al1 relevant 
compartments &et an oral administration of 300 pg [3H]4-PeCDFkg to C57BU6J mice. Table 
5.12, below, provides the results of this study compared to the sirnilar cornpartment-specific 
estimates calculated by the research steady-state model, after Cdays of exposure. 
Table 5.12 Cornparison of experimental and modelled cornpartment-specific time 
course distribution of 4-PeCDF (% administered dose/@ after oral 
administration to C57BLldJ mice, edays Post-treatment. 
Lungs 0.09 0.03 0.093 
Kidncys 0.028 * 0.002 0.07 
S p l m  0.06 * 0.0 1 0.06 
Skin 0.22 * 0.09 0.233 
Liver 25.44 * 2.13 24.6 
Adipose Tissue 1.38 * 0.14 1.43 .... I.1.*~.~~.**.*........~.*.~*.*.*.*...~............-.-.-..-~..-...-.-.*-----.~*--.--.---..-.-*.-.-.-.-..-.-.---.-.-*-.*.-*-.--... 
LivdFat Ratio 18.68 k 2-96 17.2 
Timc course tissue distribution (utprrsscd as mcans * SD) of 4PcCDF aftcr orai administration of 300 pg ['H]4- 
PcCDFtkg to C57BU6J rnicc, 4-days post-tmumcnt (Dilibcrto et al., 1999). 
While the modelled results slightly overestimated disposition in most of the assessed 
compartments, the modelled results were generally within one standard deviation of the 
experimental mean concentration (see Figure 5.19), and well within the 95% confidence interval 
of the experimental results. Given the agreement between experimental and rnodelled results in 
most compartments, as well as with the liver-to-fat ratios, it was concluded (based upon the 
minimal experimental data available) that the modified mode1 provided a reasonable estimation 
of 4-PeCDF disposition, based upon the Diliberto et al. (1 999) data. 
Figure 5.19 Cornparison of experimental and modelled cornpartment-specik 4-PeCDF 
concentrations (% administerd doselgram) after oral administration of 300 
pgkg to CS7BLl6.J mice, 4-days post-beatment 
Given the low % administered dose/gram found in the lungs, kidneys, spleen, and skin 
compartments, Figure 5.20, below, provides a closer evaluation of these particular 
cornpartmental tissue gmups. 
Figure 5.20 Cornparison of experimental and modelled cornpartment-specific 4- 
PeCDF concentrations (% administered doselgram) after oral 
administration of 300 pghg to C57BLl6.J mice, edays post-treatment 
(only Iungs, kidneys, spleen, and skin). 
5.2.3 Sensitivity Anafysis of Prototype Stea@State PBPK Mode1 
A sensitivity/uncertainty analysis was conducted on the steady-state PBPK model based upon 
5,000 Monte Carlo iterations, to detmine which variables pose the largest influence on the 
ultimate outcome of the model (Le., overall body sequestration of TCDD). Table 5.13 provides 
the contribution to variance (by percentage) of each parameter group, over a range of  
administered dose levels, ai 8-,24-, and 48-hours after exposure, for the Sprague-Dawley rat. A 
complete breakdown of the contribution to variance of each individual parameter is provided in 
Table B- 1 .O of Appendix B. 
Table 5.13 SensitMty Analysis of Contribution to Variance between TCDD PBPK 
Mode1 Variables and Sequestration Outcome for Specik Parameter 
Croups8 the Spraguc-Dawley Rat. 
Parameter Groups 
Administered Dose of TCDD (pgkg) 
O. 1 0.316 1 3.16 10 
&Houn after Exposure 
General Physiological Parameters 
Equilibrium Distribution Ratio 
Penneability 
Cornpariment Volumes 
Absorption and Elimination 
Ah Receptor Phannacodynarnics 
CYP 1 A2 Reccptor Phannacodynarnics 
24-Hours alter Exposure 
General Physiological Parameters 
Equilibrium Distribution Ratio 
Pcrmeability 
Cornpartment Volumes 
Absorption and Elimination 
Ah Receptor Pharmacodynarnics 
CYP 1 A2 Reccptor Pharmacodynamics 
72-Houm after Exposure 
General Physiological Parameters 
Equilibrium Distribution Ratio 
Permcability 
Cornpartment Volumes 
Absorption and Elimination 
Ah Reccptor Pharmacodynamics 
CYP I A2 Recmtor Phannacodynamics 2 1.2% 
Applicable parameters wcrt addcd to produce an overall total contribution to variance percentage for each 
parametcr group. A detailed list of the specific parameters combincd to fom cach group can be found in Table 
6-2.0 of Appendix B. 
Graphical cornparisons of the contribution of variance for each of the parameter groups at various 
administered dose levels are presented in Figure 5.2 1 through 5.23 at 8-, 2 4 ,  and 48-hours 
following exposure, respectively. 
Figure 5.21 Cornparison of contribution of variance (96) for key parameter 
groups at each administered dose level, &bours after exposure. 
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Figure 5.22 Cornparison of contribution of variance (%) for key parameter 
groups at each administered dose level, 244ours after exposure. 
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Figure 5.23 Cornparison of contribution of variance (%) for key parameter 
groups at each administered dose level, 72-houn after exposure. 
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Results of the sensitivity analysis indicate that while individual parameten within the set 
parameter groups do Vary as to their relative impacts on overall contribution to variance, there 
appears to be very little difference in overall group variance patterns between the three exposure 
tirnes (Le., 8-, 2 4 ,  and 48-hours following dose exposure). 
Unlike the relative lack of variance at diffenng time points after exposure, results of the 
sensitivity analyses indicates a definite dose-dependancy in those variable groups showing the 
highest contribution of variance. in addition to the overall parameter group evaluations, Table 
5.14 provides the top 15 individual parameters demonstrating the Iargest contribution to variance 
in TCDD disposition for each dose level, 2Chours following initial exposure. 
At low administered doses (i. e., below the 0.1 pgkg bodyweight level), the compartment- 
specific equilibrium ratios and general physiological parameters dominated the contribution to 
variance in TCDD disposition kinetics (i.e., > 45%), with Ligand-receptor pharmacodynamies 
typically playing a very rninor d e .  The receptor body weight, biliary excretion rate, and 
equili'brium ratio of skin tissue to blood concentration appear to be the key leverage parameters at 
this particular dose level. However, as the exposure dose increases, these roles become reversed 
with pharmacodynamie impacts dominating the overall contribution to variance. 
For example, at the 0.3 16 pgkg bodyweight dose, CYP IA2 binding kinetic parameters 
(primarily the concentration resulting in half maximum induction folds) have the largest 
contribution to variance, with Ah receptor related parameters playing a lesser (though still 
elevated) role. However, at the 1 )ig/kg bodyweight dose, the conüibution of Ah receptor 
binding parameters (primarily the Ah receptor binding capacity in the large compartments such 
as the skin and lungs) to overall variance in TCDD disposition is elevated, with CYPI A2-related 
parameters having a greatl y reduced role. 
It is interesting to note that the oral bioavailability of TCDD appears to be a significant leverage 
variable at the 0.3 16 pgkg bodyweight dose level, while playing a very minor role at the 1 pgkg 
bodyweight level. Conversely, the cornpartmental permeability of the liver is important at the 
higher dose rate, while not even in the top 15 list of parameters at lower dose exposures. 
As the administered dose increases beyond the 3.16 pg/kg bodyweight level, the contribution to 
variance fiom ligand-receptor parameters r e m  to the levels observed at the very low doses (i.e., 
s0.1 pg/kg bodyweight), while parameten related to compartmental permeability, as well as 
TCDD absorption and elirnination, play key roles in the ultimate disposition of the contaminant. 
At the 3.16 pg/kg bodyweight dose level, the equilibriurn ratio of liver tissue to blood 
concentration and the rest of the body volume as a percentage of body weight appear to be the 
dominant parameters, while at the higher 10 pgkg bodyweight dose, the compartmental 
permeability of the adipose tissue and liver compartments conûibute more than 20% of the 
overall variance in TCDD disposition. 
Tabk 5.14 Top 15 Physiological Parameten by Contribution to Variance to TCDD 
Disposition, 2CHours at each Administered Dose Level. 
Pbysiologicrl Parameter Contribution to Variance 
0.1 18 TCDDhg Dose 
Body weight of the receptor 1 1.6% 
Biliary excrttion rate 8.6% 
Equilibrium ratio of skin tissue to blood concentration 7.8% 
Allometric paramter for cardiac output fiom bodyweight 6.1% 
Absorption rate constant fiom G1 tract to blood 5.5% 
Equilibrium ratio of kidney tissue to blood concentration 5.4% 
Lung volume as a petcentilge of body weight 4.8% 
Basal level of CYPI A2 within the liver 4.4% 
Cornpartmental pcrmcability of the skin 3.9% 
Urinary cxcrction rate 3.8% 
Dissociation constant of CYP I A2 binding 3.7% 
Equilibrium ratio of spleen tissue to blood concentration 3.6% 
Equilibrium ratio of tissue in the rest of the body to blood concentration 3.3% 
Hill coefficient 2.9% 
CYPI A2 physiological delay time 2.8% 
d3 16 c4g TCDDfig Dose 
Concentration to cause half of the maximum induction fol& 
Oral bioavailability of TCDD 
Maximum induction folds over the basal induction rate 
Compartmcntal permeabiiity of the skin 
Equilibrium ratio of adipose tissue to blood concentration 
CYP 1 A2 physiological dclay timc 
Skin volume as a perccntage of body weight 
Hill coefficient 
Compattmental pcmieability of the rest of the body 
Kidncy volume as a pcrcentagc of body weight 
Venous blood volume as a percmtage of body weight 
Ah reccptor binding capacity in the liver 
Ah reccptor binding capacity in the spleen 
First-ordcr degradation rate constant of CY P I A2 binding 
Ah receptor binding capacity in the skin 
1 M TCDDhg &se 
Ah receptor binding capacity in the skin 19.4% 
Cornparmental penneability of the iiver 1 1.2Y0 
Ah receptor binding capacity in the lungs 7.1% 
Equilibrium ratio of dipose tissue to blood concentration 7.0% 
Urinary excretion rate 6.2Y0 
Atlomcmc parametcf for cardiac output fiom bodyweight 4.4% 
Cornpartmental permeability of the adipose tissue 4.0% 
tung volume as a perccntage of body weight 3.8% 
Kidney volume as a percentagc of body wcight 3.7% 
Skin voIumc as  a perccntage of body weight 3.6% 
Oral bioavailability of TCDD 2.9% 
Basai Icvel of CYPI Aî within the liver 2.6% 
Dissociation constant of Ah mcptor binding 2.6% 
Hill coefficient 2.6% 
Ah reccptor binding capacity in the spleen 2.3% 
3.16 ?CDD/Lg Dose 
Table 5.14 Top 15 Physiological Parameters by Contribution to Variance to TCDD 
Disposition, 24-Hours at each Administered Dose Level. 
Pbysiological Parameter Contribution to Variance 
Equilibrium ratio of Iivcr tissue to blood concentration 1 3 .OVO 
Rest of the body volurnc as a percentagc of body wcight 
Maximum induction folds over the basal induction rate 
Cornpartmental pemmibility of the skin 
Kidney volurnc as a pcrcentage of body wcight 
Cornpartmental pmeability of the kidncys 
B a l  level of CYP 1 A 2  within the liver 
Ah rcceptor binding capacity in the skin 
Ah reccptor binding capacity in the livcr 
Spleen volume as a percmtage of body weight 
Equilibrium ratio of kidney tissue CO blood concentration 
Lung volume as a pcrcmtage of body wcight 
Adipose tissue volurnc as a pcrccntage of body weight 
Urinary excretion rate 
Equilibriurn ratio of lung tissue to b l d  concentration 
f O TCDDhg Dose 
Compartmcntal pmncability of the adipose tissue 
Cornpartmentai pcrmeability of the livct 
Fintsrder dcgradation rate constant of CY P 1 A2 binding 
Absorption rate constant h m  Gl tract Io blood 
Maximum induction folds over the basal induction rate 
Equilibrium ratio of tissue in the rcst of the body to blood concentration 
Concmtntion to cause half of the maximum induction fol& 
Equilibrium ratio of livcr tissuc IO blood concentration 
Biliary excrction rate 
Cornparanenta1 pcnmability of the kidneys 
Skin volume as a pcrccntage of body weight 
Dissociation constant of Ah rcceptor binding 
Kidncy volume as a perccntage of body wcight 
Lung volume as a pcrccntage of body weight 
Equilibrium ratio of adipose tissue to blood concentration 2.1% 
5.3 Validation of Prototype Equüibrium-bascd Mode1 
Following construction of the prototype equilibrium-based model, it is usehl to validate the 
model against both the graphical output presented in the Evans and Andersen (2000) source 
paper. This step m e s  that an accwate duplication of the Evans and Andersen methoâology 
was used in the development of the base equilibnum-bas4 model used in this research project. 
5.2.1 Cornparison of Modoled Results versus Evans und Andersen (2000) Graph 
Evans and Andenen (2000) conducted an analysis of liver ûaction (FH) fluctuations with respect 
to changing average body concentrations, and presented a plot of the resulting cuve (see the 
default FH c w e  in Figure 5.24. below). To demonstrate an accurate reproduction of the 
published Evans and Andersen (2000) results, the equilibrium-based methodology and described 
analysis was recreated in an Excel spreadsheet. The resulting cuve is provided in Figure 5.25. 
Based upon a visuai cornparison of the two figures, it appears that the based equilibrium model 
correctly reproduces the results presented by Evans and Andersen. 
A similar anaiysis was conducted using the comected version of the Evans and Andersen (2000) 
methodology, and the resulting curve is ploned along with the previous curve in Figure 5.26. As 
outlined in the methodology section, the mis-specification in the Evans and Andersen (2000) 
model results in a lower ceiling value for the liver bction due to the 10-fold restriction in the 
maximum CYP 1 A2 induction fold increase. As noted previously, this impact is not imrnediately 
evident at lower exposure doses (i.e., < 0.01 ngkg), and only becomes apparent when Ah 
receptor occupancy is sufficient to result in an induction fold increase in rnicrosomrl CYPIA2 
levels. 
Figure 5.24 Simulation resvlts lot the liver fraction (FH) presented in Evans and 
Andersen (2000). 
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Figure 5.25 Reproduction of dose-dependency curve based on original Evans and 
Andersen (2000) methodology. 
Avmrrga Body Concantratlon (ngikg) 
Figure 5.26 Reproduction of dose-dependency crwes using both the original and 
corrected Evans and Andersen (2000) methodology. 
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5.2.2 Cornparison of Steaây41ate versus Eqailibriumdased Mode1 
A comparison of the three assessed model methodologies (i.e., steady-state PBPK model, 
original equilibrium-based model, and corrected equilibrium-based model) was conducted to 
detemine if a two-cornpartment equilibnum-based model could adequately estimate the 
disposition pattern of TCDD in the Sprague-Dawley rat. This would allow one to determine 
whether the more cornplex, steady-state PBPK model is over-parametenzed in its simulation of 
the physiological process involveû. 
To achieve this comparison, the excretion pathway was eliminated fiom the Wang et al. model to 
allow cornpartmental concentrations to reach a "pseudo" steady-state. As indicated in Figure 
5.27, this pseudo steady-state level appeared to occur 24-houn following exposure to an 
administered dose of 1 0 pg/kg bodyweight. As such, comparisons with the equilibriurn-based 
models were conducted using the data estimated at 24-hours following exposure. Interestingly 
enough, pseudo steady-state was not achieved until the 96-hour point at dose exposures less than 
0.01 pgkg bodyweight (see Figure 5.28) as a fùrther physiological delay was required while 
initial liver and fat cornpartmental concentrations equilibrated. As such, comparisons with the 
equilibrium-based models were conducted using the data estimated at 96-hours following 
exposure, for doses at and below 0.01 pgkg bodyweight. 
Figure 5.27 Graphical plot of tirne-serks chemical concentrations in the 
liver and fat compartments following a 10 pgkg bodyweight 
dose, using the steady-state PBPK model with excretion 
elimina ted. 
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Figure 5.28 Graphical plot of tirne-serks chemical concentrations in the 
liver and fat compartments following a 0.01 pglkg bodyweight 
dose, using the steady-state PBPK mode1 with excretion 
eliminated. 
O 20 40 6 0 8 0 1 O 0  120 
€lapsad Tlme (hours) 
Table 5.15 provides the dose-specific liver-to-fat ratios, Ah and CYP 1 A2 receptor occupancy, 
and CYPlA2 fold induction estimates for the steady-state PBPK model (mode1 A), the original 
equilibnum-based model (model B), and the correcteci equilibrium-based model (model C). 
Table 5.15 Cornparison of steady-state results of the three assessed modeb of TCDD 
disposition in the Sprague-Dawley rat 
Receptor Occoprncy 
Dosc Liver-t+Fit Ratio CY Pl A2 Fold induction Ab CYPlA2 
A .  ~b CC A B C A B C A B C 
Model results at pseudo steady-state fiom Wang et al. (1997) PBPK modcl with excrction eliminatcd. 
Model results fiom quiiibriurn-bad mode1 derived h m  origind Evans and Andersen (2000) met)lodology. 
Model tcsults from quilibri urn-basai rnodei dcrivcd h m  comctcd Evans and A n d a n  (2000) mtthodology. 
Results of the cornparison indicate that neither the original nor comcted equilibrium-besed 
model adequately retlected the results estimated by the modified steady-state PBPK model. 
While the original equilibriurn-based model (model B) provided an accurate reflection of the 
steady-state results (model A) at moderate to low dose levels (i-e., s 1 .O ng/kg), due to the mis- 
specification in the CYP I A2 indiction and binding calculations it failed to adequately predict 
potentially elevated exposure doses. Udortunately, as some of the parameters specified by 
Evans and Andersen (2000) appear to have been selected to ensure the modelled outcome 
accurateiy refiect the desired dose-dependency c w e s  of cornpartmental disposition, correction 
of the mis-specification (model C) produces even les-accurate results at elevated exposures 
doses. 
In an attempt to correct this over-specification in the selected receptor-ligand parameters, the 
following three parameters (Table 5.16) were systematically adjusted until the corrected 
equilibrium-based model provided a reasonably accurate prediction of the results produced by the 
steady-state model (model A) at al1 dose levels. 
Table 5.16 Revisd parameten used in the updated equilibrium-based model. 
Pbvsioloeical Parameter Abbmiation Original Valut Reviscd Valut 
- -  
Ah tcceptor binding constant KB I 0.04 nM 5 nM 
Ah rcccptor/DNA reccptor binding constant Kd 0.05 nM 0.005 nM 
CYP I A2 induction fold increase BM2i 85 fold 16 fold 
A cornparison of steady-state results to those predicted using the updated version of the 
equilibrium-based model (Model D) are presented in Table 5.17. Using these revised receptor- 
ligand based parameten, the updated model appears to adequately reflect the results estimated by 
the steady-state PBPK model. 
Table 5.17 Cornparison of steady-state results with an updated version of the 
equilibrium-bued modd of TCDD disposition in the Spraguc-Dawley rat. 
Receptor Octopracy 
DoSc Liver-t+Fat Ratio 
CY Pl A2 Fold Induction 
( w m  Ab CYPlA2 
A '  D'  A D A D A D 
- - --- 
O 0.5 0.46 0.0002% 0.0001% O% O% 1 0.0004 
0.0 1 0.5 0.46 0.002% 0.0006% OYo 0% 1 0.004 
0.1 0.6 0.48 0.0 18% 0.006% 0% OYo 1.1 0.038 
1 0.7 0.62 0.2Vo 0.062% 0.001% 0.002% 1.4 0.352 
1 O 1.2 1.45 1.5% 0.62% 0.005% 0.0 1 2% 2.4 -.- 7 7 
100 4.9 3.9 1 1.5% 5.8% 0.043% 0.063% 5.3 7.6 
IO00 7.9 6.43 43.8% 38.3% 0.259% 0.4% 10.5 13.7 
1OOOO 9.8 7.1 85.4% 86.1% 1.91% 3.8% 15.1 15.7 
Modcl results at pseudo steady-statc h m  Wang et al. (1-7) PBPK mode1 with exmtion eliminatcd. * Model results fiom equiiibrium-based rnodcl dcrived h m  the updatcd c o ~ c d  Evans and Andersen (2000) 
mcthdology. 
While this updated version of the equilibrium-based model appears to provide a reasonable 
representation of the results produced by the steady-state PBPK model, the biological validity of 
the updated values for the parameten selected to "correct" model outcomes (particularly the KB 1 
value which represents the KD for Ah receptor binding) is questionable. 
5.3 Dose-Dependent Application of PBPK Model 
A range of administered doses (i.e., 0.001,0.01,0.1, 1, 10, and 100 pg/kg bodyweight) was used 
to model a the-senes of chemical disposition for each of the assessed PCDDIFs (i.e., TCDD, 
TCDF, 1-PeCDF, and 4-PeCDF) for both the Sprague-Dawley rat and the Gapper's red-backed 
vole. The results of these simulations are presented in Tables 5.18 through 5.21 and Tables 5.22 
through 5.25 for the S prague-Daw ley rat and red-backed vole, respectively. Based upon the 
estimated daily dietary intake of PCDD/Fs (see Table 5.8), the time-senes deposition of each 
assessed congener was also modelled for the Gapper's red-backed vole at site 107 and presented 
in Table 5.26. 
To provide a better reflection of the overall deposition patterns predicted for the red-backed voles 
over time, whole body concentration and liver-to-fat ratio curves are presented in Figures 5.29 
through 5.40 for each of the administered dose levels (i.e., 0.00 1,O.O 1,O. 1, 1, 10, and 100 pg/kg 
bodyweight, respectively). Results of the time-senes modelling indicates that the highest whole 
body concentration appears to occur near the 1 5 hour mark for the lower doses, yet shi fts towards 
the 24 hour mark as the dose levels increase. Liver-to-fat ratios are demonstrated to start hi& 
(approximately 8-fold) regardless of the dose level, but drops rapidly as the model begins to 
equilibrate based upon the overall lipophilicity of each of the tissue compartments. The impacts 
of ligand binding to CYP 1 A2, in both whole body concentrations and liver-to-fat ratios, begin to 
become evident at administered doses of 1 pg/kg and higher (see Figures 5.35 through 5.40). 
Based upon an oveniew of each modelled dose level, maximal impacts appear to be in hi11 effect 
at 24-hours following initial administration. This delay is likely due to the time required for 
CYPIA2 induction to occur. These impacts can be better viewed, on an administered dose basis, 
in cornparisons of congener-specific liver-to-fat ratios presented in Figures 5.41 and 5.42 for the 
Sprague-Dawley rat and red-backed vole, respectively. Rmilts of the analyses indicate that 
while liver-to-fat ratios follow a similar inter-congener pattern at each of the dose levels, Iiver-to- 
fat ratios for the Sprague-Dawley rat are typically nearly 2-fold higher than those in the red- 
backed vole. While this patteni is due to species-specific differences in Ligand bindiag to 
CYP lA2 within the liver, there are also significant inter-congewr differences between the two 
modelled species. As indicated in Table 5.27, a cornparison of TCDF : TCDD and 1-PeCDF : 
TCDD liver-to-fat ratios indicates a similar pattern between the two modelled species. However, 
a cornparison 4-PeCDF : TCDD indicates that the 4-PeCDF liver-to-fat ratios tend to be 1.5 to 2- 
fold higher than TCDD liver-to-fat ratios in the Sprague-Dawley rat, and 2.2 to 2.9-fold higher 
for the red-backed vole. This indicates, when compared against the TCDD benchmark, that the 
red-backed vole appears to sequester more 4-PeCDF in the liver than the Sprague-Dawley rat 
(based upon the chernical-specific assumptions outlined in Tables 4.8 through 4.1 1 ). 
These differences would likely have large implications on the apparent toxicity of 4-PeCDF 
when comparing the red-backed vole to the Sprague-Dawley rat. Studies have indicated that the 
relative potency of 4-PeCDF is drarnatically different when determined based on administered 
dose or tissue dose. For example, in a mouse study conducted by DeVito et al. (1998). the 
relative potency of CPeCDF for inducing skin EROD activity based on administered dose was 
0.08, similar to that noted for hepatic EROD induction. However, when estimated based upon 
tissue dose, the relative potency of 4-PeCDF to induce skin EROD activity increased to 1.25, 
while the relative potency to induce hepatic EROD activity decreased to 0.04 when estimateci 
based upon tissue dose. The authors concluded that for some compounds. the difference in 
hepatic sequestration (as reflected in liver-to-fat ratio) compared to TCDD may impact their 
relative potencies depending on which dose metric is used to estimate the relative potency 
(DeVito et ai., 1998), as is inherent in the selection of mode1 parameters for the current study. 
niese differences in congener-specific sequestration in the liver are also apparent in the 
congener-specific difference in CYPlA2 fold induction between the two species (see Figures 
5.43 and 5.44). As expected, minimal CYPlA2 induction was viewed at the low administered 
doses for each of the evaluated congeners. However, as the administered dose increased beyond 
the 1 pgkg bodyweight level, the difference in TCDD and 4-PeCDF CYPlA2 induction, when 
compared to the comparable induction rates for TCDF and 1-PeCDF, is much greater in the red- 
backed vole than observed in the Sprague-Dawley rat. Again, these ciiffances in congener- 
specific CYP IA2 induction between the two modelied species, would have signifiant 
implications in the overall sequestration of each conguier in the liver, and species-specific 
apparent toxicity. These implications will be discussed in depth in Section 6.0. 
Table 5.18 TirneSeries Dose-Dependent Modelled Disposition of TCDD for the Sprague-Dawley Rat. 
Mas of TCDD (pmolcs) Concentration of TCDD (pmoleslg) 
Percent of Administered 
Elapscd DoselGram Liver-to-Fat Receptor Occupancy 
Pcrcent of 
Tim CYPlA2 Adminidm 
Adipose Whole Adipose M o l e  Livcr Adipose Ratio 
(houn) Liver Bodv 
d Dose 
Tissue Body Tissue Ah CYPIA2 Induction ExCrad 
Table 5.18 Time-Series Dose-Dependent Modelled Disposition OC TCDD for the Spraguc-Dawky Rat. 
Concentration of TCDD (pmoledg) Percent of Administered Elapstd Mass of TCDD (pmdes) Dose/Grarn Receptor Occupancy Percent of  Liver-to-Fat 
Timc Adrninirtere 
Adipose Whole LiVer Adipose Whole Adipose Ratio (hours) Liver Liver Tissue 
d Dore 
Tissue Body Ah CYPIA2 Induction ErcRtc<l Tissue Body 
Table 5.19 TirneSeries Dose-Dependent Modelled Disposition of TCDF for the Sprague-Dawley Rat. 
MW of TCDF (pmoles) Concentration of TCDF (pmoledg) Percent of Administcred Elapscd Receptor Occupancy 
Percent of 
Dose/Gram Liver-to-Fat 
l'imc ':I<IAZ Adrninisierc 
Adipose Whole Adipose Whole Adipose Ratio Ah 
d Dosc 
(heurs) Liver TiSSUe BOdY Tissue Body Tissue CYP l A2 Induction ExCretcd 
Table 5.19 Time-Series DoseDependent Modelled Disposition of TCDF for the Sprague-Dawley Rat. 
-- 





Adipose Whole Adipose Whole LiYer Adipose Ratio (houn) Livcr ~h 
Fold d Dose 
Body Tissue Body Tissue 
CY P l A2 Induction ExCrad 
Table 5.20 Tirne-Series Dose-Dependent Modelled Disposition of 1-PeCDF for the Sprague-Dawley Rat. 
Mass of 1-PeCDF (pmolcs) Concentration of I -PeCDF Percent of Administered Elapscd Receptor Occupancy 
Percent of 
( ~ m o w )  Dose/Gnun Liver-to-Fat Tim ' A2 Adrninisterc 
Adipose M o l e  Adipose Rot io ( h o W  LLiver Tissue Who'e ~ i v e r  Ah 
d Dore 
B ~ Y  Tirwe Body 
CY P I A2 Induction Excreted 
Tabk 5.20 TirneSeries DoseDependent Modelled Disposition OC 1-PeCDF for the Sprague-Dawley Rat. 
Concentration of I -PeCDF Percent of Administered 
Mass of I -PeCDF (pmoles) Recepîor Occupancy Percent of Elapsed (pmoW3) Dose/Gm Liver-to-Fat Timc 
CYPl Administere 
Adipose Whole Liver Adipose Wholc LiVer Adipose Ratio 
(houn) Liver Tisue Bodv ~h 
d Dore 
Tissue Body Tissue CY P 1 A2 Induction ExCretcd 
Table 5.21 Time-Serles DoseDependent Modelkd Disposition of 4-PeCDF for the Sprague-Dawley Rat. 
Elapsed Mass of 4-PcCDF (prnoles) 
Concentraiion of 4-PeCDF Percent of Adminisierd Receptor Occupancy Percent of 
Timc (pmolew DosdG rarn Liver-to-Fat ' Adrnininerc 
Adipose M o l e  Adipose Whole Adipose Ratio (heurs) Liver Liver Ah 
d Dore 
Tissue Body Tissue Body CY P l A2 Induction 
Table 5.21 Tirne-Series DoseDependent Mdelled Disposition of QPeCDF for tbe Sprague-Dawley Rat. 
E l a p d  Mass of 4-PeCDF (pmolcs) 
Concentration of 4-PeCDF Percent of Administered Reccptor Occupancy Percent of 
(pmies/6) DoselGram Liver-to-Fat A' Adrninistere Timc 
Adipose Whole Adipose Ratio (heurs) Livcr Tisrue Adipose ~ i v n  Ah d Dose 
Body Tissue Body 
CY P I A2 Induction Excret d 
Tabk 5.22 TimcSeries DoseDependent Modelled Disposition of TCDD Cor the Capper's Red-Backed Vole. 
Elapsed Mass of TCDD (pmoles) Concentration of TCDD (pmoles/g) 




Adipose Whole LiVer Adipose Whole Adipose Ratio (heurs) Liver Ah 
d Dose 
Tissue Body Tissue Body Tissue CY P l A2 Induction ExCretcd 
QOOI M TCDDAg bodywelght (&ûûûû885 rimoles) 
I 0.0008 0.0002 0.00101 0.0007 
24 0.00547 0.0189 0.0244 0.00938 
48 O.ûûO3 0.0161 0.0188 0.0218 
72 0.00191 0.0121 0.0141 0.00153 
96 0.00138 0.00905 0.0104 0.001 11 
aor T C D D ~ ~  b o d y ~ i g ~ t  (aooouus nmole) 
I 0.00821 0.00193 0.0101 0.00658 
24 0.0816 0.178 0.26 0.0654 
48 0.0403 O. 158 0.199 0.0323 
72 0.0266 0.122 0.149 0.02 13 
c. 
Vi 96 0.0186 0.0921 0.111 0.0 149 
W 
l4 1 TCDD& boâyweight (a W 8 5  nriioles) 
I 0.0821 0.0192 0.101 0.0658 
24 1.47 1-51 3 1.19 
48 0.98 1 1.45 2.34 0.714 
72 0.587 1.19 1.78 0.47 
96 0.404 0.946 1-35 0.323 
1.0 # TCDM8 bo9y»,cig&t (O. O885 ~molrs )  
1 0.823 O. 193 1.02 0.66 
24 23.2 11.9 35. l 18.6 
48 18.1 11.6 29.6 14.5 
72 14 10.2 24.2 11.2 
Table 5.22 TirneSeries Dose-Dependent Modelled Disposition of TCDD for the Gapper9s Red-Backed Vole. 
Mass o f  TCDD (pmoles) Percent o f  Adrninistered Elapsad Concentration o f  TCDD (pmoledg) DosetGram Receptor Occupancy 




Adipose Whole Adipose Ratio 
(hou@ Liver 'd'porc ~i~~~ Ah 
Fold d Dose 
Tissue Body 
CYP l A2 Induction ExCretcd 
Table 5.23 TirneSeries Dose-Dependent Modelled Disposition of TCDF for the Capper's Rd-Backed Vole. 
Mass of TCOF (pmoles) Concentraiion of TCDF (pmoleslg) 
~e r&  of~drninistered 




Adipose Mo le  Adipose Fat Ratio 
(~OUE) Livcr Adipow Mole ~ i v e r  Ah 
d Dow 
Bodv Tissue Body 
CYPI AZ Induction 
ROOl ~g TCDFhg b&wcight (~0000885 nmolu) 
I 0.0002 0.0002 0.0004 0.0001 0.001 0.0002 0.150% 0.125% 1.21 0.0389% 0.0000082% 
24 O 0.001 19 0.00123 0.0003 0.0006 0.0006 0.0323% 0.695% 0.0464 O.W823% 0.0000017% 
48 9.13 x IO" <0.ûûûûûO1 9.14 x 10" 7.3 1 x 10" ~0.0000001 7.32 x 10" 0.000826% 0.0278% 0.0297 0.0000214% 0.00000045% 
72 2.37 x 1 W' 1.40 x 10" 1.43 x 1 O" I .90 x 10" 7.23 x 10.' 7.42 x 1 O'7 0 . 0 0 2  14% 0.0008 1 7% 0.0263 0.0000006% ~0.000000 1 % 
96 6.20 x 3.8 1 x IO'' 3.87 x 10" 4.97 x 1.96 x 10" 2.01 x 10'' 0.0000006% 0.000022% 0.0253 <0.0000001% ~0.0000001% 
0.01 TCDFdg bodywrighr (&ûûûûbS nnroles) 
I 0.00166 0.00212 0.00378 0.00133 O.Wlû9 0.00243 0.150% 0.124% 1.22 0.0389% O.OQOO819% 
24 0.00Q4 0.01 19 0.0123 0.0003 0.00616 0.00646 0.0345% 0.695% 0.0496 0.00824% 0.0000173% 
48 9.28 x IO6 0.0005 0.0005 7.43 x I O 4  0.0002 0.0003 0.000840% 0.0278% 0.0302 0.0002 14% 0.0000045 1% 
72 2.38 x la7 ~0.0000001 2.39 x IO" 1.90 x IOa7 7.23 x IO6 7.42 x IO6 0.00002 15% O.W8 17% 0.0263 0.0000056% 0.00000012% 
C 
V, % 6.2 1 x IO"  3.8 1 x 10" 3.87 x IO" 4.97 x 1.97 x IQ" 2.02 x 10.' 0.0000006% 0.000022% 0.0253 0.0000001 5% 4.0000001 % 
VI 
a I T C D F ~ ~  bodyw~ight ( m w w  nmdm) 
1 0,0166 0.0212 0.0379 0.0133 0.0109 0.0243 0.150% 0.124% 1.22 0.388% 0.000820% 
24 0.00478 0. 119 0.124 0.00383 0.0616 0.0655 0.0433% 0.696% 0.0622 0.0828% 0.000174% 
48 0.0001 0.00478 0.00088 0.0007 0.00247 0.00255 0.000895% 0.0279% 0.0321 0.00215% 0.0000Q45% 
72 2.41 x IO6 0,0001 0.0001 1.93 x 10.' 0.0001 2.93 x 10.' 0.00002 18% 0.0008 18% 0.0266 0 . 0 5 6 %  0.0000M)I 2% 
96 6.23 x Io'' 3.82 x IO*' 3.08 x IO6  4.99 x IO" 1.97 x IO4  2.02 x 10" 0.0000006% 0.000022% 0.0253 0.00000147% ~0.0000001% 
1.0 TCD Ffig boûyweight (0.0885 rimotes) 
I O. 167 0.2 13 0.38 O. 134 0.1 1 0.244 O. 15 1% 0.1224% 1.22 3.75% 0.0082 1 % 
24 0.0866 1.2 1.29 0.0694 0.618 0.688 0.0784% 0.698% 0.1 12 0.839% 0.00 1 78% 
48 0.00123 0.048 1 0.00494 0.001 0.0248 0.0258 0.001 12% 0.0280% 0.0398 0.02 17% 0.0000457% 
72 O 0.00141 0.00144 0 0.W7 0.0007 0.0000228% 0.000823% 0.0277 0.000564% 0 . 0 1  87% 
Table 5.23 TirneSeries DoseDependent Modelled Disposition of TCDF for tbe Gapper's Red-Backed Vole. 
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Table 5.24 Tirne-Series Dose-Dependent Modelled Disposition of 1-PeCDF for the Capper9s Red-Backed Vole. 
Mass of I -PeCDF (prnolcs) Concentration o f  I -PeCDF Percent o f  Administered E l a p d  Reccptor Occupancy Percent of  ( p ~ l e w  DoselGram Liver-IO- Timc 
Adminiacre 
Adipose Whole Adipose Fat Ratio (hours) Liver Adipose ~ i v e r  Ah 
d DoSc 
Tissue Body Tissue Body 
CYP l A2 Induaion Exnetcd 
Table 5.24 Time-Series Dose-Dependent Modelled Disposition of 1-PeCDF for the Capper9s Red-Backeâ Vole. 
ElWscd Mass of  I -PeCDF (pmoles) (pmoledg) Dosc/Gram Liver-to- 
~ o n ~ t r a t i o b f  I -PeCDF Percent of Administerd Recepior Occupancy Percent of 
Timc 
'KfdA2 Adminiacre 
Adipose Whole Ad'pa* Adipose Fat Ratio ~ i v e r  Ah 
d D o s  
(hours) Liver Tisuc Body CY P l A2 Induction Excrcied Tissue Body 
Table 5.25 Time-Series Dose-Dependent Modelled Disposition of 4-PeCDF for the Gapper9s Red-Backed Vole. 
Mass of CPeCDF (pmolcs) Concentra~ion of 4-PeCDF Percent of Adminisiered Elapscd Receptor Occupancy 
Percent of 
(pmolesk) DosdGtam Liver-IO-Fat CYPl Administew Time 
Adipose Whole Liver Adiv Liwr Adipose Ratio (hou@ L i w  Body d Dow 
Body 
Ah CY P l A2 Induction Exere,ed Tissue 
Table 5.25 TimcSeries Dose-Dependent Moddled Disposition of 4-PeCDF for the Gapper9s Red-Backed Vole. 
Mass of 4-PeCDF (prnolcs) Concentration o f  4-PeCDF 
Percent of Administered 
Elapscd Receptor Occupancy 
Percent o f  
(pmoleslg) DoselGram Liver-to-Fat Time CYPIA2 Adminisiere 
Adipose Whole Liver Adipose Whole Adipose Ratio (houn) Liver Body 
Fold d Dose 
Tissue Body Tissuc Ah CY P l A2 Induction E~~~~~~ 
Table 5.26 Time-Series Modelled Disposition of eacb Assessed PCDDJF Congener for the Gapper9s Red-Backed Vole, 
based upon Intake Rates at Site 107 following Emissioo Incident. 
Elapsed Mass of Asscsseâ PCDD/F (prnoles) 
Concentration of  Assessed PCDD/F Percent o f  Administered Receptor Occupancy Percent of (PwW~) Dose/Gram Liver-to- Time CYPI A2 Adrninistcre 
Adipose Whole Adipose Fat Ratio   ho^ Livcr Body Adipose ~ i w r  Tissue ~h 
d Dose 
Tissue Body CYP 1 A2 Induction Excetcd 
0.136 TCDFAg Mywcighr (0.0120 ri mol^^) 
I 0.0226 0.0288 0.0515 0.0181 0.0149 0.0331 0.150% 0124% 1.22 0.527% 0.001 11% I 5 1.5% 
24 0.00687 O. 162 0.169 0.0055 0.0838 0.0893 0.0457% 0.696% 0.0656 0.1 13% 0.000237% 1.59 96.8% 
48 0 . 0 1  0.0065 1 0.00665 0.0001 0.00336 0.0347 O.Q00910% 0.0279% 0.0326 0.00293% 0.000006% 1.14 99.6% 
c. 72 <0.000001 OMO2 0.0002 2.63 x IOd 0.0001 0.0001 0.000022% 0.0008 19% 0.0267 0.0000762% <0.000001% 1 .O2 99.7% s 
96 8.48 x 10.' 5.19 x IO" 5.28 x IOa  6.79 x 10" 2.68 x IO6 2.75 x IO4 <0.0001W)I% 0.000022% 0.0254 <0.000001% <0.000001% 1 99.7% 
Table 5.26 Tirne-Series Modelled Disposition of eacb Assessed PCDDIF Congener for the Gapper's Red-Backed Vole, 
based upon Intake Rates at Site 107 following Emission Incident. ' 
-- -- -- 
E l a p d  Mass of Assessed PCDDIF (pmolcs) 
Concentration o f  Assesseâ PCDDIF Percent o f  ~drninistered Receptor Occupancy Percent of  
(pmoles/g) DodGram Liver-to- Timc 
Adrninistcre 
Adipose Whole Adipose Whole Adipose Fat Ratio Ah 
d Dosc 
(houn) Liver Tissue Body Tissue 
CY P l A2 Induction ExCrCid 
- - 
&OH5 1 4 ~  TCDD TEQquivAg bo&wI&hr (a tWS36 nmoles) 
I 0,0497 0.01 16 0.0613 0.0398 0.006 0.0458 0.743% 0.1 12% 6.63 0.939% 0.00271% I 2.26% 
24 0.79 1 0.96 1.75 0.634 0.495 1.13 11.8% 9.25% 1.28 4.57% 0.0137% 3.69 29.2% 
48 0.445 0302 1-35 0.357 0.466 0.823 6.66% 8.70% 0.766 2.90% 0.00852% 3.31 47.1% 
72 0.288 0.73 1 .O2 0.23 1 0.377 0.607 4.31% 7.03% 0.613 2.14% 0.00626% 2.89 59.9% 
% O. 197 0.57 1 0.768 O. 158 0.294 0.452 2.94% 5.50% 0.535 1.63% 0.00473% 2.59 69.4% 
9 d m i n i s t c r r d  doses werc calculatcâ b a d  upon ambient congener-specific concentrations masurd  on sampled Labraâor tea ai site 107 in winier 1996 (pst-incident), and 
thc typical daily food consuinpiion rate for Gapper's red-backed voles of  0.3 1 g/g/day (McManus, 1979). 
Figure 5.29 ModeUed red-backed vole time-series whole body concentration 
results for eacb assessed PCDD/F congener for an administered dose 
of 0.001 pg/kg* 
Figure 5.30 Modelled red-backed vole time-series liver-to-fat ratios for each 
assessed PCDDIF congener for an administered dose of 0.001 (ig/kg. 
Figure 5.3 1 Modelled rd-backd vole tirne-series w hole body concentration 
results for each assessed PCDD/F congener for an administered dose 
of 0.01 plkg* 
Figure 5.32 Modelleâ rd-backed vole time-series liver-to-fat ratios for each 
assessed PCDD/F congener for an administered dose of 0.01 pg/kg. 
Figure 5 J 3  ModeIlcd red-backed vole tirne-series whole body concentration 
results for eacb assessed PCDD/F congener for an administered dose 
Figure 5.34 Modelled red-backed vole time-series üver-tctfat ratios for each 
assessed PCDDIF congener for an administered dose of 0.1 (iglkg. 
Figure 5.35 Modelled rd-backed vole tirne-series whole body coacentration 
results for each assessed PCDDIF congener for an admhistered dose 
of 1 cwg* 
Figure 5.36 Modelled red-backed voie tirneseries liver-twfat ratios for each 
assessed PCDDIF congener for an administered dose of 1 (igkg. 
Figure 537 Modelled red-backed vole tirneseria whole body concentration 
results for each assessed PCDD/F congener for an administered dose 
of 10 m g *  
Figure 5.38 Modelled red-backed vole tirneseries liver-tefat ratios Cor each 
assessed PCDD/F congener for an administered dose of 10 pgkg. 
Figure 5.39 Modelled red-backd vole tirneseria whole body concentration 
results for eacb assesseci PCDDJF congener for an administered dose 
Figure 5.40 ModeUd rd-backed vole tirneseries liver-to-fat ratios for eaeh 
assessed PCDD/F congener for an administered dose of 100 pglkg. 
F i p r e  SA1 Congener-speclc liver-twfat ratios Cor various adrninistered doses (pg/kg 
bodyweight) for the Sprague-Dawley rat after 24 houn. 
F i p r e  5.42 Congener-specific liver-to-fat ratios for various administered doses (pgkg 
bodyweight) for the red-backed vole after 24 hours. 
Figure 5.43 Congener-Spceific CYPlA2 fold induction for various administered doses 
(pg/kg bodyweigbt) for the Sprague-DawIey rat after 24 hours. 
Figure 5.44 Congener-Specific CYPlA2 fold induction for various administered doses 
(pgkg bodyweigbt) for the rd-backed vole after 24 hours. 
Table 5.27 Cornparison of Liver-To-Fat Ratios between TCDF, 1-PeCDF, and 4- 
PeCDF to that of TCDD for the Sprague-Dawley Rat and Gapper's Red- 
Backed Vole. 
TCDF : TCDD Ratio 1 -PeCDF : TCDD Ratio 4-PeCDF : TCDD Ratio 
Sprague- Red-Backed Spraguc- Rd-Backed Spnguc- Red-Backed 
Dawley Rat Vole Dawlcy Rat Vole Dawley Rat Vole 
- - p . .  
Note: nie TCDF:TCDD, I -PeCDF:TCDD, and 4-PcCDF:TCDD ratio values were calculated by dividing the Liver-to-Fat 
ratio value for each of the congcncrs by thaî of TCDD, for cach dose group. 
Based upon the predicted red-backed vole whole body concentrations, congener-specific vole-to- 
plant BAF values can be calculated and compared to similar values observed in the actual 
environmental data (see the calculated vole-to-plant BAF vaiues for site 107 provided in Table 
5.6). A dose-specific comparison of the modelled versus measured vole-to-plant BAF values for 
each assessed PCDDE congener and the TCDD-TEQ is provided in Table 5.28. Results of this 
comparison indicate that the modelled results under-estimate the vole-to-plant BAF for al1 
congeners, when compared to the comparable BAFs calculated based upon environmental 
sampling data. However, given the cunent PBPK model is designed to only simulate the 
congener-specific deposition based upon a single acute dose, rather than chronic exposures, 
whole body concentrations arising fiom bioaccurnulation of specific congeners over time would 
be greatly underestimated (development of a chronic administration submodule was attempted 
but could not be effectively integrated into the existing model methodology). Accordingly, it 
would Iikely be useful to observe the BAF values of various congenen to that of TCDD to 
determine whether similar congener-speci fic patterns are evident between modelled and 
measured BAF data As indicated in Table 5.29, the congener-specific BAF pattern observed in 
the modelled data closely approximates that observed in the environmentally sarnpled data for 
the TCDF and 1-PeCDF congeners. However, this similarity breaks down when one compares 
the congener-specific BAF patterns for the 4-PeCDF congener and the TCDD-TEQ group. 
Again, this is not unexpected, given the acute dosing nature of the PBPK model, which would 
ultimately result in underestirnation of chronic whole body concentrations for the more 
bioaccumulative PCDD/F congeners (i.e., 4-PeCDF and the TCDD-TEQ group) over an 
extendeci period of time. 
Table 5.28 Dose-Specific Cornparison of ModeUed versus Measured Vole-t+Plant BAF 
values for eacb Assessed PCDDF Congener. 
0.0248 pg 1-PeCDFkg bodyweight (0.00220 nmoles) 
1 0.00829 2.82 
24 0.098 33.4 
48 0.05 18 17.6 
72 0.026 1 8.88 
96 0.0131 4.46 
0.0 713 ~ q p  4-PeCDFhg bodpeight (0.00631 nmoles) 
I 0.058 1 19.8 
24 1.48 504 
48 0.945 3 22 
72 0.564 192 
96 0.323 110 
0.0605 #J TCDD TEQ-equivhg bo&weight (0.00536 rimoles) 
I 0.458 14.7 
24 1.13 364 
48 0.823 265 60.5 
72 0.607 195 
96 0.452 1 46 
Tabk 5.29 Cornparison of Congener-Specilic to TCDD BAF values in based on 
Modelled and environ men ta^ Data. 
Modelld Dit8 Environmatal Data 
Volclt+Plant BAF Ratio to TCDD ' Volata-Piant BAF Ratio to TCDD 
TCDD 4.43 63.75 
TCDF 0.2 0.045 1 2.9 1 0.0456 
I -PeCDF 1.35 0.305 10.67 O. 167 
CPeCDF 7.07 1.6 240.96 3.78 
TCDD-TEQ 6.01 1.36 320.99 5.04 
BAF ratios for each congaers to TCDD (Le., TCDF-to-TCDD, 1-PcCDF-to-TCDD, CPeCDF-to-TCDD, and TCDD-TEQ- 
to-TCDD). 
6.0 DISCUSSION 
The principal objectives of the current research involveci: (1) the empirical characterization and 
prelirninary validation of cornputer-based models used for exposure and toxicological (i.e., 
PBPK modeling) assessrnent; (2) characterization of the potential health consequences related to 
environmental exposure to bioaccumulative chemicals; and (3) improved scientific support for 
risk management decisions conceming industrial activities, such as incineration. 
As indicated in the methodological overview, there were three key research aims and questions 
stressed, which follow a chronological order of implementation: a) modelling issues; b) empirical 
issues, and; c) application issues. 
6.1 Modelling Issues 
I .  Evaluation of relative merils of simple (i.e.. two-cornpartment or equilibrlum-based) 
pharmacokinetic models versus compler (i.e.. multi-cornpartmentai) PBPK models for the 
assessment of health riskr related to environmental erposures to dioxins and furans. 
Detailed multi-compartmental PBPK models, such as the prototype steady-state model used in 
this research, provide an excellent framework by which to estimate the effects of absorption, 
disposition, metabolisrn, and excretion on the tissue-specific distribution and ultirnate toxicity of 
contaminants. This is particularly the case when non-linear ligand-receptor binding kinetics alter 
the natural lipophilicity-drîven tissue disposition of the chemicai. For example, TCDD typically 
partitions primarily according to its lipophilic nature at low doses, while higher doses result in 
binding to CYP 1 A2, leading to prefefential accumulation in the liver. However, extension of the 
model to very high doses predicts that, as specific hepatic binding sites become saturated, TCDD 
concentrations in liver will plateau, and TCDD will again preferentially accumulate in adipose 
tissue. 
While these multi-compaitmental models appear to adequately reflect the disposition of POPs, 
such as the PCDDEs, across a wide variety of exposure doses, there is always some concem thai 
these large, complex models may be over-parameterized. This becomes pertinent as the inherent 
uncertainty within the model invariably increases with incorporation of each additional variable 
into its framework, especially given the inherent difficulty in quantiSing many of these 
parameters. As such, there is considerable interest in determinhg whether less complex models, 
such as the equilibrium-based model proposed by Evans and Andersen (2000), can adequately 
simulate the disposition kinetics of TCDD, using fat fewer model parameters. 
To evaluate the significance of this concem, the steady-state PBPK model was adjusted to 
approxirnate the equilibriurn-based conditions of the Evans and Andersen model, by disabling 
both urinary and biliaqdfecd excretion. With the two models being evaluated on an "even 
playing field", if the two-cornpartment equilibrium-based model could accurately duplicate the 
key indicator variables (Le., liver-to-fat ratio, receptor occupancy, and CYP 1 A2 induction fold), 
then the more complex, steady-state model may be deerned as "over-parametenzed". 
This investigation indicated that the TCDD disposition following a variety of exposure doses did 
not result in close agreement between the equilibrium-based model and the prototype PBPK 
model. Results were even more divergent after the equilibnum-based model was correcied for a 
mis-speci fication in its methodology (i. e., incorrect calculation of CYP 1 A2 fold induction). As 
with the more complex steady-state PBPK model, many of the parameters used in the 
equilibriurn-based model were "fitted to allow the model outcome to correctly duplicate a set of 
experimental data While this allows for the accurate prediction of TCDD disposition under 
these particular exposure conditions, the use of fitted parameters to represent biological funcrions 
makes it v w  difficult to generalize model predictions outside of a particular set of exposure 
scenarios (i.e., impacts of hi& versus low exposure doses). 
This is particularly the case when pararneters were fitted to a mis-specified model methodology, 
as viewed in the biologically impossible results predicted by the bbcorrecteû" Evans and Andersen 
model using the originaily dehed parameters. For example, the "comected" model predicted a 
CYPlA2 induction increase exceeding 80-fol& when research snidies have indicated that the 
maximum induction fold hcrease, at hi& TCDD exposure doses, is approxirnately 20-fold in 
rats (Xu et al., 2000). Given the amount of leverage the CYPlA2 induction fold parameter has 
on the uitîmaie outcome (see resuits of the sensitivity analysis in Section 5.2.3), a four-fold 
difference in this parameter would have serious implications on the empirical validity of the 
model results. 
The equilibrium-based mode1 was able to closely duplicate the results predicted by the more 
complex PBPK model with the adjustment of the Ah receptor binding constant m l )  to 5 nM 
(125-fold higher than the original value of 0.04 nM), the Ah receptor/DNA binding constant (Kd) 
to 0.005 nM ( IO-fold less than the original value of 0.05 nM), and the CYP 1 Aî induction fold 
increase to t 6-fold (approximately 5-times less than the original value of 8Sfold). While this 
updated version of the equilibrium-based model appeared to provide a reasonable representation 
of the results produced by the steady-state PBPK model, the biological reality of the updated 
values for the parameters selected to "correct" model outcornes is questionable. Many studies 
into TCDD-Ah receptor binding kinetics have indicated that the binding constant (Kd) for 
Sprague-Dawley rats is less than 1 nM, if not 0.1 or 0.01 nM, depending on the particular type of 
study (Sloop and Lucier, 1987; Tukey et al., 1982; Gasiewicz and Rucci, 1984; Safe, 1988). 
Wang et al. (1997) indicated that, as the reported values of the Ah receptor concentration in each 
tissue and the dissociation constant of TCDD bound to the Ah receptor from different studies 
were different, those values were selected as initial seed values and the final results (e.g., a Kd of 
0.1 nM) were obtained by fitting the model to an experimental TCDD tissue distribution. While 
certainly possible, it is iikely that a value of 5 nM would over-estirnate the degree of TCDD 
disassociation from the Ah receptor. It is difficult to detemine whether the values selected for 
the Ah receptor/DNA binding constant and CYP 1 A2 induction fold increase are biologically 
unlikely given the considerable amount of uncertainty sunounding these types of 
phmacodynamic parameters. 
While the modified equilibium-based model may be able to provide a reasonable estimation of 
TCDD disposition, it is iikely that the inhereut uncertainty in its methodology outweighs any 
benefits gaineci by its simpiicity. Furthmore, this methodology is only appropriate when 
exposun conditions have reached a bbquasi'* steady-state, and body burden concentrations have 
reached an equilibrium plateau. However, given that the elimhation half-life of TCDD, based 
upon a single dose, can range h m  10 to 43 days depenâing on the rodent species being tesied, it 
may take some time to reach a steady-state body burden plateau (Deltell et al., 1994). Moreover, 
as the elimination half-life of TCDD in humans is least 5 years, it could conceivably take well 
over 15 years to reach 90% of steady state, and over 30 years to reach 99% of steady state levels 
in human populations (U.S. EPA, 1994). As such, it is questionable as to whether an equilibrium- 
based model could ever adequately estimate the complex dispositionai patterns of TCDD, arising 
fiom typicai environmental exposure conditions over an extended p e n d  of tirne. B a d  upon 
these arguments, it is likely that the steady-state PBPK model provides a more appropriate 
methodology to address potentially complex exposure conditions, despite the increased level of 
uncertainty arising fiom the higher degree of inherent parameterization. However, one must be 
aware that the model assumptions play a dominant role in determinhg the predicted model 
outcornes, and that any uncertainty associated with these assumptions will ultimately affect the 
overall validity of the predicted PBPK model results. 
2. Evaluation of the jeasibility ojusing u PBPK model developed using laboratory rodents for 
use with the vole sentinel species (i.e., availabi lity of detaifed physiological data for the vole 
receptors or adequate allometric methodologies to produce equivalen t data for the 
oppropriate bio logical receptor). 
Results of the application of the PBPK model developed using laboratory rodents for use with the 
vole sentinel species has indicated that this model methodology appears to provide a reasonably 
accurate estimation of chernical-specific disposition and elimination patterns within the vole 
sentinel species. Thus, it appears that the vole is a usehl and relevant sentine1 species to 
evaluate the pharmacokinetic and pharmacodynamic issues smounding the environmental 
impacts of PCDDtFs released as a result of anthropogenic activities. PBPK model systems, such 
as the one developed based upon the Wang et al. (1997) methodology, provide valuable tools for 
use in long-term environmental monitoring programs such as that in place at the Swan Hills 
Treatment Centre. 
Uncertainties surroudning the use of this methodology cm be attributed to the lack of species- 
specific pharmacokinetic and pharmacodynamic parameter information for the vole sentinel 
species. While some tissue-specific physiological data, pnmady tissue volumes, are available 
from the scientific literature and field researchers, there are still significant data gaps in the 
physiological data available for voles. In this work, allometric equations developed for similar 
rodent species (i.e., the C57BU6J mouse) were used. However, experimental values of the 
parameters related to the ligand-receptor binding @oth Ah and CYP lA2) are required to reduce 
the inherent uncertainty present within the model outcornes. A number of research labs which 
work with Gapper's red-backed voles were contacted for such information. Unfortunately, none 
of them perfonned this type of detailed analyses. Nor was any of the information discovered 
during an extensive review of the scientific literature on the Mimoius and Clethrionomys vole 
families. 
While not currently available, it is likely that this type of information could be obtained for hture 
expansion of the current research. It wodd likely require the caphire of a number of live red- 
backed voles as part of the ongoing monitoring program (or h m  other stock sources), and 
immediate transport of the live specimens or extracted liver tissues (properly packed for 
transport) to a laboratory capable of perfonning this type of analyses. Obviously, the transport of 
live specimens would be preferable (especially given the Ah receptor is notoriously unstable), as 
it would allow a more complete characterization of the necessary physiological parameters (e.g., 
tissue weights, fraction of overall tissue volume composed of blood, tissue permeability, etc.), in 
addition to the required pharmacodynamie information. 
Unfortunately, research has indicated that the vole species are notonously difficult to maintain 
long-terni under laboratory conditions, and tend to react detrimentally to extended contact or 
captivity @. Skinner, personal communication, 2000). As such, it would be difficult to do an 
extended the-series study of the impacts of TCDD (or other congeners) on voles, so that the 
current PBPK models may be better calibrated for this use. However, until this type of 
information is obtained, there will still be considerable uncertainty expressed within the outcome 
of any PBPK model-based assessrnent of PCDD/F environmental exposure. 
3. Discussion of the relative sirengths and weaknesses of the selected PBPK model for dioxins 
and fürans. Objective measures of model strength and weakness such as i) robustness, ii) 
sensitivity, iii) parsimony, and iv) explanatory value will be evaluated to provide a better 
indication of the potential uncertainty related to the application of this particular model 
design. 
Various model methodologies used to descnbe the pharmacokinetics of PCDDFs within a 
biological system each have their own relative strengths and weaknesses, depending on the 
exposure scenario. For the cunent research, a PBPK model and an equilibrium-base mode1 were 
evaluated to determine their relative effectiveness in predicting the disposition of PCDD/Fs. The 
following criteria, provided in Table 6.1, were used to evaluate the overall appropriateness of 
each model in addressing the research objectives. Refer back to Section 3.2.4 for a more detailed 
description of each criterion. 
Table 6.1 Cornparison of Prototype Models based upon Several Validity Criteria. 
Stndy-Sirtt Mode1 
(Wang n al, 1997) 
Equilibrium-Bd Modtl 
(Evans and Andtrsca, 2000) 
With the modification of a fcw paramctcrs, this The use of "custom" fitted parameters has greatly 
mode1 is able to accuratcly predict the disposition rduced the applicabiIity of this mode1 
Gencralizability of various PCDDIF congencrs in a nurnber of mcthodology outside of the specific scenario it 
biological test specics. was dcsigned in. 
.f.*.*.......flff......**~.........*.~*....-.....*................*.................~......*-*.........*....*...*.............*...~*.*~*...**.....~~..*.....*........................~....................... 
Intcrnal diagnostic routines ensure consistency in The lowtr nurnber of murncd paramctcrs dlows 
variablu&ch as total organism-bad blood 
Internai consistency volumcs. The designcd shcll systcm also ensure consistency for othcr variabla amss 
cornpartments (i.e., consistency in Ah reccptor 
Kd value betwecn tissue m o u ~ s ~ .  
The original Wang et al. ( 1997) mode1 contained 
Computational numemus gaps and inaccuracics in the published 
corT?xmess methodology. These wctt concctcd through mcarch into its original saurcc papcrs and 
logical adjustrncnts for biological validity. ........................................... ~*................~.~.......*............**..*..**...~*........*.....*...~*..-.--. 
for casier maintenance of inteha1 consistency. 
Howeva. the origind mode1 methodology had 
very fcw "consistency" checks, resulting in the 
mis-specitication not being aught by any 
QNQC P ~ ~ -  ............................................................................... 
The original Evans and Anderscn (2000) modcl 
contained a serious mis-spccification in the 
CYP IA2 fold induction calculation. 
............................................... ~..-.-*..**..-......-..*.*..**-.....-........-*---..~.~.~.*~*........*.~..*..........................*.....**...*.......*....-.~...........**.*.*....... 
While the mode1 did initially show significant 
instabili tics at low exposurc doses, this was Due to the large numbcr of fitted paramaers, this 
rcdUction of the rnodel h d  considcrable difficulty unda dinéring stcp. Once rectifiai, the modcl has dcmonstratcd input and exposure sccnarïos. 
considerable tobusmcss across doses, chcmicais, 
and succies. 
Table 6.1 Cornparison of Prototype Models based upon Several Validity Criteria. 
Stndy-Strte Modd 
(Wang a ai, 1997) 
Equiiibrium-Bucd Modcl 
(Evins and Andersen, 2000) 
Sensitivity 
While appeating to follow the correct induction 
Analysa of d e l  results indicatc that changes to curve pancm (i.e.., inflstion the 
input variables appear to have biologidly 
appropriatc changes to mode1 outcornes. 





nie  multi-compartmentai nature of this PBPK 
rnethodology allows for a biologically rcalistic 
and relevant dcpiction of PCDDIF 
pharmacokinetics. The biological rcalisrn does 
not complctely cxtcnd to dctailcd 
pharmodynamic and mtabolic processes, 
which are assumcd "lumDtdW in with exmetion. 
This quilibrium-based mcthodology lacks 
detailed biological rcalisrn (e.g., only two 
compartments, no modeIlcd movcmcnt betwcen 
compartments via the blood, etc). Furthmre,  
the impacts of absorption, rnetabolism, and 
excrction are ignored. 
...*.....*.........~.....~..................~.................*...........~..*~.*......*.**~**~....*..................~...*.~.....................................*....~.*..*.....*....-.......-.....*....... 
Agrecmcn t ktwem Considerable amount of manipulation of the fincd parameters within the quilibrium-based mode1 
diffmnt models was rquircd to achicve a rcasonable duplication of the disposition outcorncs predicted by the 
describing the same stcady-state PBPK modcl. Howcver, it is questionable as to whether these adjustcd paramctcrs arc 
process biologically rcalistic. ............................................................................................................................ ~.....*....**..........*....*.*.-**............**.....*..*...........-.........-. 
Heuristic value 
A hiIl suite of excellent indicator variables is A full suite of exccllmt indiutor v ~ a b l a  is 
availablc at each significant point in the pst- available for the one quilibrium state. 
neamnt time series. .........*........*.................~*~*..--*.........~.....~.....*.............*~.......*...*..*....-.....................-....~..............**..*................*~.*..-...............-............*.... 
Using the original mcthodology, this d e l  
showed a significant lack of capacity to estirnacc 
Capacity to deal with The modcl is hIly capable of cstimating disposition outside of the limittd dose levcls on 
dose-ciependen t disposition kinetics under dosedependcnt which it was built. Howevcr, oncc "correcteci" 
ùchaviour conditions. and rnoâifieâ, this mode1 was abie 10 estimate 
disposition kinctics under dosedependent 
conditions. .............................................................................................................................................................................................................. 
Due to the more sirnplistic n m n  of the d e l  
(as compartd to the full PBPK modcl), it appcars 
Whilc the model did initially show significant to bc gencrally fict of nuincrical artifact.. Whilc 
Absence of numerical instabilities at low cxpomre doses, this was not neccssarily an artifact or error, the 
art i facts correctcd through reduction of the model tirnc inefficiencics of using the implicit equation 
stcp. solver IO dcterminc blood concentrations does 
pose problm (particularly when artcrnpting 
Monte Carlo simulations or scnsitivity analyses). ........................................... ~.~..............*.*.*....*..-...-**.~.~.~..~*..*...............*............*.**.......*....~..*..................*****..*...............*...~~*......~~...**.... 
Given the quilibrium-based nature of this 
This d e l  can adquatcly evduate relative rncthodology, it is very limitcd in its ability to 
absorption, disposition and elimination kinctics extrapolate to conditions outside of those for 
Useful in extrapolation io across a variety of cxposure routes, doses, and which it was originally dcsigned. As it handles 
0th- conditions dose-rates, with v&minor adjustmcnts to its dose as an intemal dose at e&ilibrium, cxtemal 
undolying rnethodology (mmy of which werc dculuionr would be rqÜircd to allow for 
addeâ during this tcscarch projcct). asscssmcnts using alternative exposure routes or 
dose rates. 
Based upon this evaluation of the relative strengths and weaknesses of each model methodology, 
it would appear that the steady-state PBPK model provides the more robust, sensitive, and 
parsimonious methodology for predicting PCDDR disposition kinetics in a variety of biological 
species. 
6.2 Empirical Issues 
1. Evaluate the apparent empirical relationship between the octanol-water partitioning 
coefficient (log K,J und Biouccumuhtion Factor (BAF) or Bioconcentmtion Factor (BCF) 
of dbxins andjitrans in the vole sentine1 receptor. 
The octanoi-water partitioning coefficient, also referred to as the kW, provides an empirical or 
expenmental representation of the distribution of a particular organic chemicai between water 
and an organic liquid phase. Al1 organic compounds have an inherent level of lipophilicity, 
which is indicative of their general afilnity for lipids (or fats). The more lipophilic (or 
hydrophobie) the compound, the larger the K, that would be assigned. Given the large range in 
potential kW values (i-e., O to > 1 x 108), the lipophilicity of a compound is typically presented as 
the log of the K,,,. Table 6.2, below, pmvides an oveniew of the log q, values for each of the 
dioxin and furan congener groups. 
Table 6.2 Overview of Log Octanol-Water Partition Coef'ficient 














Sumniarizcd in U.S. EPA (2000). 
Physico-chernical properties have demonstrated that the log K, of an organic compound 
hcreases with the compound's propensity to accumulate withln the tissues of biological 
organisrns (i.e., due to storage within fats or tissues, the concentrations of the compound within 
the organîsrn are greater than the ambient concentrations found in the environment of the 
organism). Based upon this behaviour, compounds with log K, values which exceed 3 are 
generally viewed as "bioaccumulative" in nature. Bioaccumulate compounds, such as the 
PCDDIFs, are of particular concern as they concentrate the compound within the organism, 
greatly increasing the opportunity for a potentially toxic exposure dose to occur over an extended 
penod of time (sometimes well after the initial environmentai release). 
As indicated by Table 6.2, as the degree of chlorination increases, the log K, and lipophilic 
tendencies of a particular congener also increase (if one ignores the potential impacts of 
solubility and gastric absorption on congener-specific bioavailability). Based upon this pattern, 
one would expect the degree to which a particular congener bioaccumulates within an organism 
would also increase with degree of chlorination (e.g., one would expect the OCDDRs to be more 
bioaccurnulative than the TCDDRs). However, if one evaluates the vole-to-plant 
bioaccumulation factors (BAFs) calculated based upon the SHTC environmental monitoring data 
(refer to Tables 5.4 through 5.6), it becomes quite evident that the PeCDD/Fs and HxCDDRs are 
far more bioaccurnulative than their HPCDD/F and OCDDR counterparts. As this behaviour 
would typically be counter-intuitive, obviously there are other factors in addition to the 
lipophilicity of the compound which impact upon the disposition and rate of elimination of these 
congeners. 
As previously discussed, research has demonstrated that the variable ligand-receptor binding of 
the PCDDF congenen to CYP 1 A2 results in a significant sequestration/accumulation of the 
compound within the îiver. This sequestration temporarily prevents the metabolisrn (if 
applicable) and excretion of a large portion of the interna1 congener dose; thus leading to a much 
greater degree of bioaccumulation within the organism than would be expected through 
lipophilici ty partitioning to adipose tissue depo ts alone. 
Of al1 the congeners, the PeCDFs and the HxCDFs appear to have the greatest amnity to 
CYPIA2, resulting in a much larger degree of sequestrahon and accumulation, than their weakly 
binding, higher-chlorinated counterparts. This makes the weaker binding, higher-chlorinated 
congeners relatively more susceptible to metabolic breakdown and/or excretion in marnmalian 
systems, typically leading to a much lower degree of bioaccumulation once the congener has 
been mobilized from adipose tissue stores (Le., through stress or elevated activity). Other issues, 
such as the gastric bioavailability (or lack thereof) of the higher-chlonnated congeners (Le., 
OCDDlFs), also impact upon the degree to which a particular congener will accumulate with a 
particular biological organim. 
As such, the apparent toxicity of compounds such as PCDDFs (Le., a biological endpoint) can 
never be simply related to their inherent lipophilicity as desctibed by its log kW (a physio- 
chernical parameter), but requires a more significant evaluation of the toxicokinetics and 
toxicodynamics of the particular congener being assessed (i.e., through the use of PBPK 
modelling). 
2. Evaluate whether the Toxic Equivalency Factors (TEFs) for dioxins and furans provide a 
suitable surrogate for toxicity in the vole species. considehg such parameters as chernicul 
biouvaiiability, phannacokinetic factors. and toxicodynamic equivalency. 
Based upon the current research, it is likely that phannacokinetic and pharmacodynamie 
differences between the vole and the Sprague-Dawley rate may result in significant implications 
on PCDDR toxicodynamic equivalency in an environmental setting. For example, a larger 
proportion of the persistent 4-PeCDF congener appears to become sequestered in the liver of the 
vole, than observecl in its rat counterpart, when scaled on a species-specific basis to the TCDD 
benchmark (see Table 5.2 1). While the adipose tissue can be viewed as a temporary depot for 
PCDDR concentrations (easily mobilized under stress or elevated activity), 4-PeCDF appears to 
bind tightly to the CYPI A2 in the liver, causing the liver to serve as a ligand sink, binding and 
effixtively removing fiee 4-PeCDF from the general body circulation until CYPI A2 protein 
turnover a d o r  slow ligand disassociation occurs. The same pattern is observable with TCDD 
and the other Ah-responsive congenen, though to a lesser extent. 
As noted previously, the overt signs of toxicity in animals &om exposures to chlorinated dioxins 
and hirans are characterized by a general wasting syndrome, with an overall loss in body weight, 
even though food consurnption is normal. These effects are typically accompanied by wide- 
ranging impacts upon the functions of the immune, reproductive, adrenocortical, and thyroid 
endocrine systems. These toxic outcomes have been largely traced back to ligand-receptor 
interactions between the PCDDFs and the Ah receptor, resulting in a cascade series of systemic 
impacts (e.g., inhibition of glucocorticoid-regulated enzymes, abnormal impacts on levels of 
growth factor receptors, antiestrogenic impacts mediated through receptor-based "cross-talk", 
etc.). 
As these toxic outcomes appear to be mediated by Ah receptor ligand interactions principally 
within extrahepatic tissues (e.g., thyroid, adrenal cortex, reproductive organs, thymus, spleen, 
etc.), it is likely that a high degree of ligand sequestration within the liver (as denoted by a high 
liver-to-fat ratio) would result in less "M ligand available in the body circulation to bind to Ah 
receptors in these tissue organs. Accordingiy, the lower number of ligand-receptor binding 
events would result in fewer AhR-mediated toxic outcornes, decreasing the overall apparent 
systemic toxicity of the administered congener dose. 
This variability in inter-species (and even inter-strain) toxicity has been observed in a number of 
toxicity studies. For exarnple, the acute LD, values of PCDDs in guinea pig and various rat 
strains have been shown to follow the typical order (and accordingly, potency) predicted by their 
TEF values. However, in the resistant Ham-Wistar rat strain for exarnple, the order of potency 
for male and female rats was 1,2,3,4,7,8-hexaCDD > 1,2,3,4,6,7,8-heptaCDD > l,Z,3,7,8- 
pentaCDD > TCDD. The data ftom these studies indicate that 1,2,3,4,6,7,8-heptaCDD was 
slightly more acutely toxic than TCDD in Ham-Wistar rats, whereas in other rat strains and the 
guinea pig, TCDD is at l es t  100 times more toxic than 1,2,3,4,6,7,8-heptaCDD (Safe, 1998b). 
For example, acute LD, values for TCDD in guinea pigs, the most sensitive species tested, 
ranged from 0.6 to 2.1 pg/kg bodyweight (Schwetz et al., 1973; McComeii et id., 1978). while 
an LD,, value for the hamster, the least sensitive species tested, was determined to be 5000 pg/kg 
bodyweight (Olson et al., 1980; Henck et al., 198 1). in addition to differences in relative 
adiposity, research has demonstrated that differences in ligand-receptor binding afinity to the Ah 
receptor (Poland and Glover, 1990; Poland a al., 1994), as well the degree to which the congener 
is sequestered in the liver through binding to CYPIA2 protein, c m  result in significant species- 
and strain-specific differences in potency. 
This hypothesis has considerable implications on the selection of representative TEFs for specific 
PCDD/F congeners for environmentai sentine1 species, such as the red-backed vole. For the 
rnost part, TEF values are established based upon in vivo a n d h  Ni vitro laboratory assays using 
species such as the Sprague-Dawley rat. Therefore, if the red-backed vole is less sensitive to the 
4-PeCDF congener than the rat, due to its higher degree of hepatic sepuestration or more rapid 
metabolism and excretion, it is likely that the established TEF would also overestimate the toxic 
potential of 4-PeCDF in the vole sentine1 species. Given the 4-PeCDF congener represents the 
vast rnajority of both the mass- and TEF-based concentration of PCDD/F measured in biota 
surrouuding facilities such as the SHTC (see Table 5.4), a systemic over-estimation of the TEF 
for the 4PeCDF congener would have significant impacts on the outcorne of an environmental 
nsk assessment, based upon the red-backed vole as a sentinel species. 
3. Evaluate the '~actionation " characteristics of the dioxin//uran congener emission mixtures 
in both the environment and within the vole receptor, on a (i) mass ratio and (ii) TEQ ratio. 
More spectjcaIly. the relative congener and isomeric 'pngerprint " breclkdown of dioxin 
and furan concentrations present in 60th environmental (e.g.. water, soil, und sediment) and 
biological (e.g., Labrador tea plants and voles) sinh are highly dependent upon a variety 
factors. For erample, each specifc congener group hm differing physico-chemicul 
properties. leading to dtffering physiologicul disposition. metabolism und ultimately 
toxicological impacts on biologicnl receptors. such os the red-backed vole. These 
' pactionation " characteristics provide much of the basis for the TEQ methodology for 
evaluating the toxicity of individual dioxin-like congeners as an overall functional group. 
When evaluating the PCDD/F congener-specific fractionation characteristics in both the 
environment (using Labrador tea as a surrogate for ambient environmental concentrations) and 
the vole sentine1 receptors, at each of the three primary monitoring sites (Le., sites 1 1, 107, and 
1 14), an interesting pattern emerges (see Table 5.4 and Figures 5.7 and 5.8). Environmental 
sampling conducted on Labrador tea indicates that 2,3,7,8-TCDF dominates the congener 
fingerprint pattem on a mass basis, typically representing between 50 and 60% of the total 
PCDDF mas, with 2,3,4,7,8-PeCDF representing a m e t  10 to 20% of the total PCDDR 
m a s .  As expected, this particular congener-specific pattern closely m i m  the PCDDE 
ernission pattern of the SHTC facility, arising h m  the PCB incineration process (Ferguson, 
1998). However, when these congener-specific concentrations are adjusted to TCDD TEQ- 
equivalent concentrations, 2,3,4,7,8-PeCDF typically dominates representing between 45 and 
60% of the total TEQ-adjusted PCDDF concentration, with 2,3,7,8-TCDF a close second 
(typically 30 to 40% of the total TCDD TEQ-eqivalent concentration). 
When one examines the congener-specific pattern observed in the vole sarnples, 2,3,4,7,8-PeCDF 
is by far the most important congener, typically representing 65 to 80% of the total PCDD/F 
mas ,  with the HxCDF isomeric group providing approximately 10% of the total PCDD/F mas, 
and TCDF less than 5% of the total congener mas. On a TEQ-equivalent basis, the 2,3,4,7,8- 
PeCDF congener represents more than 90% of the total. While the TCDF congener was a heavy 
contributor to the pattern viewed in ambient concentrations, the lack of hepatic sequestration and 
its rapid excretion rate resulted in no significant disposition in the voles over time. The 
2,3,4,7,8-PeCDF congener, on the other hand, was heavily stored in the liver due to CYPlA2 
sequestration, which resulted in significant bioaccumulation and dominance of the overall m w -  
and TEQ-based congener-specific hctionation within the vole. As such, this particular pattem 
is as expected based upon the research presented in this project. 
interestingly enough, the congener-specific fingerprint patterns do not appear to differ 
significantly in relative contribution percentages, for both mass- and TEQ-based concentrations, 
between pre-incident (summer 1996) and post-incident (winter 1996), for either biota sampling 
set. The only noticeable differences in the pattern are the significant elevation in ambient 
PCDD/F, particularly the PCDF congeners, in post-incident biota sampling when compared to 
those observeci immediately pnor to the October 1996 release incident, and the slightly elevated 
environmental concentrations of 2,3,7,8-TCDF. Both of these observations are consistent with 
stack monitoring data during and immediately following the October 1996 incident event. 
During the incident, dioxin concentrations were ten times higher than normal, while HxCDDs, 
which nonnally accounts for 33% of dioxin emissions, were not present during the process gas 
release. Overall, the concentrations of total dioxin were also much higher during the release 
(2.5 pg/m3 versur 4.9 nglm)) when compared to normal operational conditions (CanTox, 1998). 
Furthemore, the typical incinerator stack gas composition demonstrates that PeCDFs and 
HxCDFs are important mission constituents, accounting for a majority of total huans on a mass 
basis. However, during the incident, the TCDF congener was a more important emission 
constituent, accounting for appmximately 47% of the total furans in the stack gas (as opposed to 
16% under nomai conditions). As with the dioxins, the concentrations of total furans were 
much hîgher d u ~ g  the incident release than under normal operational specifications (520 pg/m3 
versur 56 ng/m3 in normal stack gas) (CanTox, 1998). As such, the similar but elevated PCDD/F 
congener-specific concentration pattem and the observable spike in TCDF concentrations noted 
in the winter 1996 ambient sampling data can be directly linked to the congener-specific 
emission pattern arising h m  the October 1996 incident event. A more detailed discussion of the 
incident emissions and the corresponding environmental congener-specific fingexprint can be 
found in this mearcher's Masters thesis report (Ferguson, 1998). 
6.3 Appücation Issues 
1. Discuîs the impliccrtions of research results on mammolian (both vole and huma)  risk 
assessments, and the applicability ofloboratory developed TEF values under environmental 
conditions. 
in the past, hazard and risk assessrnent of PCDD/Fs have focused on the quantitation of TCDD 
concentrations in various environmental media However, with development of high-resolution 
analytical techniques coupled with studies on structure-toxicity relationships, it has become 
apparent that the bulk of the toxicity induced by most PCDDIF mixtures is not due to TCDD 
alone, but has significant contribution fiom other less-studied congeners. Furthmore, as 
confirmed in sampling done as part of the SHTC monitoring prograrn, TCDD has been 
demonstrated to represent only a very srna11 portion of the overall PCDD/F m a s  present in the 
environment (typically < 1 %). 
As a result, the complex nature of environmental mixtures of persistent organic pollutants, such 
as PCDDlFs and PCBs, greatly complicates the task of risk evaluation for humans, fish, and 
wiidlife. For this purpose, the concept of toxic equivalency factors (TEFs) was developed and 
introduced to facilitate risk assessrnent and regulatory control of exposure to these mixtures. 
White widely accepted, it is also generally understood that the TEF concept is based on 
assumption that the individual compounds al1 act through the same biologic or toxic pathway 
(i.e., Ah receptor mediated effects), and that the combined effects of the different congeners are 
dose or concentration additive. 
While many studies support this assumption (summarized in Van den Berg et al., 1998), research 
has indicated that the TEF for each 2,3,7,8-substituted congener compared to TCDD is variable 
among ce11 types, laboratory animal species, target organs, and responses. For example, ment 
studies done by Safe (1998~) with immunotoxicity-derived TEFs for several HAHs in mouse 
models has indicated that the TEFs for inhibition of the plaque-forming ce11 response to 
trinitrophenyi-Iipopol~accharide by 2,3,~,7,8-pemtachlorodibenzo~ in CS 7BU6, DBN2, and 
B6C3F 1 rnice varied by approximately 7-fold, and in some arsays this congener was more 
potent than TCDD. Over a broder spectrum of responses, TEFs for individual PCDDKDF 
congeners have been shown to Vary by over 100-fold (Safe, 1998~). As such, the broad range of 
potencies for a specific congener compromises the use of a single TEF for this congener and may 
over- or underestimate the calculated TEQ for a mixture. While this overall variability in 
calculated TEF values is due to many factors, it is primarily a result of the differential 
phamacokinetics and metabolism of HAHs in different exposed species. 
Given this variability in potency values and the potential implications this variability has on the 
predictive power of human and ecological risk assessments, validation of its applicability under 
mixture conditions typically observed in the environment, becomes a vital concem. Validation 
of the TEF value can be investigated by detemiining the in vitro or in vivo toxicities of 
reconstituted mixtures of PCDDs and PCDFs and comparing their observed verstu calculated 
potencies. in a limited number of validation studies using mixtures, a good correlation was 
found between the observed in vivo or in vitro response and TEQ values calculated fiom the 
relative concentrations of individual congenen in the mixture using multiple end points (Van den 
Berg et al., 1998; Schrenk et al., 1990; Eadon et al., 1986). However, for more complex 
mixtures containing compounds that act through multiple pathways to give both similar and 
different toxic responses, recent thought is that the TEFITEQ approach may not be appropriate 
(Safe, 1998~). For exarnple, even for PCDDslPCDFs, there is some evidence that TEFs do not 
always predict relative congener potency in di fferent rat strains (Pohj anvirta et al., 1 995). 
Several studies have also demonstrateci that the coplanar PCBs (i. e., 3,3 ' ,4,4'-tetra-, 
3,3',4,4',5-penta, and 3,3',4,4*,5,5'-hexachlorobiphenyl) bind to the AhR and induce a broad 
spectrum of AhR-mediated biochemical and toxic responses (sumarizeci in Safe, 1994). 
Provisional TEFs have been proposed for coplanar and mono- ortho coplanar PCBs and these 
values are used routinely for detennining total TEQs in risk assessments (Van den Berg et ai., 
1998). While the relative TEQ conhibutions of different classes of HAHs are variable, there are 
numerous exampla that demonstrate that PCB TEQs contribute >50% of total TEQs (Safe, 
1998~). 
While many of these PCBs integrate well hto the TEF approach, one of the major problems 
associateci with the TEF approach for HAHs is the potential nonadditive antagonistic interactions 
between ALiR agonists (Le., PCDDs/PCDFs and certain PCBs) and PCB congeners that exhibit 
response and cell/species-specific antagonistic activity. Table 6.3, below, provides a few 
examples of the antagonistic impacts of various HAHs have on the AhR-mediated HAHs, such 
as TCDD. 
Tabk 6.3 Examples of Antagonistic Interactions of Halogenated Aromatic 
Hydrocarbons through Inhibition of TCDD or 3,3',4,4',5=PentaC&induced 
Responsa (Ssfe, 1998~). 
- - - - 
1 $,6,8-TctraCDF 
2,3,6,8-TetraCDF AHH/EUOD activities (H411E cells) 
Aroclor 1254 ............................................................................................................................................................................................................. 
2,2',4,4',5',6-HexaCB EROD activity (chick embryo hepatocytcs) ............................................................................................................................................................................................................. 
2 J',S 3'-TctraCB Luciferase activity (rnouse and rat cell lincs) ............................................................................................................................................................................................................. 
Aroclors 1232,1242,1248, 1 254, and 1260 
Reconstitutd PCB mixtures 
1,3,6,8-TctraCDF 
2,3,3',4,5'-PentaCB 
2,3,3',4,4',5-HcxaC8 Splenic plaque-forming ccll rcsponse to sheq r d  bIood cells or 





2,î',4,4',5,5'-HcxaCB Scrum IgM units (micc) 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Aroclor 1254 
2J.5 ,Sv-TctraCB Fm1 cleA palate and hydronephrosis (micc) 
2,2'.4,4',5,5'-HexaCB ............................................................................................................................................................................................................. 
2$',4,4',5,S1-HexaCB Chick embryotoxicity, malformations ,edcma, liver lesions 
For exarnple, 2,2',4,4',5,SP-hexachforobiphenyl (PCB 153), a major persistent congener in 
environmental samples, inhibits the following TCDD or 3,3',4,4',5-pentachlorobiphenyl-induced 
responses: i) induction of ethoxyresorufin O -deethylase activity in chick embryo hepatocytes; ii) 
inhibition of the plaque-forming ce11 response to sheep red blood cells in mice; iii) inhibition of 
the plaque-fomllng ce11 response to trinitrophenyl lipopolysaccharide in mice; iv) inhibition of 
senun IgM units in mice; v) induction of fetai cleft palate in mice; vi) induction of chick embryo 
malformations; vii) induction of chick embryo edema; Mii) induction of chick ernbryo liver 
lesions, and; ix) induction of fetal hydronephrosis in mice (Safe, 1998~). 
While not discussed directly in the current research project, the implications of such antagonistic 
HAHs on the ligand binding kinetics and overall tissue-specific disposition of PCDDIFs are quite 
far-reaching. Humans and wildlife are constantly environrnentally exposed (primarily through 
diet) to complex mixtures of these persistent HAHs. Hazard and risk assessment of these 
mixtures is a difficult process and the TEF approach has been utilized to attempt to address these 
issues. However, these nonadditive interactions, coupled with the unusually broad range of TEF 
values obsened for some PCB congeners (e.g., 3,3',4,4'-tetraCB), compromises the utility of the 
TEF approach for hazard and nsk assessment of HAHs that contain PCBs (Safe, 1998~). 
These and other uncertainties that impact upon the applicability and utility of the TEF concept 
(e.g., differences in shape of the dose-response curve, species responsiveness, etc.) were 
discussed in detail at an expert meeting organized by the World Health Organization (WHO) and 
held in Stockholm on June 15-18, 1997. In spite of these uncertainties, it was concluded that the 
TEF concept is still the most plausible and feasible approach for risk assessment of HAHs with 
dioxin-like properties. in view of the available scientific evidence f5om studies with mixtures, it 
was concluded that it is unlikely for the use of this additive mode1 to result in a great deal of error 
in predicting the concentrations of TCDD-TEQs or responses at environrnentally relevant levels 
due to non-additive interactions (Van den Berg et al., 1998). 
Despite these assurances, these uncertainties may have significant implications on the predictions 
of toxicological impacts in environmental nsk assessments. For exarnple, based upon the tissue 
sarnpling conducted on voles living in the area surrounding the SHTC following the October 
1996 release incident, the PCDDIF and PCB whole body concentrations (on a TEQ-basis) were 
sumciently elevated as to result in the prediction of an observable population-wide negative 
impact on reproductive success. However, vole populations levels have actually increased in the 
years following the incident, with no obvious short- or long-term deleterious impacts appearing 
as a result of the significant short-tenn increase in enviionmental HAH levels (Chem-Security 
Ltd, 1999). 
Obviously there is still a significant amount of uncertaiuty present in the cunent TEF 
methodology, likely arising h m  some of the inter-species phmacokinetic and 
pharmacodynamie issues identified in the current research project. Therefore, while the 
prediction of TEQs according to the TEF mode1 is considered to be plausible and to be the most 
feasible approach for risk assessrnent of HAHs with dioxin-like properties, given these 
uncertainties, the application of TEFs to evaluate overall toxicity in environmental nsk 
assessments of facilities such as the SHTC must be made with caution. As aptly concluded by 
Safe (1998c), TEFs/TEQs for HAHs must be used very selectively, and more research on the 
utility, applications, and limitations of this method should be conducted. 
2. Ushg uncertainty analyses, evaluate the potential impacts of leverage variables on the 
PBPK model, and accordingly the results of a health assesment involving these variables. 
Results of the uncertainty analyses conducted on the steady-state PBPK model for the Sprague- 
Dawley rat provided some very interesting indications of the key leverage variables. and the 
relative dose-dependencies involved. At low doses, general physiological parameters (i. e., body 
weight, biliary excretion rate) and cornpartment-specific equilibrium ratios play the most 
sipificant role in TCDD disposition. However, as the exposure dose increases (i.e., above the 
0.1 pg/kg bodyweight level), ligand-receptor pharmacodynarnics appear to become the dominant 
faftor. with binding kinetic parameters providing the largest leverage on the model outcome. At 
the lower doses (Le., around the 0.3 16 pgkg bodyweight dose level), the CYPI A2 binding 
kinetic parameters appear to play the largest role in model outcome. While at the more elevated 
doses (i.e., around the 1 pgkg  bodyweight dose level), the contribution of Ah receptor binding 
parameters to overall variance in TCDD disposition has a dominant impact on model outcome. 
Finally, as the administered dose increases beyond the 3.16 pglkg bodyweight dose levei, the 
contribution to variance fiom ligand-receptor parameters r e m s  to the levels observed at the 
very low doses (i.e., 50.1 &'kg bodyweight), while the parameters related to compartmental 
pemeability, as well as TCDD absorption and elimination, become the key leverage variables in 
the pattern of TCDD whole-body disposition. 
This dose-dependent pattern of leverage parameter impacts on TCDD disposition is as expected 
based upon the research presented in this paper. At low doses, there are not sufficient levels of 
TCDD within the body to result in significant occupancy of the Ah recepton or CYPlA2 
proteins. Furthemore, the levels of TCDD-Ah receptor complexes are too low to result in a 
signi ficant induction of CYP 1 A2 protein levels. As such, TCDD disposition is controlled b y 
tissue-specific equilibrium and pemeability parameters related the lipophilicity of the 
compound, as well as relative rates of elimination viu urinary and fecahiliary excretion. 
However, as the concentration of TCDD within the organism increases, the Ah receptor 
occupancy level increases leading to m e r  induction of CYPlA2 protein within the liver. The 
binding to the Ah receptor and CYP 1 A2 protein results in sequestration of the TCDD within the 
liver, dramatically irnpacting upon the whole-body disposition and elimination pattern. This 
bepatic sequestration results in CYP 1 A2 binding kinetic pararneters (primarily the concentration 
resulting in half maximum induction folds) initiaily playing the largest role in TCDD disposition. 
It is important to rernember that the Ah receptor is a constitutive high aflinity, low-capacity 
receptor, while CYPlA2 are inducible, low-afinity, and hi@-capacity receptor proteins. As 
such, as the concentration of ligand increases, the Ah receptors become more sattuated and result 
in sipificant induction of CYP1A2 protein in response. Thus, at concentrations approaching 
levels which result in saturation of available Ah receptor, ligand-Ah receptor binding kinetics 
become a dominant factor over those related to CYP 1 A2 sequesiraiion. 
Similar results were observed in sensitivity analyses conducted by Evans and Andersen (2000) on 
Sprague-Dawley rats. Their research indicated that, at elevated doses nearing 0.1 @kg 
bodyweight, the inflection point indicative of the major shift in liver-to-fat ratio was more related 
to charactenstics of DNA bindinghduction steps of the Ah receptor-DNA complex than by the 
CYP lA2 affinity of TCDD or concentrations of CYP lu. 
Finally, once the concentration of TCDD within the body reaches a sufficient level as to result in 
complete saturation of both the available Ah receptors and CYP 1 A2 protein pool, remaining free 
TCDD can no longer be sequestered within the liver and pharmacokinetic processes (primarily 
cornpartmental permeability and TCDD absorption and excretion rates) begin to dorninate its 
disposition throughout the body (i.e., disposition in the adipose tissue increases as the Iiver-to-fat 
ratio begins to fall). 
Given the obvious importance of ligand-receptor pharmacodynamies on the dose-dependent 
nature of PCDDR absorption, disposition, metabolism, and excretion, it is vital that any inherent 
uncertainty within these phmacodynamic pararneters be minimized. Results of the 
uncertainty/sensitivity analyses indicate that the pharmacodynamie pararneters which have the 
greatest impact on PCDDIF disposition are: concentration to cause half of the maximum 
CYPlA2 induction folds; maximum CYPlA2 induction fol& over the basai rate; Ah receptor 
binding capacity in each of the key compartments; CYPlA2 physiological delay tirne, and; the 
Hill coefficient (see Tables 5.13 and 5.14). Ud'ominately, these parameters are also the most 
difficult to characterize, not only on a chernical-specific basis, but particularly on a species- 
specific basis. While QSAR research provides significant promise in bridging these data gaps, a 
considerable amount of research is still required to better characterize the uncertainty inherent 
within these key leverage variables. 
3. Discuss the value of the results of the research as well usfitture ernpirical research neeak. 
Based upon a limited set of validation exercises, it appears that the current research has 
successfully developed an integrated PBPK model system for evaluating the absorption, 
disposition, metabolism, and excretion of key PCDDIF congenen (i.e., TCDD, TCDF, 1 -PeCDF, 
and 4-PeCDF) in three separate test organisrns (i.e., the Sprague-Dawley rat, the C57BU6J 
mouse, and the Gapper's red-backed vole). As a result of the research, significant differences in 
tissue-specific disposition of key congeners (i.e., TCDD and 4-PeCDF) has been noted between 
the laboratory rat and the vole. These differences have significant implications for the 
application of congener-specific TEF values, and the overall predicted toxicity (on a TCDD-TEQ 
equivalency basis) to the vole population evaluated as part of an ongoing environmental nsk 
assessrnent process. 
As noted previously, there are a number of uncertainties and conservative assumptions inherent 
within the development of the curent PBPK modelling system, especially as it pertains to the 
red-backed vole. in addition to the relative strengths and weaknesses of the selected PBPK 
model discussed previously, other areas of uncertainty include: 
Due to the limited data set on which the model was developed, the appropnateness and 
accuracy of the model predictions at very low and very high doses has not been validated. 
Due to a lack of species-specific data, many of the pharmacokinetic and phmacodynamic 
parameten used for the red-backed vole were based upon those used for the C57BU6J 
mouse (based upon similar size and body composition). Given the lack of time-series 
congener-specific data for vole, it is difficult to determine whether these parameter 
selections are appropriate or not. 
Differences in pharmacokinetic disposition due to the chernical-specific lipophilicity were 
incorporated into the model by using a lipophilicity adjustment factor calculated for each 
congener based upon the ratio of its octanol-water partition coefficient KW) to that of 
TCDD. While likely an acceptable measure of variability in tissue-to-blood equilibrium 
ratios, more accurate data can be easily gathereâ through simple tissue-based assays. 
Based on the similarities in lipophilicity of the assessed congeners, the Eraction of the total 
dose absorbed 0 via the GI tract was assumed to be equal to that used for TCDD. While 
likely reasonable for these congeners, such an assurnption would be highly inappropriate for 
the higher chlorinated congeners should they be assessed with the current mode1 
methodology (i.e., research has demonstrated that very linle of the OCDD and OCDF 
congeners is absorbed through the gut wall and is quickly excreted following an oral 
administration dose). 
Ah and CYPI A2 ligand-receptor binding affinities (K, values) were estimated and modelled 
based upon their relative differences to the TCDD base ligand. Due to the lack of suitable 
chernical- and species-specific phamacodynamic data, this is likely the largest source of 
uncertainty in the current model methodology. 
Congener-specific metabolism (specifically CYPl Al modulated) was included as part of the 
overall urinary and biliary/fecal excretion rates, and excretion half-lives were used to 
calculate chernical-specific excretion rate adjustment factors. Depending on the 
administered dose and treatment scenario, excretion half-lives can Vary drarnatically fiom 
study to study and species to species. 
Results of the model-based uncertainty/sensitivity analyses indicates that one would get the most 
"bang for your buck" by investing resources into gathering more detailed phamacodynamic 
information reiated to Ah and CYP1 A2 ligand-receptor interactions (Le., concentration to cause 
haif of the maximum CYPIA2 induction folds; maximum CYP1 A2 induction folds over the 
basal induction rate; Ah receptor binding capacity in each of the key compartments; CYP 1 A2 
physiological delay time, and the Hill coefficient). As indicated previously, these parameters are 
also the most difficult to characterize, not only on a chernical-specific basis, but particularly on a 
species-specific basis. While QSAR research provides significant promise in bridging these data 
gaps, a considerable amount of research is still required to better characterize the uncertainty 
inherent within these key leverage variables. 
On important issue for resolution in friture research is the conversion of the model bais  to allow 
for a better approximation of whole body concentrations under chronic dosing conditions. The 
curent model is designed based upon an initial acute oral bolus exposure to a particular 
congener, and appears to be able to effectively predict short-term whole body concentrations 
when faced with sudden elevated ambient PCDDIF levels (i.e., immediately following a release 
incident). However, the model is less successfbl in predicting body loads when the voie is 
chronically exposed to low levels of PCDD/Fs, particularly when assessing the more 
bioaccumulative congeners (i.e., TCDD, 4-PeCDF, and some HxCDFs). This discrepancy is 
obvious when one compares modelled vole-to-plant BAF values to those estimated based upon 
environmental sampling (see Tables 5.28 and 5.29). Given their much longer 
metabolic/excretion half-lives, elevated concentrations of the bioaccumulative congeners would 
concentrate in the liver and adipose tissue over time. While short-term levels rnay not be 
sufliciently elevated as to result in a threshold-based toxic outcome, bioaccumulation of these 
congeners may result in significant toxicological impacts in the longer term. Unfortunately, the 
version of the PBPK model used in the current research is unable to assist in the assessment of 
these risks. 
7.0 CONCLUSIONS 
Exposure concentrations of contaminants fond  in air, water, soil, dust, food, or other 
environmental media to which populations are in contact are typically the dose scales most 
commonly used when evaluating potential health effects for environmental or occupational 
pollutants. However, research has indicated that extemal exposure is oflen only a rough 
approximation for the overail intemal exposure delivered at the critical target sites in the body. 
This discrepancy can have significant implications on the overall toxicity manifested based upon 
a given environmental concentration and exposure scenatio. 
Pharmacolcinetic models have been shown to provide the rnuch needed functional relationship 
between external measures of chemical exposure and intemal, target tissue measures of exposure 
to the actual toxic moiety. Accordingly, physiologically based phmacokinetic modelling has 
becorne a scientifically attractive method of conducting this aspect of toxicological risk 
assesment. A nurnber of recent toxicological evaluations (e.g., arsenic, trichlomethylene, 
benzene, etc.), conducted by the U.S. EPA, have incorporated PBPK modelling in its decision 
making process. This methodology has been shown to be particularly appropriate for the 
evaluation of the potential impacts that pharmacokinetics and pharmacodynamies may have on 
the ultimate toxicity of persistent organic pollutants, such as dioxins and h s .  
Around midday on July 1 O", 1976, an explosion occurred in a 2,4,5-ûichlorophenol reactor of 
the ICMESA chemical plant on the outskiris of Meda, a srnail town about 20 kilometres north of 
Milan, Italy. A toxic cloud containing TCDD and other related compounds was accidentally 
released into the atrnosphere. The bbdioxin" cloud contaminated a densely populated area about 
six kilometres long and one kilometre wide, lying downwuid fbm the site. This event becarne 
intemationally knomi as the Seveso disaster, after the name of a neighbouring municipality that 
was most severely affected. The Seveso accident, in addition to the outcry arising fiom the U.S. 
military's use of dioxin-contaminated Agent Orange during the Vietnam war, tnggered a rarely 
precedented global surge of interest in one single class of chemical substances, the 
polyhalogenated dibemo-p-dioxins and dibenzofurans. One rnember of this group of several 
hundred individual cornpounds, TCDD, suddenly became the focus of media attention and in the 
ensuing years dominated the public debate al1 over the world. 
This public interest and scrutiny has resulted in a considerable arnount of research into the 
dispersion, deposition, and bioaccumulation of these compounds in the environment. 
Unfominately, the history of PBPK modelling use by regulatory agencies, suc h as the US. EPA, 
is a rather checkered one. In Apnl 199 1, EPA announced that it would undertake a reassessment 
of the risks of exposure to dioxin. When released in draft fom in 1994 (U.S. EPA, 1994), most 
of the chapters in the reassessment had been appropriately reviewed at peer review workshops. 
Strangely, Chapter 9 - "Risk Characterization of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
and Related Compounds" was not subjected to early peer review and did not appear to have the 
significant involvement of anyone in the scientific community outside the EPA. in particuiar, a 
group of well-known dioxin researchers stated that "[tlhe conclusions in the EPA's current risk 
charactenzation are thus heavily dependent upon many unproven assumptions and untested 
hypotheses that deserve carehil scrutiny by the scientific community" (Conolly, 1994). In 
response to the criticisms put forward by the EPAs own Science Advisory Board (SAB), public 
comments, and newly available scientific information EPA has been working to revise and 
update the 1994 draA, and recently issued a revised draft document (U.S. EPA, 2000) which 
provides a more complete review of the current state of scientific knowledge surrounding the 
pharmacokinetics and phamacodynarnics of dioxin. 
in an effort to provide an on-going assessrnent of the potential environmental impacts related to 
the inadvertent release of these anthropogenic compounds, regulatory agencies (in response to 
public concern) have aiso mandated that extensive long-tenn monitoring programs be typically 
u n d d e n ,  as part of the facility approval and operation licence. These programs endeavour to 
monitor and assess mission releases, as well as mesure ambient environmental concentrations 
in a variety of key sentinel biota species (e.g., red-backed voles, Labrador tea, moss, etc.), to 
provide a better indication of the cwent and hinue human and ecological health risks related to 
facility emissions. 
While emission release and dispersion kinetics play a significant role in the ultirnate congener- 
specific fingerprint observed in environmental biota, as discussed previously, pharmacokinetics 
c m  have considerable impact on congener-specific disposition, metabolism and excretion rates. 
Alteration of the disposition and elimination behaviour of a particular congener can have 
particularly significant implications on tissue-specific sequestration. Given the importance of 
these congener-specific diffaences on the overall toxicity observed in a variety of species, it is 
vital that a reasonably accurate model of the congener-specific pharmacokinetic and 
phannacodynarnic processes be developed to better characterize the toxicodynamic properties of 
the compound. This would also allow for a truer evaluation of the appropriateness of the 
congener-specific TEF values used as part of the toxicological nsk assessrnent process, on a 
species-speci fic basis. 
Results of the current application of the PBPK model developed using laboratory rodents for use 
with the vole sentine1 species has indicated that this model methodology appears to provide a 
reasonable estimation of chemical-specific disposition and elimination patterns within the vole 
sentine1 species, at l es t  under short-tem acute exposure scenarios. Accordingly, it appears that 
the vole is a useful and relevant sentine1 species to evaluate the pharmacokinetic and 
phannacodynamic issues surrounding the environmental impacts of PCDD/Fs released as a result 
of anthropogenic activities. PBPK mode1 systems, such as the one developed based upon the 
Wang et al. (1997) methodology, may provide valuable tools for evaluating data from long-term 
environmental monitoring programs, such as that in place at the Swan Hills Treatment Centre. 
However, the current PBPK modelling systems still have a considerable amount of inherent 
uncertainty associated with the parameter and methodological assurnptions. Research is 
continuing to attempt to provide a better comprehension of the intricate ligand-receptor 
mechanisms at play withh hepatic and extrahepatic tissues, particularly at the P45O isozyrne 
molecular level. While great strides forward have been taken in the past decade, it is only 
through M e r  detailed research into the pharmacokinetic and pharmacodynamie properties of 
these compounds, will a more accurate and precise understanding of the disposition and ultimate 
toxicity of these intrîguing persistent organic pollutants be achieved. 
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APPENDIX A 
Detailed Overview of Mathematical Equations 
used in Prototype PBPK Models 
A-1.0 Prototype Steady-State PBPK Model (Wang et ul., 1997) 
The following section provides the detailed mathematical equations used in the development of 
the prototype steady-steate PBPK model for the current research on PCDDfF phannacokinetics. 
The model methodology is based upon the Wang et al. (1997) published model, with a 
considerable amount of information added (based upon other published source material) to fil1 in 
gaps in the methodology provided by the Wang et ai. (1997) source paper. 
Figure A 4  A scbematic representation of the cquilibrium TCDD PB-PK model 
(Wang et al., 1997) 
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Figure A-2 TCDD Distribution in a Generic Tissue Compartment 







The total concentration of TCDD in a typical intracellular domain can be sirnulated as: 
CT = fw CT,f + fi>* CL@ f fnb C n b  f Cs61 + C3b2  
Total concentration of TCDD in the intracellular tissue (moledg tissue) 
Concentration of TCDD in the water fktion of the tissue (nmoles/g tissue) 
Concentration of TCDD in the lipid fraction of the tissue (nmoledg tissue) 
Concentration of TCDD non-specifically bound in the tissue (nmoles/g tissue) 
Concentration of TCDD bound to resident Ah receptors (nrnoledg tissue) 
Concentration of TCDD bound to mident CYP 1 A2 (nmoledg tissue) 
Water- filled volume fraction in the tissue compartment (unitless) 
Lipid-filled volume fraction in the tissue compartment (unitless) 
Volume fraction of linear binding constituents in the tissue compartment 
(unit less) 
The concentration of TCDD bound to proteins and other cellular constituents (Cn,,) cm be 
calculated as: 
Where: 
= the linear binding constant for that tissue compartment (unitless) 
Therefore, the concentration of TCDD non-specifically bound to proteins and other linear 
binding constituents of the tissue (i.e., not bound to Ah receptors or CYPlA2 metabolic sites) 
can be represented as: 
Ct (specijic bound) = fi Ctf + jLip Ki CT/ + f i b  Kn CTf 
Linear Binding of TCDD to Plasma Proteins 
The total TCDD concenûation in the blood entenng this cornpartment can be expressed as: 
Where : 
C, = Total TCDD concentration in the compartment blood supply (nmoledg) 
C,, = Free TCDD concentration in the compartment blood supply (nmoles/g) 
C, = Plasma-bound TCDD concentration in the compartment blood supply (nmoles/g) 
f,, = Water âaction of the compartment blood supply (unitless) 
Whexe: 
Km = the linear binding constant of TCDD to plasma proteins.(unitless) 
TOTAL BODY WIGHT CHANGE 
W=Ko(l+ (a0 x t )  
(bo + t )  1 
Where: 
W, = Body weight at time t (g) 
W, = Body weight at time of exposwe (g) 
*O = Body weight fitting parameter A (0.41) 
bo = Body weight fitting parameter B (1402.5) 
t = Elapsed time following exposure (hours) 
CALCULATION OF COMPARTMENT VOLUMES 
Tissue Volume 
v =  V, m 
Where: 
V = Tissue volume within the cornpartment (g tissue) 
vc = Allometric constant used to calculate artenal cornpartment volume 
(g tissudg bodyweight) 
W, = Body weight at tirne c (g) 
Tissire Blood Volume 
V b  = Vk v 
Where: 
V, = Tissue blood volume within the cornpartmeni (g tissue) 
V, = Tissue blood volume as a fraction of tissue volume (unitless) 
CALCULATION OF CARDIAC OUTPUT 
Where: 
Q, = Total cardiac output for the test species (rnl/hour) 
Q, = Allometric coefficient to calculate cardiac output h m  bodyweight (rnl/kg!min) 
W, = Body weight at t h e  t (g) 
CALCULATION OF ABSORBED DOSE 
Flow rate of delivery of administered oral dose of TCDD to the stomac h (nmoleshour) 
Flow rate of absorption of TCDD h m  stomach through the gut wall into the lumen 
(nmoleshour) 
ML,, is calculated through an integration of R, over time, using A, as the 
initial amount of TCDD present in the lumen. 
Flow rate of TCDD transfer fiom lumen to venous blood supply via lymphatic flow 
(nmo leshour) 
R L ~ ~ ~ ~  = a x KA* ML- 
Flow rate of TCDD transfer nom lumen to liver via portal vein (nmoledhour) 
Proportion of absorbed oral dose entering venous blood via lymphatic flow 
fkom the GI tract (unitless) 
initial amount of TCDD in the lumen (nrnoles) 
Fraction of the total dose absorbed/bioavailable (unitless) 
TCDD absorption rate h m  the lumen to the systemic circulation (Vhour) 
the stomach emptying rate (Ihour) 
the amount of TCDD absorbed into the lumen (nmoles) 
the amount of TCDD in the stomach (nmoles) 
Flow rate of absorption of TCDD h m  stomach through the gut wall into the 
lumen (nrnoledhour) 
Flow rate of TCDD tramfer h m  lumen to liver via portal vein (nmoles/hour) 
Flow rate of TCDD tramfer h m  lumen to venous blood supply via lymphatic 
flow (nmoledhour) 
Flow rate of delivery of administered oral dose of TCDD to the stomach 
(nmoles/hour) 
Weight of the blood (g) 
Concentration of TCDD in the arterial blood (nmoledg tissue) 
Concentration of TCDD in the kidney venous blood (nrnoledg tissue) 
Concentration of TCDD in the lung venous blood (nrnoledg tissue) 
Concentration of TCDD in the skin venous blwd (nmoles/g tissue) 
Concentration of TCDD in the venous blood of the adipose tissue 
(nmoledg tissue) 
Concentration of TCDD in the venous blood of the rest of the body 
(nmoledg tissue) 
Concentration of TCDD in the liver venous blood (nmoledg tissue) 
Blood flow in the kidneys (rnhour) 
Blood flow in the skin (mlhour) 
Blood flow in the adipose tissue (mihour) 
Blood flow in the rest of the body (ml/hour) 
B l d  flow in the liver (myhour) 
Flow rate of TCDD transfer from lumen to venous blood supply via lymphatic 
flow (nmoleshour) 
LUNGS Flow-Limited Cornpartment 
(only blood flow rate controls tissue uptake) 
a) Concentration of unbound (free) TCDD in lung compartment (nmoVg tissue) 
b) Concentration of TCDD in lung tissue blood (nmoVg tissue) 
(this is the concentration leaving the lungs into the arterial blwd supply) 
Note: As membrane permeability has no impact on tissue concentrations in fîow-limited 
compartments, such as the lungs, the outgoing TCDD blood concentration would be 
qua1 to the concentration of unbound TCDD found within the lung compartment 
(i. e., flow-through except for those bound to cornpartmental tissue constituents). 
c) Overall tissue concentration of TCDD in lung cornpartment (moVg tissue) 
AL. 
C =  
VLUB Lu+- 
P L U  
d) Rate of change of TCDD in cornpartment (nmoühour) 
e) Ovedl TCDD concentration (tissue and blood) in the lungs (moVg tissue) 
Amount of TCDD concentration in the lungs (nmol) 
(Based on integration of Rh at a specific time slice) 
Ah recep tor nonlinear binding capacity (nmoVg) 
Concentration of TCDD in the lung tissue at a specific time (nrnoVg) 
Concentration of TCDD in the blood entering the lungs (nrnol/g) 
Concentration of bound TCDD in the lungs (nmoVg) 
Concentration of unbound TCDD in the lungs (nmoVg) 
Concentration of TCDD in the lung tissue blood (nmoVg) 
Overall TCDD concentration (tissue and blood) in the lungs (nrnoVg tissue) 
Equilibrium dissociation constant for Ah receptor binding (nmoVg) 
Equilibriurn ratio of the lung tissue concentration to blood concentration (unitless) 
Blood flow in the lungs (mhour) 
Rate of change of TCDD concentration in the lungs (nmolhour) 
Tissue volume of the lungs (g) 
Tissue blood volume within the lungs (g) 
Tissue weight of the lungs (g) 
Weight of blood in the lungs (g) 
KIDNEY S Mem brune-Lim ited Compurtm ent 
(only membrane tram fer controls tissue uptake) 
Concentration of unbound (fiee) TCDD in kidney compartrnent (nmoVg tissue) 
Overall tissue concentration of TCDD in kidney cornpartment (nmoVg tissue) 
Rate of change of TCDD in compartment (mol/hour) 
Flow rate of TCDD lost due to renal urinary excretion (nrnollhour) 
Concentration of TCDD in kidney tissue blood (mol& tissue) 
(this is the concentration leaving the kidneys in the venous blood supply) 
Overall TCDD concentration (tissue and blood) in the kidney (nmoVg tissue) 
(Ar  + C X ~  x V K ~ )  cm = 
(VK + V K ~ )  
Amount of TCDD concentration in kidneys (nmol) 
(based on integation of RK at a specific time slice) 
Ah receptor nodinear binding capacity (nmoVg) 
Concentration of TCDD in the kidney tissue at a specific time (nrnoVg) 
Concentration of TCDD in the blood entering kidneys (nmoVg) 
Concentration of bond TCDD in the kidney (nmoVg) 
Concentration of TCDD in the kidney tissue blood (nmoVg) 
Concentration of unbound TCDD in the lridney (nrnoVg) 
Overall TCDD concentration (tissue and blood) in the kidney (nmoVg tissue) 
Equilibrium dissociation constant for Ah receptor binding (nmoVg) 
Urinary linear elimination constant (1 hour) 
Equilibrium ratio of the kidney tissue concentration to blood concentration 
(uni tless) 
Pemieability of the kidney (mVhour) 
Blood flow in the kidney (mlhour) 
Rate of change of TCDD concentration in the kidneys (nmolhour) 
Flow rate of TCDD lost due to renal urinary excretion (nmohour) 
Tissue volume of the kidneys (g) 
Tissue blood volume within the kidneys (g) 
Tissue weight of the kidneys (g) 
IUST OF BODY Membrane-Limited Cornpartment 
(only membrane transfer controls tissue uptake) 
a) Overall tissue concentration of TCDD in the rest of the body (nmo Vg tissue) 
b) Rate of change of TCDD in compartment (nmoVhour) 
c) Concentration of TCDD in tissue blood within the compartment (nmoVg tissue) 
(this is the concentration leaving the rest of the body in the venous blood supply) 
d) Overall TCDD concentration (tissue and blood) in the rest of the body (moVg tissue) 
Amount of TCDD concentration in the rest of the body (nmol) 
(based on integration of R, at a specific thne slice) 
Concentration of TCDD in the rest of the body tissue at a specific time (nmoVg) 
Concentration of TCDD in the blood entering the rest of the body (nmoVg) 
Concentration of TCDD in the tissue blood within the rest of the body (nmoVg) 
Overall TCDD concentration (tissue and blood) in the rest of the body 
(nmoVg tissue) 
Equilibrium ratio of the tissue concentration to blood concentration in the rest of 
the body (unit less ) 
Permeability of the rest of the body (mhour) 
Blood flow in the rest of the body (mllhour) 
Rate of change of TCDD conceniration in the rest of the body (nmoVhour) 
Tissue volume of the rest of the body (g) 
Tissue blood volume within the rest of the body (g) 
Tissue weight of the mt of the body (g) 
SKIN Membrane-Influenced Cornpartment 
(Both blood flow rate and membrane transfer control tissue uptake) 
a) Concentration of unbound (free) TCDD in the skin (moVg tissue) 
b) Overall tissue concentration of TCDD in the skin (nmoVg tissue) 
c) Concentration of TCDD in tissue blood within the skin (nmoVg tissue) 
(this is the concentration leaving the skin in the venous blood supply) 
d) Rate of change of TCDD in cornpartment (nrnol/hour) 
Tissue 
e) Overall TCDD concentration (tissue and blood) in the skin (moYg tissue) 
( A s  + ASB) Cs = 
(VS + VSB) 
Amount of TCDD concentration in the skin (nmol) 
(based on integration of R, at a specific tirne slice) 
Amount of TCDD concentration in the skin blood (nmol) 
(based on integration of &, at a specific time slice) 
Ah receptor nonlinear binding capacity (nrnoVg) 
Concentration of TCDD in the skin tissue at a specific time (nmoVg) 
Concentration of TCDD in the blood entering the skin (nmoVg) 
Concentration of bound TCDD in the skin (nmoVg) 
Concentration of TCDD in the skin tissue blood (nrnoVg) 
Concentration of unbound TCDD in the skin (nmoVg) 
Overall TCDD concentration (tissue and blood) in the skin (nmoVg tissue) 
Equilibrium dissociation constant for Ah receptor binding (nrnoVg) 
Equilibrium ratio of the skin tissue concentration to blood concentration (unitless) 
Permeability of the skin (rnVhour) 
Blood flow in the skin (mVhour) 
Rate of change of TCDD concentration in the skin (nmoihour) 
Rate of change of TCDD concentration in the skin blood (nmoühour) 
Tissue volume of the skin (g) 
Tissue blood volume within the skin (g) 
Tissue weight of the skin (g) 
Weight of blood in the skin (g) 
ADIPOSE TISSUE/FAT Membrane-Lhited Compattment 
(only membrane transfer controls tissue uptake) 
a) Overall tissue concentration of TCDD in the adipose tissue (nmoVg tissue) 
b) Rate of change of TCDD in compartment (nmolihour) 
c) Concentration of TCDD in tissue blood within the compartment (nmoVg tissue) 
(this is the concentration leaving the adipose tissue in the venous blood supply) 
d) Overall TCDD concentration (tissue and blood) in the adipose tissue (nrnoVg tissue) 
Amount of TCDD concentration in the adipose tissue (mol) 
(baseâ on integration of RF at a specific tirne slice) 
Concentration of TCDD in the adipose tissue at a specific time (nmoVg) 
Concentration of TCDD in the blood entering the adipose tissue (nrnoVg) 
Concentration of TCDD in the tissue blood within the adipose tissue (nmoVg) 
Overall TCDD concentration (tissue and blood) in the adipose tissue 
(nrnoVg tissue) 
Equilibnum ratio of the tissue concentration to blood concentration in the adipose 
tissue (unit less) 
Penneability of the adipose tissue (mhour) 
Blwd flow h the adipose tissue (mVhour) 
Rate of change of TCDD concentration in the adipose tissue (nmolhour) 
Tissue volume of the adipose tissue (g) 
Tissue b l d  volume within the adipose tissue (g) 
Tissue weight of the adipose tissue (g) 
SPLEEN Flow-Limited Cornpartment 
(only blood flow rate controls tissue uptake) 
a) Concentration of unbound (fiee) TCDD in spleen (nmoVg tissue) 
b) Concentration of TCDD in spleen tissue blood (nmoVg tissue) 
(this is the concentration leaving the spleen into the portal vein) 
Note: As membrane permeability has no impact on tissue concentrations in flow-limited 
compartments, the outgoing TCDD blood concentration would be equal to the 
concentration of unbound TCDD found within the spleen (i-e., flow-through except 
for those bound to cornpartmental tissue constituents). 
c) Overall tissue concentration of TCDD in spleen (nmoVg tissue) 
d) Rate of change of TCDD in cornpartment (nrnolhour) 
e) ûverall TCDD concentration (tissue and blood) in the spleen (nmoVg tissue) 
Amount of TCDD concentration in the spleen (nrnol) 
(based on integration of kP at a specific time slice) 
Ah receptor nonlinear binding capacity (moVg) 
Concentration of TCDD in the spleen tissue at a specific time (moVg) 
Concentration of TCDD in the blood entering the spleen (mol@ 
Concentration of bound TCDD in the spleen (nmoVg) 
Concentration of unbound TCDD in the spleen (nmoVg) 
Concentration of TCDD in the spleen tissue blood (nmoUg) 
Overall TCDD concentration (tissue and blood) in the spleen (nmoUg tissue) 
Equilibrium dissociation constant for Ah receptor binding (nmoUg) 
Equilibrium ratio of the spleen tissue concentration to blood concentration 
(unitless) 
Blood flow in the spleen (mhour) 
Rate of change of TCDD concentration in the spleen (nrnolhour) 
Tissue volume of the spleen (g) 
Tissue blood volume within the spleen (g) 
Tissue weight of the spleen (g) 
Weight of blood in the spleen (g) 
PORTAL VEIN Miscellaneous Compartm ent 
(Handles mass flow into liver via portal vein) 
a) Flow rate of TCDD leaving portal vein hto liver (nmoles/hour) 
Where : 
C, = Concentration of TCDD in the blood entering the portal vein (nmoUg) 
C, = Concentration of TCDD in the blood entering âom the spleen (nmoVg) 
Q, = Blood flow in the liver (mUhour) 
QSp = Blood flow in the spleen (mVhour) 
RMd = Flow rate of TCDD transfer from lumen to liver via portal vein (nmolhour) 
R,, = Flow rate of TCDD in the blood leaving portal vein into the liver (nrnohour) 
LIVER Mem brtzne-hjluenced Conzpartment 
(Both blood flow rate and membrane transfer control tissue uptake) 
Concentration of unbound (free) TCDD in the liver (nmoVg tissue) 
Overall tissue concentration of TCDD in the liver (nmoVg tissue) 
Concentration of TCDD in tissue blood within the liver (nmoVg tissue) 
(this is the concentration Ieaving the liver in the venous blood supply) 
Rate of change of TCDD in cornpartment (nmolhour) 
d) Flow rate of TCDD lost due to biliary excretion (nmollhour) 
e) Concentration of Ah receptor occupied by TCDD ligand and available for binding to 
CYPlA2 (nmoVg) 
f) Overall TCDD concenüatioo (tissue and blood) in the liver (nmoVg tissue) 
Where: 
Amount of TCDD concentration in the liver (nmol) 
(based on integration of R, at a specific tirne slice) 
Amount of TCDD concentration in the liver blood (nmol) 
(based on integration of R ~ ,  at a specific t h e  slice) 
Ah receptor nonlinear binding capaci ty (nmo Vg) 
Concentration of TCDD in the liver tissue at a specific time (nmoUg) 
Concentration of Ah receptor occupied by TCDD ligand, available for binding to 
CYP I A2 in the liver (moVg) 
Concentration of unbound CYPlA2 available in the liver (nmoVg) 
Concentration of bound TCDD in the liver (nrnoVg) 
Concentration of TCDD in the liver tissue blood (nmoUg) 
Concentration of unbound TCDD in the liver (nrnoVg) 
Overall TCDD concentration (tissue and blood) in the liver (nmoVg tissue) 
Equilibriurn dissociation constant for Ah receptor binding (nrnoVg) 
Equilibriurn dissociation constant for binding to CYP I A2 (nmoVg) 
Biliary linear elimination constant (llhour) 
Permeability of the liver (mhour) 
Equilibnum ratio of the liver tissue concentration to blood concentration (unitless) 
Blood flow in the liver (ml/hour) 
Flow rate of TCDD lost due to biliary excretion (nmoühour) 
Rate of change of TCDD concentration in the liver (nmoVhour) 
Rate of change of TCDD concentration in the liver b l d  (nmoUhour) 
Flow rate of TCDD in the blood leaving portal vein into the liver (nmoühour) 
Tissue volume of the liver (g) 
Tissue blood volume within the liver (g) 
Tissue weight of the liver (g) 
Weight of blood in the liver (g) 
CYPlA2 Binding 
In the ccurrent model, the degradation of free CYPI A2 and bound CYPI A2 are assumed to be the 
same. The change of CYPlA2 with time was obtained from a simulation model proposed by 
Dayneka et of. (1993). As such, the concentration of unbound CYPlM available for TCDD-Ah 
binduig was simplified using the following set of equilibrium binding equations: 
a) Calculate zero-order basal induction rate for CYP 1 Aî synthesis (nmoles/g/hour) 
b) Rate of change of initially available CYPl A2 within the liver (nmolhour) 
C) The CYP1A.2 stimulation hc t ion  is represented as follows (unitless) 
As the binding of TCDD to available CYPlA2, Ma Ah-receptor complexing, is not an 
instanteous process, a set of two interconnected holding periods were used to represent 
physiological induction delays in the processing of free CYPlA2. The concentration of kee 
CYPlA2, after completion of the two physiological holding periods, is what ultimately is used by 
the liver cornpartment to determine the amount of free CYPl Aî available for binding to existing 
concentrations of the TCDD ligand. 
d) Calculation of the concentration of available CYPlA2 in the liver d e r  the fint physiological 
holding period (nrnolesfg) 
C, is then calculated based upon its integration with the basal 
concentration of CYPI A2 within the liver (Cm). 
e) Caiculation of concentration of available CYPl A2 in the liver afler the second physiological 
holding p e n d  (nmoledg) 
Cm is then calculated based upon its integration with the basal 
concentration of CYP lA2 within the liver (C,). This concentration is 
used by the liver compartment as the arnount of free CYP 1 A2 available for 
TCDD binding . 
Where: 
Concentration of Ah receptor bond  to TCDD ligand and available for binding to 
CYPl A2 in the liver (nrnoVg) 
Concentration of unbound CYP I A2 available in the liver after the two 
physiological induction holding penods (nmoVg). This concentration is used by 
the liver compartment as the amount of free CYP lA2 available for TCDD 
binding. 
Basal concentration of unbound CYP 1 A2 available in the liver (nmoVg) 
Concentration of unbound CYPlA2 available in the liver before first 
physiological holding period (nmo Vg) 
Concentration of unbound CYPl A2 available in the liver following first 
physiological holding penod (nmoVg) 
Concentration of TCDD in the liver tissue (pg/g tissue) 
the Hill coefficient (unitless) 
Michaclis-Menten constant of CYP 1 A2 induction (nmoVg) 
the maximum induction of CYPlA2 synthesis rate over the basal rate (unitleu) 
the zero-order basal induction rate for CYP 1 A2 synthesis (nmoVghour) 
the first-order rate constant for CYP 1 A2 degradation (1 hour) 
the rate of change of unbound CYPl A2 available within the liver (nmoihour) 
the rate of change of unbound CYP1 A2 available within the liver after the first 
physiologicai holding period (nrnoühour) 
the rate of change of unbound CYPl A2 available within the liver after the h t  
physiological holding period (molhour) 
CYP 1 A2 induction delay holding t h e  (hours) 
the stimulation fùnction (unitless) 
the tissue weight of the liver (g) 
A-2.0 Prototype Equiiibrium-based PBPK Mode1 (Evans and Andersen, 2000) 
The following section provides the detailed mathematical equations used in the development of 
the prototype steady-state PBPK model for the cumnt  research on PCDD/F pharmacokinetics. It 
is based upon the Evans and Andersen ( 2 0 )  published model, with modifications to correct 
minor inaccuracies and gaps in the methodology provided by the Evans and Andersen (2000) 
source paper. 
Figure A-3 A sehematic representation of the steady-state TCDD PBPK 
model (Evans and Andersen, 2000) 
Fat Cornpartment 
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CALCULATION OF AVAILABLE BINDING RECEPTORS 
Ah Receptor Bhd- 
a) Calculation of total amount of Ah-TCDD cornplex in liver (moles) 
Ah: TCDD = Cb x 
BMi 
ml + cb 
b) Concentration of TCDD bound to Ah receptors in the liver (nM) 
- Ah: TCDD 
CYPIA2 Binding 
C) Amount of induced CYP I A2 in the liver (moles) 
B M ~ T  = BM2o t BMzo x BM2i x 
Ah: TCDD" 
Kdn + Ah:TCDDn 
d) Calculation of total CYPIA2:TCDD complex in liver (moles) 
e) Calculation of overall CYPl IV occupancy by TCDD (unitless) 
f )  Calculation of overall CYPI A2 fold increase (unitless) 
f) Concentration of TCDD bound to CYP 1 A2 in the liver (nM) 
Arnount of TCDD bound to Ah recepton in the liver (moles) 
Amount of TCDD bound to CYPI A2 in the liver (nmoles) 
Basal level of CYPlA2 in the liver (nmoles) 
CYP 1 A2 fold incnase due to induction (unitless) 
Amount of induced CYP 1 A2 in the liver (nmoles) 
Concentration of TCDD in the pooled blwd (nM) 
Concentration of TCDD bound to Ah recepton in the liver (nM) 
Concentration of TCDD bound to CYP 1 A2 in the liver (nM) 
Concentration of TCDD bound to CYP 1A2 in the liver (nM) 
Fraction of total CYPI A2 occupied by TCDD (unitless) 
CYP 1 A2 induction fold increase over basal level (unitless) 
Ah receptor binding constant (nM) 
Binding amnity for CYP 1 A2 (nM) 
Ah receptor complex/DNA receptor dissociation constant (nM) 
Hill coefficient (unitless) 
Liver weight (kg) 
CALCULATION OF TCDD BLOOD CONCENTRATION 
The following equation is used to calculate the amount of TCDD that is present in the blood pool 
at steady-state. As the Cb variable is present on both sides, the equation is tenned an implicit 
equation, and must be solved with an application capable of resolving the equation to a point of 
stable convergence. The authors (Evans and Andersen, 2000) recommend the use of Sirnusolv's 
IMPL algorithm with the number of points set to 200, supplied with an initial value for blood of 
zero, a convergence criterion of 0.000001, and the number of allowable iterations set at 10. 
Other options include using the IMPLC algorithm in ACSL Tox, using the Solver system built 
into Microsofi Excel, or simply adjust the ternporary blood concentration manually in a 
spreadsheet version of the mudel until a satisfactory convergence occurs. As multiple solutions 
are possible, only the maximum value should be used. 
For the cuirent research, the methodology was created in an Excel spreadsheet, and solved using 
both the built-in Solver as well as manual convergence. 
a) Concentration oiTCDD in blood pool (nM) 
Ah receptor maximum availability (moles) 
Amount of induced CYP 1 A2 in the liver (nmoles) 
Concentration of TCDD in the pooled blood (nM) 
Administered dose of TCDD (nM) 
Ah receptor binding constant (nM) 
Binding affini ty for CYP 1 A2 (nM) 
Fat partitioning coefficient (unitless) 
Liver partitioning coefficient (unitless) 
Blood volume as a percentage of bodyweight (unitless) 
Fat volume as a percentage of bodyweight (unitless) 
Liver volume as a percentage of bodyweight (unitless) 
CALCULATION OF TCDD TISSUE FRACTIONS 
Blood Fracrion 
a) Fraction of TCDD in blood (unitless) 
Liver Tissue Fraction 
b)  Concentration of TCDD bound to liver tissue (nM) 
cl* = c b  x pl x vl 
c) Concentration of TCDD bound to Ah recepton in the liver (nM) 
d) Concentration of TCDD bound to CYPlA2 in the liver (nM) 
e) Overall concentration of TCDD found in liver tissue (nM) 
CL = CII + c ~ h  + CCYPIA~ 




Fat Tissue Fracîion 
g )  Fraction of TCDD stored in adipose tissue (unitless) 
FF = (1 - FH - FB) 
h) Overall concentration of TCDD found in liver tissue (nM) 
Làver to Fat Mass Ratio 
h) Calculation of liver to fat mass ratio (unitless) 
CL 
LTOF = - 
CF 
Where: 
FB = Fraction of TCDD stored in blood (unitless) 
FF = Fraction of TCDD stored in adipose tissue (unitless) 
FL = Fraction of TCDD stored in liver (unitless) 
LTOF = Livertofatmassratio(unit1ess) 
Ah receptor maximum availability (nmoles) 
Amount of induced CYPl A2 in the liver (nmoles) 
Administered dose of TCDD (nM) 
Concentration of TCDD in the pooled blood (nM) 
Concentration of TCDD bound to Ah receptors in the liver (nM) 
Concentration of TCDD bound to CYPl A2 in the liver (nM) 
Concentration of TCDD in adipose tissue cornpartment (nM) 
Concentration of TCDD in liver cornpartment (nM) 
Concentration of TCDD bound to liver tissue (nM) 
Ah receptor binding constant (nM) 
Binding affinity for CYP l A2 (nM) 
Liver partitionhg coefficient (unitless) 
Blood volume as a pcrcentage of bodyweight (unit less) 
Fat volume as a percentage of bodyweight (unitless) 
Liver volume as a percentage of bodyweight (unit less) 
A-3.0 Evans and Andersen (2000) Simubolv Source Code 
The following source code was provided by the primary author (M. Evans, persona1 
communication, 2001; reproduced with permission), and is designed for the Simulsolv (Dow 
Chernical Company, Midland, MI, Version 3 .O, 1993) computer simulation package. 
'PROGRAM DIOXN STEADY STATE MODEL - WITH DATA GAETAN.CSL1 
'MEL E. ANDERSEN 
'STEADY STATE MODEL 16 NOV 1993' 
iNITIAL 
CONSTANT PL=l O. $'BLOOD LIVER PARTITION COEFFICIENT' 
CONSTANT PF=350. $TAT/BLOOD PARTITION COEFFICIENT' 
CONSTANT PS= 1 O. $'SLOWLY PERFUSED TISSUEiBLOOD PARTITION' 
CONSTANT PR= 1 O. $'RICHLY P E W S E D  PARITION COEFFICIENT' 
CONSTANT VLC 4-04  $'LIVER VOLUME PROPORTION BW' 
CONSTANT VFC = 0.06 $'FAT VOLUME PROf ORTION BW' 
CONSTANT BW30.215 $'BODY WEIGHT IN KG' 
CONSTANT MW=322 $'MOLECULAR WEIGHT OF DIOXIN' 
te*** *****D[OXIN SECTION FOR LV'ER BIM>~G*******S*****' 
CONSTANT BM14.054 $'DIOXIN BINDING CAPACITY TO AHH LOCUS' 
CONSTANT KB 1 4 - 0 4  $'DIOXIN BINDING CONSTANT AHH LOCUS' 
CONSTANT BM20 = 10. $'DIOXING BINDING CAPACITY TO P448' 
CONSTANT BM2I = 85. $'INCREASE DUE TO MICROSOMAL INDUCTION' 
CONSTANT KB2 = 7. S'DIOXIN BINDINB CONSTANT TO P--448' 
CONSTANT N=l . $'HILL COEFFICIENT' 
CONSTANT -1. $'LIGANDED RECEPTOR-DNA BINDING' 
........................................................ 
TIMING SECTION' 
CONSTANT PDOSEM = 10. $'MAXMUM DOSE FOR CALCULATION 
LMDOSE = ALOG(PDOSEM)/2.303 OZûG(10) MAX BURDEN' 
CONSTANT POINTS=100 S'NUMBER OF P O M S  IN LOG PLOT 
CINT = ALOG(PDOSEM)/POINTS $'INTERVAL FOR OUTPUT' 
'INITIAL PARAMETER CALCULATIONS' 
VARIABLE LPDOSE=6 $'INDEPENDENT VARIABLE-LOG BODY BURDEN 
CLBT4.0 $'SETS INITIAL VALUE FOR VARIABLE IN IMPL' 
VL=VLC*BW $'LIVER VOLUME' 
VF=VFCSB W S'FAT VOLUME' 
F H 4 . 0  $'INITIAL VALUE OF FRACTION OF DOSE IN LIVER' 
fh& 
BM2T=BM20 %TNlTML VALUE OF P450-1 A2 IN LIVER' 
END $'ENDINITIAL' 
DERIVATIVE 
PDOSE = 10**LPDOSE 
DOSE = PDOSE*BW/MWS 1000 
CLB = AMAX 1(IMPL(CLBT,.000001,lO,EF ,... 
DOSW(PL*VL+PF*+BM 1 +CLB)+BM2T/(KB2+CLB)),. .. 
.O00 1 ),O.) 
'CLB FREE CONCENTRATION IN BODY' 
'SET DUMMY INTEGRATOR SO THAT DERIVATIVE FUNCTION WORKS' 
DUMMY=ENTEG(O.,O.) 
PROCEDURAL 
DBI = BM1*CLB/(KB1+CLB)NL 
BOUND=DB 1 **N/@B 1 **N+KD**N) 
BM2T = BM2O+BM2I*BOUND 
FH=(CLB)*(PL*VL+BM l/(KB 1 +CLB)+BM2T/(KBZ+CLB))/(DOSE) 
DERFH=DERIVT(O.O,FH) 
C H = D O S E * r n  
CF=DOSE*(l -FH)NF 
LTOF = CWCF 
DERLF = DERIVT(O.O,LTOF) 
CCH=DOSE/BW*MW 
END $'END OF PROCEDURE' 
'DBl CONCENTRATION OF BOUND AH RECEPTOR NM' 
'BOUND PROPORTION OCCUPANCY OF DNA BINDING SITES' 
BM2T AMOUNT OF P4501A2 NMOLES' 
'FH FRACTION OF BODY BURDEN IN LIVER' 
'CH CONCENTRATION IN LIVER NM' 
'CF CONCENTRATION IN FAT NM' 
'LTOF LIVER FAT RATIO' 
'CCH AVERAGE BODY CONCENTRATION NM/KG' 
TERMT(LPDOSE.GE.LMDOSE) 
END $END OF DERIVATIVE' 
END $'END OF DYNAMIC' 
END $'END OF PROGRAM' 
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APPENDIX B 
Detailed Results of Sensitivity Analyses of 
PBPK Mode1 System 
Table B-1.0 Sensitivity Aaalysis Results for Contribution to Variance behveen TCDD PB-PK M d e l  Variables and 
Sequestration Outcome. 
Bodywcight 15.9% 0.0% 












PAc - Fat 
PAc - Kidney 
PAc - Liver 
PAc - Rest 
PAc - Skin 
Ciputmeat Volumos 
Vc 2.4% 4.8% 
Vfc 0.3% 1.8% 
V kc 0.3% 2.0% 
Vlc o. 1% 0.2% 
Vluc 3.8% 0.0% 
V rec 3.0% 0.3% 
Vsc 3.1% 3.9% 
vspc 0.1% 0.1% 
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Table E2.0 Detailed Descriptions for eacb Parameter Evaluated in the Seisitivity 
Analysis. 
-- - 
Genml Physiologieal Pammners 
Bodyweight Body wcight of rcccptor 
Bar Allometric coefficient for cardiac output frorn bodyweight 









PAc - Fat 
PAc - Kidney 
PAc - Livef 
PAc - Rcst 










Equilibrium ratio of adipose tissue to blood concentrations 
Equilibnum ratio of kidncy tissue to blood concentrations 
Equilibrium ratio of liver tissue to blood concentrations 
Equilibrium ratio of lung tissue to blood concentrations 
Equilibrium ratio of Rcst of the Body tissue to blood conccntrations 
Equilibrium ratio ofskin tissue to blood concentrations 
Equilibnum ratio of splccn tissue to b l d  concentrations 
Membrane pcnmability of fat cornpartment 
Membrane permcability of kidney cornparmient 
Membrane pemieability of liver cornpartment 
Membrane pemieability of rat of the body cornpartment 
Membrane permcability of skin cornpartment 
Vcnous blood volum as pcrccntage of M y  wcight 
Adipose tissue b l d  volumc as percentage of bodywcight 
Kidney tissue blood volume as percentage of bodyweight 
Liver tissue b lood volume as percentage of bodyweight 
Lung tissue b l d  volurnc as percmtage of bodyweight 
Rcst of the body tissue blood volumt as perccntagc of bodyweight 
Skin tissue blood volume as percmtage of bodyweight 
Spleen tissue b l d  volurnc as pcrcentagc of bodyweight 
Absorption and Eliminarion 
BAtcdd Oral bioavailability of compound 
Kabs Chernical absorption rate constant fiom Gl tract to blood 
Kk Urinvy exaction rate 
Kli Biliary cxcrction rate 
Ah Recepfor Pharmaco&~amiu 
Bmax - Kidney Ah reccptor binding capacity in the kidncy 
Bmax - Livcr Ah rcccptor binding capacity in the liver 
Bmax - Lungs Ah receptor binding capacîty in the lung 
Bmax - Skin Ah reccptor binding capacity in the skin 
Bmax - Spleen Ah rcccptor binding capacity in the spleen 
Kd Dissociation constant of Ah reccptor binding 
Table E2.0 Detailed Descriptions for each Parameter Evaluated in the Sensitivity 
An aly sis. 
CYPIA2 Recrpior Pkormrcodynamics 
CCYPO Basal level of CYP 1 A2 within the liver 
h Hill coefficient 
Ica2 Concmtfation resulting in half maximum induction folds 
Ma2 Maximum induction fol& over the basal induction rate 
K2 CYP 1 A2 first-ordcr degradation rate constant of binding 
KdcP Dissociation constant of binding to CYP l A 2  
tau CY P I A2 physiological delay tirnc 
